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Drug addiction is a chronically relapsing disorder characterised by compulsive and 
uncontrollable drug consumption despite negative consequences. It is considered 
that in addiction, associative memories are formed, which trigger cravings and 
prompt relapse during abstinence, which is the largest unmet need of current 
addiction treatments. Nicotinic acetylcholine receptors (nAChRs) have been 
implicated in modulating addiction behaviours with drugs of abuse other than 
nicotine, and studies have provided evidence for a role of α7nAChRs in a 
morphine reward-based learning paradigm, conditioned place preference (CPP). 
The aim of this thesis was to characterise the role of α7nAChRs in motivational 
learning using a more potent opioid, heroin. The selective α7nAChR antagonist 
methyllycaconitine (MLA) was used to determine if these receptors contribute to 
the rewarding effects of heroin, the acquisition or the reinstatement of heroin CPP 
and heroin intravenous self-administration (IVSA). In 6-7 week old male Wistar 
rats, MLA had no effect on the primary rewarding effects of heroin in either CPP or 
IVSA experiments. When administered prior to heroin-primed reinstatement of 
CPP, MLA significantly inhibited reinstatement, demonstrating a selective effect of 
α7nAChRs on the reinstatement of CPP. Its effects on the heroin- and cue-primed 
reinstatement of IVSA were however inconclusive due to large variability. The 
molecular mechanisms of this effect were investigated by immunohistochemistry in 
brain slices of rats treated with either saline or MLA prior to heroin-primed 
reinstatement of CPP. AMPA GluA1 and phosphorylated GluA1 subunits were 
quantified by near-infrared scanning or confocal microscopy but no changes were 
detected due to methodological issues. The possible mechanistic actions of 
α7nAChRs in the relevant brain circuits are discussed.  
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1. CHAPTER 1 INTRODUCTION 
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1.1. Opioid addiction 
1.1.1. Prevalence and social impact 
 
Figure 1.1: Opioid drugs involved in overdose deaths in the USA from 2000 to 
2016 (NIDA, 2016). 
 
Drug use and addiction are major public health issues, as it has been estimated 
that 3.5-7% of the world’s population aged 15-64 tried an illicit drug at least once in 
2012, and approximately 33 million drug users worldwide abused opioid drugs 
(UNODC, 2014). The number of deaths related to heroin abuse in the USA has 
risen greatly since 2010 and there is a more recent spike in deaths related to 
synthetic opioid abuse, which includes fentanyl, the highly potent heroin analogue 
(see Figure 1.1). In the UK in 2015, it was reported there were approximately 60 
cases/million population of opioid-related overdose deaths, and 42% of all drug 
3 
 
addicts entered into treatment programmes were heroin users (European 
Monitoring Centre for Drugs and Drug Addiction, 2018).  
 A major part of the opioid abuse problem occurs from the abuse of prescription 
opioids before transitioning to illicit drugs (Centers for Disease Control and 
Prevention, 2017). In 2015, it was reported that over 12 million people aged 12 or 
over declared abusing an opioid prescription pain relief medication in the USA 
(Centers for Disease Control and Prevention, 2017). The rate of prescriptions of 
opioids increased greatly between 2000 and 2012; they have recently begun to 
decrease but still remain high (66.5 per 100 people in 2016 in the USA, Centers 
for Disease Control and Prevention (2017)).  
Currently, therapies to treat opioid addiction involve either replacement therapy, 
using alternative µ opioid agonists such as methadone and buprenorphine; or with 
the µ and κ opioid receptor antagonist naltrexone, or behavioural therapy (for 
review, see Bart (2012)). Use of psychosocial treatments alone has a limited 
success rate, with 80% of patients relapsing. Opioid replacement with methadone 
and buprenorphine are used to prevent the negative affective and physiological 
state associated with withdrawal; and the use of naltrexone reduces the rewarding 
effects of opioids in addicts, however benefits diminish with time and again, the 
majority of patients undergoing this form treatment relapse (Bart, 2012). A major 
failure of these current therapies is cravings and relapse, and there is currently no 
treatment which is able to prevent this. It is therefore essential to study the brain 
circuitry and molecular mechanisms that underlie craving and relapse in order to 
develop more efficient pharmacotherapies. 
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1.1.2. Addiction Circuitry 
Addiction is a chronic relapsing neuropsychiatric disorder characterised by 
compulsive seeking and consumption of drugs (and other hedonic activities), and 
the loss of control over drug intake despite negative consequences (Koob, 2013). 
There are several stages in the development of addiction. The primary stages of 
the acquisition of addiction were widely accepted to be manifested by rapid 
increases in dopamine release in the mesocorticolimbic pathway in the brain, 
however the role of dopamine in reward has since shifted Nutt et al. 
(2015).Studies have shown that dopamine receptor antagonists and the ablation of 
mesolimbic or nigrostriatal dopamine neurons have no effect on the palatability of 
food in animals but rather affect the incentive motivational value of these rewards 
(Berridge and Robinson, 1998, Berridge and Kringelbach, 2015). . 
PET studies in humans have shown that ketamine, alcohol and cannabis do not 
necessarily induce dopamine release in the striatum (Aalto et al., 2002, Yoder et 
al., 2007, Barkus et al., 2010). Furthermore, dopamine receptor antagonists have 
conflicting effects on opioid self-administration and conditioned place preference 
behaviours in rodents (Pettit et al., 1984, Hnasko et al., 2005, Ribeiro Do Couto et 
al., 2005, Bossert et al., 2007, Galaj et al., 2015, Assar et al., 2016), and in 
humans, heroin was shown to have no effect on striatal dopamine levels, despite 
producing a pronounced euphoric high (Daglish et al., 2008). 
In humans, dopamine receptor antagonists have been shown to have no effect on 
the subjective ratings of drug pleasure (Brauer and De Wit, 1997). In a discrete 
trial runway task, where rats approach a box in response to an olfactory cue 
signalling the availability of food or heroin; haloperidol had no effect on operant 
runway performance. Interestingly, the following day, rats that received haloperidol 
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were significantly slower in approaching the box. This suggests that the 
motivational arousal of the animal on the day of receiving haloperidol was intact, 
but rather the memory of a degraded reward discouraged the animals to seek the 
reward.  
Additional studies have also shown that dopamine plays a role in the anticipatory, 
preparatory, appetitive, or approach phases of motivated behaviour (Blackburn et 
al., 1987, Schultz et al., 1993, Berridge and Robinson, 1998, Apitz and Bunzeck, 
2014). Furthermore, dopamine transmission is also important in aversive 
motivational states, as elevated extracellular dopamine levels have been reported 
in the nucleus accumbens and forebrain regions in response to foot-shock and 
other types of stressor (Davis et al., 1994, Guarraci et al., 2000, Fadok et al., 
2009), suggesting it is more than a ‘liking’ signal.  
As the drug-taking behaviour becomes associated with the pleasurable effects of 
the drug, it is repeated in a Pavlovian manner as non-pharmacological contextual 
factors such as environments, people or paraphernalia become associated with 
drug intake (Stewart, 2008). These factors are repeatedly associated with the 
rewarding effects of the drug; therefore through Pavlovian conditioning they 
become triggers for craving and relapse. Because these strong associations are 
formed and become salient cues for drug taking, it is now believed that addiction is 
more than just a reward deficit and involves a component of learning and memory 
(Hyman et al., 2006). This chapter will introduce the reward circuitry involved in the 
acquisition of addiction and will rationalise the concept of addiction being a 
learning and memory disorder. Additionally, the pathways involved in mediating 




1.1.3. The dopamine circuitry in addiction 
 
Figure 1.2: Diagram of the dopaminergic circuitry in the rodent brain. 
Dopaminergic neurons project from the substantia nigra compacta (SNc, light 
orange) to the caudate putamen (CPu) or dorsal striatum (light blue), which forms 
the nigrostriatal pathway. The ventral tegmental area (VTA, orange) projects to the 
nucleus accumbens (NAc, dark blue), which forms the mesolimbic pathway; and to 
the prefrontal cortex (light green), which forms the mesocortical pathway. To a 
lesser extent, the VTA also projects to the dorsal striatum (dotted line). Taken from 
(Livingstone and Wonnacott, 2009).  
 
Most drugs of abuse increase dopaminergic transmission, by either directly 
targeting dopaminergic neurons in the ventral tegmental area (VTA) or increasing 
extracellular dopamine levels in the nucleus accumbens (NAc) or both (Van den 
Oever et al., 2010). The mesocorticolimbic dopaminergic pathway is composed of 
axons of dopaminergic neurons in the VTA that project to the NAc (see Figure 1.2 
above), prefrontal cortex (PFC), but also to the amygdala and hippocampus (van 
Huijstee and Mansvelder, 2014). Dopaminergic neurons from the substantia nigra 
(SN) extend to the dorsal striatum to form the nigrostriatal pathway (Figure 1.2). 
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These midbrain dopamine neurons are tonically active but show phasic activation 
following primary food rewards or stimuli associated with the presentation of 
rewards (Schultz, 2013). The importance of these regions in reward seeking was 
shown by 6-OHDA lesions (Smith et al., 1985), microinfusions of dopamine 
antagonists (Bachtell et al., 2005) and dopamine D1 receptor knockout mice 
(Caine et al., 2007), as these interventions all reduced reward seeking.  
Despite the vast research in dopamine and reward (Koob, 2013), the dopamine 
model of addiction is too simplistic. Studies have shown that although dopamine is 
important in the acquisition of hedonic behaviours, it is not essential for 
reward-based learning. Lesions of dopaminergic cells in the SN produced aphagia 
in rats but reactivity to aversive or palatable tastes remained normal, showing a 
dissociation of hedonic responses to dopamine (Berridge and Robinson, 1998). In 
another study, genetically engineered dopamine-deficient mice produced similar 
responses to control mice in the learning of salient cues and in responding to the 
hedonic effects of rewards (liking), but dopamine was necessary for the seeking of 
rewards in a T-maze model of goal oriented behaviour (wanting) (Robinson et al., 
2005). In opioid models of reward-based learning, it was shown that dopamine 
was not required for the hedonic responses to opiate administration or for learning 
cues predictive of opioid administration, as dopamine-deficient mice were still able 
to acquire robust morphine conditioned place preference (CPP) (Hnasko et al., 
2005). These dopamine-deficient mouse models however required intermittent L-
DOPA treatment to survive, and due to locomotor deficiencies, required caffeine to 
perform tasks, therefore the results from these studies cannot be directly 
correlated to a lack of dopamine (Fields and Margolis, 2015). Other studies have 
however shown that lesions to the NAc in rats inhibit cocaine self-administration 
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but do not inhibit heroin self-administration (Pettit et al., 1984). These initial 
findings support the hypothesis that additional neural substrates than dopamine 
are required in addiction.  
Dopamine has two main roles in reward processing, which are believed to be 
mediated by different pathways in the reward circuitry. The first role is linked to 
motor behaviour, to elicit behavioural responses previously paired with the 
stimulus, and is thought to be mediated by the mesolimbic circuit (Hyman et al., 
2006). The second role is to inform the individual of the appearance of a novel 
salient stimulus to prompt neuromodulatory changes associated with learning and 
memory. This behaviour is thought to be mediated by the mesocortical pathway 
(VTA to medial PFC), as this pathway is involved in cognitive control and 
motivational responses.  
 
1.1.4. Beyond the mesolimbic circuit 
A common feature in addicts is that taking drugs becomes valued above all other 
goals and abstinence can prove very difficult as drug-associated cues and 
emotions can trigger feelings of craving (Van den Oever et al., 2010). This implies 
addiction is a learned behaviour involving plasticity. Many neuroimaging studies in 
humans have demonstrated a key role of the frontal cortex (FC) in compulsive 
behaviours and in the regulation of cognitive and emotional processes which 
results in the over-valuing of drug reinforcers over other rewards (Volkow et al., 
1993, Volkow and Fowler, 2000, Goldstein and Volkow, 2002).  
The prefrontal cortex (PFC) has been shown to be a major region involved in 
working memory, which is the ability to process information, update it with other 
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information and use it to guide behaviour (reviewed by Van den Oever et al. 
(2010)). Reversible pharmacological inhibition of the medial PFC (mPFC) has 
been shown to inhibit the reinstatement of drug seeking in self-administration 
paradigms (McLaughlin and See, 2003, Rogers et al., 2008). Dopaminergic 
modulation of plasticity in the PFC has been closely linked to reward-related 
learning, as NAc core (the inner part of the NAc) glutamate levels can be 
enhanced by direct injection of cocaine in the mPFC (Park et al., 2002), and can 
also be inhibited by pharmacological inactivation of mPFC projections to the NAc 
core (LaLumiere and Kalivas, 2008). This pharmacological inactivation of 
glutamate release in the NAc core also inhibits the reinstatement of drug seeking 
(LaLumiere and Kalivas, 2008), suggesting an important role of the PFC in 
modulating drug-seeking behaviour.  
The mPFC also receives dopaminergic input from the VTA (Van den Oever et al., 
2010, Sheynikhovich et al., 2013), which is believed to be involved in reinforcing 
working memory associated with reward. Intra-mPFC injections of dopamine 
receptor agonists have been shown to trigger reinstatement, whereas antagonists 
have been shown to attenuate this behaviour (McFarland and Kalivas, 2001, See, 
2009). Furthermore, the context-induced reinstatement of heroin seeking has been 
shown to be associated with Fos induction in the mPFC as a marker of neuronal 
activation, and the selective inhibition of mPFC neurons has been shown to inhibit 
this reinstatement behaviour (Bossert et al., 2011). It has therefore been 
hypothesised that the PFC is involved the assignment of values to rewards and to 
gate goal-oriented behaviour. It has vast connections with many brain regions (see 
Figure 1.3), which places it in a prime position to integrate motivational information 
and drive drug-seeking behaviour. The dopaminergic input from the VTA to the 
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PFC posits a role of the PFC in reinforcement learning, and a distorted dopamine 
signal in this pathway has been hypothesised to produce the over-learning of drug-
related cues (Van den Oever et al., 2010).  
Although the mesocorticolimbic system is heavily implicated in the processing of 
natural and unnatural rewards, the activation of this pathway is not sufficient to 
explain drug-seeking behaviour and the persistence of this behaviour. Dopamine 
is not thought to drive drug-seeking behaviour, but rather to gate it (reviewed by 
Wise (2004) and Schultz (2013)); revealing that the role of dopamine release in 
the NAc is more subtle and complex than a mere consequence of drug intake. 
 
1.1.5. GABAergic modulation 
GABAergic signalling is also thought to be important in modulating motivational 
responses. The main projections from the NAc and dorsal striatum are GABAergic 
(see Figure 1.3) and it is thought that acute drug use decreases GABAergic output 
from the NAc shell, the outer region of the NAc (Carlezon and Thomas, 2009). 
Furthermore, VTA dopamine cells (Kalivas, 1993) and glutamatergic neurons in 
the hippocampus (Mann and Paulsen, 2007) and PFC (Banuelos and 
Woloszynowska-Fraser, 2017) modulated by GABAergic neurons. The importance 
of GABAergic projections has been emphasised, particularly in the genesis of 
theta rhythms in the medial septum and hippocampus (Mann and Paulsen, 2007). 
It is thought that GABA regulates overall circuit tone and all drugs of abuse have 
been shown to influence inhibitory synaptic plasticity (Fields and Margolis, 2015). 
The present study will however focus on glutamatergic synaptic plasticity. 
11 
 
1.1.6. Glutamatergic circuitry 
 
Figure 1.3: Left: Schematic diagram of the glutamatergic (blue), GABAergic (orange) and dopaminergic (purple) pathways involved 
in addiction-associated behaviour. HPC: hippocampus; Thal: thalamus; VP: ventral pallidum; FC: frontal cortex; NAc: nucleus 
accumbens; VTA: ventral tegmental area; BLA: basolateral amygdala. Summarised from (Luscher and Malenka, 2011, Madsen et 
al., 2012a). Right: Representation of converging glutamatergic and dopaminergic inputs onto striatal and other corticolimbic 
neurons (Kelley, 2004).  
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As previously discussed, dopamine is important for the reinforcement of a reward, 
but it cannot explain how repeated use of drugs abuse becomes compulsive, how 
drug-related cues can drive drug-seeking behaviour, or how the risk of relapse can 
persist for years after abstinence. The integration of dopamine and 
glutamate-coded signals at the molecular and cellular level in the NAc has been 
proposed as the drive behind addiction-related behaviour, and that synaptic 
plasticity is the substrate for these persistent changes in behaviour (Kauer and 
Malenka, 2007). As shown in Figure 1.3, there is extensive glutamatergic 
innervation of the NAc and the VTA, which converges with dopaminergic circuits. 
Furthermore, dopaminergic and glutamatergic terminals are localised in close 
proximity to each other on the same dendritic spines, demonstrating a potential for 
cellular plasticity involving glutamatergic and dopaminergic processes (Kelley, 
2004). Studies have shown that drugs of abuse induce long-lasting changes in the 
brain, and although drugs of abuse alter many different synapses, they are thought 
to mainly alter glutamatergic transmission (Lüscher, 2013). 
Changes in synaptic plasticity have been shown to occur after the first exposure to 
the drug of abuse. An original study showed that a single in vivo administration of 
cocaine to mice and rats resulted in an increase in ratios of AMPA/NMDA 
receptor-mediated excitatory postsynaptic currents (EPSCs) in the VTA 24 hours 
after administration (Ungless et al., 2001). It was demonstrated that this increase 
in AMPA/NMDA ratio was due to an increase in AMPA receptor transmission. This 
cocaine-induced effect was found to be specific to dopaminergic cells in the VTA, 
since no effect was observed in GABAergic cells, or in the hippocampus (Ungless 
et al., 2001). Furthermore, this synaptic strengthening was found to be NMDA 
receptor-dependent, as co-administration of cocaine with an NMDA receptor 
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antagonist showed no changes in NMDA/AMPA ratios in the VTA. Since this 
study, it has been shown that all drugs of abuse (nicotine, morphine, ethanol, 
amphetamines and benzodiazepines) induce a potentiation of AMPA receptor 
transmission in dopaminergic cells in the VTA (for review, see van Huijstee and 
Mansvelder (2014)). Thus, a single exposure to drugs of abuse induces synaptic 
changes similar to NMDA-dependent long-term potentiation, which will be 
discussed further in section 1.2.2. 
 
1.1.7. How does this relate to drug-related behaviour? 
Establishing a causal relationship between drug-evoked synaptic plasticity and 
drug-related behaviour is challenging, in part because of the temporal discrepancy 
between the two phenomena. Non-contingent drug administration results in short-
term synaptic plasticity in the VTA (van Huijstee and Mansvelder, 2014). These 
initial alterations in synaptic strength are the molecular underpinnings of circuit 
remodelling, which, with repetitive exposure, leads to behavioural alterations. In 
vivo models of drug self-administration allow contingent drug administration in 
animals, and synaptic potentiation in VTA dopaminergic neurons was shown to still 
be present 3 months after cocaine self-administration in rats (Chen et al., 2008), 
which suggests that synaptic strengthening in the VTA is an essential 
phenomenon in the development of addiction. 
Mice with genetic deletions of the AMPA GluA1 (but not GluA2) or the NMDA 
GluN1 subunit selectively on dopaminergic neurons lacked drug-induced plasticity 
in the VTA (Engblom et al., 2008b); but the acquisition of significant conditioned 
place preference to cocaine was observed in these transgenic mice. Extinction 
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was however absent in the GluA1-lacking mice, and reinstatement was abolished 
in CPP, suggesting plasticity in additional brain regions other than the VTA is also 
important in the behavioural manifestation of addictive behaviours. 
Unlike in the VTA, a single acute injection of a drug of abuse does not induce 
synaptic plasticity in the NAc (Kourrich et al., 2007). The NAc gates rewarding and 
aversive stimuli and directs goal-oriented behaviour. The principal neurons of the 
NAc (core and shell) are GABAergic medium spiny neurons (MSNs) which receive 
glutamatergic inputs from brain regions (see Figure 1.3) including the PFC and 
thalamus, which are involved in goal-oriented behaviour; the dorsal hippocampus, 
which likely provides spatial and contextual information about stimuli; the ventral 
hippocampus, and the amygdala, which contribute to a limbic circuit important for 
emotional processing of stimuli (Chartoff and Connery, 2014). Glutamate 
transmission is kept under tight control in the NAc. Glutamatergic afferents 
synapse on dendritic spines and these are modulated by extrasynaptic 
dopaminergic inputs (Figure 1.3, Chartoff and Connery (2014)). This allows the 
close regulation of excitability of these neurons by local release of dopamine, 
where Gαs-coupled D1 dopamine receptors leads to the excitation of MSNs and 
Gαi-coupled D2 receptors inhibit MSNs (Carlezon and Thomas, 2009). In general, 
aversive stimuli activate NAc neurons, which project to the VTA and ventral 
pallidum, whereas rewarding stimuli appear to inhibit NAc neuron firing.  
Microinjections of AMPA into the NAc have been shown to elicit the reinstatement 
of cocaine seeking behaviour (Cornish and Kalivas, 2000), while AMPA receptor 
antagonists have been shown to inhibit reinstatement (Ribeiro Do Couto et al., 
2005). Additionally, reduction of NMDA GluN2 subunit expression by siRNA 
injection into the NAc was shown to inhibit morphine CPP in rats (Kao et al., 
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2011), demonstrating this is also present with opioid drugs. These findings 
demonstrate that glutamatergic synaptic plasticity is a key component of all stages 
of addiction, notably for the formation of drug-associated cues.  
 
1.2. Addiction is a learning and memory disorder 
As previously mentioned, the development of environmental contexts into salient 
cues for drug taking and the long-lasting risk of relapse cannot merely be 
explained by dopaminergic transmission in the mesocorticolimbic system (Koob, 
2013). Rather, it has been long postulated that the different stages of addiction 
(acquisition, withdrawal and relapse) involve the hijacking of learning and memory 
systems in different brain regions for the encoding of persistent drug-related 
memories (Kelley, 2004, Hyman et al., 2006). It is therefore important to 
understand the molecular mechanisms underpinning memory encoding and how 
behavioural paradigms can be used to model these addiction-related memories. 
 
1.2.1. LTP underlies memory processes 
 
Figure 1.4: Schematic representation of the processes that occur following re-
exposure to a drug associated cue. Brief cue exposure initiates LTP mechanisms 
which lead to memory reconsolidation and the strengthening of the drug-
associated memory, which increases relapse potential. Figure adapted from (Rich 




Memories are stored and can be retrieved in response to social and environmental 
cues, termed consolidation. They can also be reinforced when they are retrieved 
by the process termed reconsolidation, where the synapses involved are 
strengthened further by LTP (Figure 1.4, Rich and Torregrossa (2018)). 
Adrenergic receptor agonists were among the first ligands to be proposed to 
interfere with drug-cue memory reconsolidation as following the re-activation of 
fear-conditioned memories, treatment with the α1 agonist clonidine or the β 
adrenergic receptor antagonist propranolol disrupts memory reconsolidation in the 
context of post-traumatic stress disorder (Debiec et al., 2011, Gamache et al., 
2012). Moreover, propranolol has been shown to disrupt the reconsolidation of 
cocaine and morphine-paired memories (Bernardi et al., 2006, Robinson and 
Franklin, 2007) and the inhibition of proteins involved in synaptic plasticity in 
neurons such as CAMKII, PKC, ERK and mTOR all inhibit the reconsolidation of 
drug-related memories (for review, see Rich and Torregrossa (2018)). 
Reconsolidation is the mechanism believed to underlie drug craving and seeking, 
triggered by stress, social and environmental cues associated with drug-taking, 
and exposure to even small doses of the drug (Bouton, 2002). Animal behavioural 
paradigms of drug-related learning and memory have been used to understand the 
causes of drug craving and seeking, and could potentially reveal new targets for 





1.2.2. Long term potentiation as a substrate of learning and 
memory 
One of the key molecular mechanisms underpinning memory processes is thought 
to be long term potentiation (LTP). Long-term depression (LTD) is also a key 
mechanism of memory processing, but this thesis will focus on the most 
extensively studied form of LTP, NMDA-dependent LTP (Figure 1.5, Kauer and 
Malenka (2007)).  
LTP triggers the trafficking of further AMPA receptors to the surface to increase 
receptor density at the synapse (Figure 1.6). AMPA receptors are tetrameric 
ionotropic glutamate receptors that mediate fast excitatory transmission in the 
brain. There are four genetically distinct subunits of AMPA receptors (GluA1-4) 
and combinations of these form tetrameric receptors in the endoplasmic reticulum 
(ER) (Luscher and Malenka, 2012). In neurons of the rat hippocampus, AMPA 
receptors mainly contain either GluA1/2 or GluA2/3 subunits (Wenthold et al., 
1996), with mainly the former present at the synapse (Lu et al., 2009). GluA4 
subunits are rare in the adult rat brain and are mainly expressed in the developing 
brain (Henley and Wilkinson, 2013). The GluA2 subunit contains a modifiable 
glutamine residue which can be switched for an arginine residue in the channel 
lining (Greger et al., 2002). This switch functions as an ER retention motif and 
causes the GluA2-containing AMPA receptors to be impermeable to calcium 
(Wright and Vissel, 2012). Most GluA2 subunits in the adult brain contain this 
arginine switch, which regulates the permeability and channel conductance of the 
receptor. The GluA1 receptor does not express this motif and is thus permeable to 
calcium. Subunits possess either short or long intracellular C-terminal domains 
which determine their trafficking (Greger et al., 2017). Long-tailed subunits (GluA1 
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and GluA4) are trafficked rapidly from the ER to the synapse and predominate the 
trafficking of the short-tailed C-terminus containing subunits (GluA2 and GluA3), 
which is slower (Mah et al., 2005, Kessels and Malinow, 2009). Thus, if an AMPA 
receptor contains GluA1 and GluA2 subunits, it is trafficked rapidly from the ER. 
Studies have shown that calcium-permeable homomeric GluA1 AMPA receptors 
are rapidly trafficked to the synapse at the onset of LTP (Hayashi et al., 2000, 
Isaac et al., 2007, Greger et al., 2017) and then heteromeric calcium-impermeable 
GluA2/3 AMPA receptors slowly replace the homomeric receptors over hours to 
maintain LTP (Isaac et al., 2007). Studies have also shown GluA2/3-containing 
receptors are trafficked slowly (Mah et al., 2005) and replace existing AMPA 





Figure 1.5: Schematic diagram of NMDA receptor (NMDAR, dark purple)-
dependent long term potentiation (LTP) and representative AMPA/NMDA current 
ratios in the basal state (A) or during LTP (B). Strong and persistent release of 
glutamate (glu) from the presynaptic terminal (A) depolarises the postsynaptic 
terminal via AMPA receptors (AMPAR, light purple), which results in the relief of 
the voltage-dependent magnesium (Mg2+) block from NMDA receptors (B) and the 
influx of calcium (Ca2+) into the postsynaptic terminal. Intracellular calcium 
activates calcium/calmodulin-dependent protein kinases (CAMKII), which, though 
downstream mechanisms results in the insertion of AMPAR into the postsynaptic 
membrane, resulting in an increase in AMPA receptor density at the synapse, 
which can be measured by an increase in AMPA/NMDA ratios. This results in the 
strengthening of the synapse. Adapted from Kauer and Malenka (2007). 
 
A diagram of the mechanisms is shown in Figure 1.5, where persistent release of 
glutamate from the presynaptic terminal results in a large influx of Ca2+ into the 
postsynaptic terminal. The resulting large increase in intracellular Ca2+ 
concentration activates a calcium/calmodulin-dependent protein kinase II 
(CAMKII), which triggers the insertion of further AMPA receptors to the synapse. 
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CAMKII undergoes autophosphorylation following induction of LTP and is essential 
in AMPAR exocytosis. CAMKII knock-out studies (Silva et al., 1992, Hayashi et al., 
2000) and removal of the autophosphorylation site (Giese et al., 1998, Chang et 




Figure 1.6: Proposed steps of the induction of LTP involving the trafficking of 
AMPA receptors to synapses. In basal conditions (left), AMPA receptors routinely 
cycle to and from the synapse by transmembrane AMPA receptor regulatory 
proteins (TARPs). Middle: the activation of PKA by depolarisation of the 
postsynaptic terminal results in the phosphorylation of GluA1-containing AMPA 
receptors into perisynaptic sites, therefore dendritic spines are deemed primed for 
LTP. Right: NMDA receptor activation results in the increase in calcium influx, 
which triggers the trafficking of perisynaptic AMPA receptors to the synapse via 
CAMKII (and potentially PKC) signalling. AMPA receptors are stabilised in the 
postsynaptic membrane by the scaffolding protein PSD-95. GluA1 subunits are 
phosphorylated at serine 831 to increase channel conductance and at 845 to 
increase channel open probability for the potentiation of synaptic strength. Figure 
taken from Derkach et al. (2007). 
 
The development of LTP also involves phosphorylation of AMPA receptor subunits 
(Soderling and Derkach, 2000). The phosphorylation of GluA1 receptors at serine 
845 by phosphate kinase A (PKA) in the intracellular C terminus of GluA1 subunits 
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results in an increase in the channel open probability (Banke et al., 2000). 
Importantly, phosphorylation of serine 845 also regulates the surface expression of 
AMPA receptor expression by the delivery of intracellular stores of GluA1 AMPA 
receptors to perisynaptic sites (illustrated in Figure 1.6), coincident with synaptic 
activity (Oh et al., 2006). Increasing the extrasynaptic pool of AMPA receptors was 
shown to result in stronger theta burst LTP in rat hippocampal slices and in 
cultured rat hippocampal neurons (Oh et al., 2006); demonstrating that the 
phosphorylation of GluA1 at serine 845 primes AMPA receptors for the induction 
of LTP. CAMKII phosphorylation of serine 831 in results in increased channel 
conductance in homomeric GluA1 receptors (Benke et al., 1998). Another study 
found there is no increase in conductance of GluA1/2 heteromeric AMPA 
receptors following phosphorylation by CAMKII (Oh and Derkach, 2005), thus 
GluA2 plays an inhibitory role in CAMKII phosphorylation.  
This dynamic exchange of AMPA receptors at the synapse drives either synaptic 
strengthening or synaptic weakening, processes which underlie memory encoding 
and retrieval. In vivo models have been used to model learning and memory tasks, 
and these models can be used in the context of addiction-related behaviours.  
 
1.3. In vivo models to study drug-related memory 
The two most commonly used behavioural paradigms for studying drug-related 
behaviour and memories are conditioned place preference (CPP), a Pavlovian 
conditioning model of learning and memory, and self-administration, an operant 
correlate of learning and memory. Both of these models were used in this thesis 
(Chapters 2 and 3). Both paradigms can measure associative learning by classical 
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conditioning where a conditioned stimulus (CS, originally neutral stimulus) is 
presented with an unconditioned stimulus (US, an innately rewarding stimulus) 
sequentially, so that the animal learns to associate the CS with the US and 
consequently the probability of the behaviour is increased (Tzschentke, 2007, 




1.3.1. Conditioned Place Preference 
 
Figure 1.7: Schematic diagram of the habituation and conditioning stages of the 
CPP paradigm 
 
The conditioned place preference (CPP) paradigm is used to study motivational 
memory associated with a rewarding or aversive stimulus (Cunningham et al., 
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2006). The apparatus is generally divided into two compartments, differentiated by 
different patterns on the walls and different textured floors, and an optional third 
central neutral compartment (Figure 1.7). The neutral value of the compartments is 
measured during one or more (in this study, two) initial habituation sessions in 
which the time spent in either side is recorded before conditioning, and a baseline 
preference is established for each animal. This session also reduces the effect of 
novelty seeking. The next stage of the CPP protocol is the conditioning stage, 
where the conditioned stimulus, here, a CPP compartment, is repeatedly paired 
with an unconditioned stimulus (such as a heroin injection), so the association of 
reward from the US is formed with the CS (Figure 1.7). The opposite compartment 
is paired with vehicle and has no salient value for the animal. A post-conditioning 
test records the amount of time spent in either compartment in the absence of 




Figure 1.8: Schematic diagram of the extinction and reinstatement stages of CPP.  
 
The next stage of CPP is the extinction phase. Extinction is defined as the 
disappearance of the conditioned behavioural response after the removal of the 
unconditioned stimulus that has reinforced the learning (Cunningham et al., 2006). 
This is usually done by re-exposing the animal to the previously drug-paired 
context in a drug-free state; either by administering repeated injections of vehicle 
in both the previously drug-paired and unpaired compartments, or by repeating 
CPP tests until the preference is no longer observed (Figure 1.8, Aguilar et al. 
(2009)). In the present study, the former method of repeated vehicle 
administrations in both compartments was used. A post-extinction test then 
records the time spent in the drug-paired side and the CPP (Figure 1.8) is 
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considered extinguished when there is no significant difference compared to the 
time spent in the drug-paired side during habituation.  
The reinstatement stage of CPP is often used as an animal correlate of cravings 
and a return to drug seeking in studies investigating addiction treatments (Bossert 
et al., 2013). The extinguished drug-associated behaviour has not erased the 
drug-related memory, but it has been suppressed (Bouton, 2002). Reinstatement 
therefore refers to the retrieval of the conditioned behaviour in response to a cue. 
In the case of CPP, the cue is often the non-contingent exposure of animals to a 
priming dose of the drug, but can also be induced by other drugs of abuse or 
stress (Bouton, 2002). In the present study, reinstatement was induced by the re-
exposure to heroin. The conditioned behaviour is deemed reinstated when there is 
a significant difference in the time spent in the previously drug-paired side 
compared to the post-extinction test (Aguilar et al., 2009).  
 
1.3.2. Intravenous self-administration 
Intravenous self-administration is a comprehensive behavioural paradigm which 
can model multiple complex aspects of motivational behaviour towards a drug 
reward. It is often used to predict the abuse liability of drugs and to study relapse-
like behaviour (reviewed by Panlilio and Goldberg (2007)). In this model, animals 
are trained to perform an operant conditioned response (in this study, lever press) 
for a drug reward. Other types of reward such as food can be used but this study 
will focus on drug reinforcement. The motivational value of the drug can be 
determined by increasing the number of lever presses required to receive the 
reward (i.e. on a fixed ratio or progressive ratio), and the drug infusion is usually 
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paired with a contingent cue (such as a tone or light), which is presented 
simultaneously with the drug (Davis and Smith, 1976, See et al., 1999, Perry et al., 
2014).  
 
1.3.3. Schedules of reinforcement  
The amount of work that has to be done to obtain the reward can be altered in 
self-administration studies. These are termed ratio schedules, which determine the 
number of responses required to obtain the reward (see Panlilio and Goldberg 
(2007) for review). The requirement can be constant (fixed ratio) or variable 
depending on the reward. The aim of these schedules is to maintain a 
characteristic pattern of responding, which are used as correlates of different 
aspects of addiction-related behaviour (Panlilio and Goldberg, 2007). Fixed ratio 
schedules are often used to determine the abuse liability of a drug, and the fixed 
ratio schedule was used in this thesis. Another type of schedule is the progressive 
ratio schedule, which assesses the effectiveness of a reinforcer, as under this 
schedule, the number of responses required for drug delivery progressively 
increases with repeated injections, until the subject ceases to respond for a certain 
amount of time (Panlilio and Goldberg, 2007). The progressive ratio therefore 
measures the motivational strength of the tested drug, and the highest response 
requirement that is achieved by the subject is termed the breakpoint.  
There are other methods to determine the salient value of drug reinforcers. The 
unit price of the drug can be manipulated so the number of responses can 
determine the dose of drug to be received. For example, one lever press can 
result in a low dose of drug reinforcer, whereas three presses could result in a 
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higher dose, and the animal decides on the response. Choice can also be 
introduced into the paradigm, where an alternative reinforcer (food or a different 
drug of abuse) can also be an option for the subject to determine the value of the 
studied drug. Other types of schedule include second-order, chained, and multiple 
schedules (Panlilio and Goldberg, 2007), demonstrating the variety of parameters 
that can be modified to study a specific type of addiction-related behaviour. 
Once self-administration is stabilised, the conditioned behaviour can be 
extinguished by the replacement of the drug with saline or by being placed in the 
operant chamber without being attached to the infusion pumps in the absence of 
the conditioned cues (Panlilio and Goldberg, 2007). In the present study, saline 
infusions were used to extinguish lever responses. Reinstatement procedures are 
used as a correlate of relapsing behaviour following a period of abstinence, where 
exposure to the previously drug-paired associations reinstates the previously 
extinguished conditioned behaviour (Davis and Smith, 1976, Perry et al., 2014). 
Three major types of treatment have been found to induce reinstatement of drug 
seeking in this paradigm, and each of these is analogous to the events that can 
trigger relapse in humans (Bouton, 2002). The first is drug priming by the re-
exposure to the drug reinforcer or a different drug of abuse; the second is 
exposure to drug-associated cues and the third is stress (usually induced by 
foot-shock in self-administration studies) (Panlilio and Goldberg, 2007). 
Drug self-administration is a highly adaptable technique for modelling various 
aspects of drug-related behaviour. Studies using this paradigm have elucidated 
key brain regions involved in the reinstatement of drug seeking, and interestingly, 
have determined that, though there are common regions involved in drug and cue-
29 
 
primed reinstatement, there also appear to be distinct regions which respond to 
either type of stimulus to produce reinstatement.  
 
1.3.4. Mechanisms of opioid relapse 
 
Figure 1.9: Proposed circuitry mediating relapse to heroin seeking. The only brain 
region to be reported to be involved exclusively in cue-induced reinstatement was 
the hippocampus (HPC, orange) (Namba et al., 2018). Light blue areas represent 
neural regions necessary for drug-primed reinstatement only and white areas 
represent neural regions involved in both cue- and drug-primed reinstatement of 
opioid seeking. mPFC: medial prefrontal cortex; NAc core/shell: nucleus 
accumbens core/shell; CEA: central nucleus of the amygdala; BLA: basolateral 
amygdala; BNSTmp: posteromedial bed nucleus of the stria terminalis; BNSTv: 
ventral bed nucleus of the stria terminalis; VP: ventral pallidum; VTA: ventral 
tegmental area. Purple arrows indicate dopaminergic signalling and teal arrows 
indicate glutamatergic signalling. Summarised from Rogers et al. (2008), Stewart 
(2008), Brown and Lawrence (2009) and Namba et al. (2018). 
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The previous sections have discussed the synaptic plasticity events in brain 
regions involved in the development of addiction. Relapse has been shown to 
involve the recall of drug-related memories, often brought about by the 
presentation of a drug-associated cue (Bouton, 2002). There are many in vivo 
studies investigating the roles of different brain regions involved in rodent models 
of relapsing behaviour with cocaine. Cocaine self-administration studies reported 
that reversible inactivation of the dorsal (not ventral) mPFC, nucleus accumbens 
core (but not shell) and ventral hippocampus decreased the reinstatement of 
cue-induced reinstatement of cocaine seeking (for review, see Bossert et al. 
(2013)). Brown et al. (2010) identified the brain regions that became activated in 
rats that reinstated drug-seeking behaviour in response to a cocaine prime in CPP, 
by the quantification of fos-positive cells (a marker of neuronal activation). They 
identified the PFC, BNST and nuclei (paraventricular and lateroanterior) of the 
hypothalamus, which were all shown to be involved in the reinstatement of cocaine 
in self-administration studies (Brown et al., 2010). They also showed activation of 
the lateral habenula, which receives inputs from the PFC, hypothalamus and basal 
ganglia (Baker et al., 2015); and is thought to drive behavioural flexibility. The 
activation of the lateral habenula has not previously been shown in operant 
studies, suggesting that there could be a distinction in the activation of certain 
brain regions in either CPP of self-administration studies.  
The brain regions discussed above were thought to be common regions involved 
in reinstatement paradigms with all drugs of abuse; therefore there are few reports 
of brain regions involved specifically in opioid relapse. A study by Rogers et al. 
(2008) however identified additional regions such as the NAc shell, BNST, ventral 
mPFC, substantia nigra and ventral pallidum, which were involved in both the cue- 
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and drug-primed reinstatement of heroin seeking in heroin self-administration (see 
Figure 1.9). Furthermore, another study by Madsen et al. (2012b) compared brain 
regions involved in cue-induced reinstatement of either sucrose or morphine self-
administration after protracted abstinence in mice. They found a multitude of brain 
regions activated with both rewards (including NAc shell, BNST, VTA, 
hippocampus, LC and lateral habenula), but the structures which were more 
activated in morphine seeking included the NAc core, BLA, SN pars reticulata and 
the CEA. These findings support a cortico-striatal limbic circuit activated during the 
reinstatement of opioid seeking, supporting previous findings.  
 
1.3.4.1. Cue-induced reinstatement 
Wikler (1973) and O'Brien et al. (1992) discovered that environmental contexts 
associated with drug taking could trigger relapse in humans. An initial study 
conducted by Davis and Smith (1976) showed that pairing a neutral cue (buzzer) 
with morphine intravenous infusions in rats produced robust lever pressing 
responses. Subsequent extinction replacing morphine with saline infusions in the 
absence of the cue reduced lever pressing. It was found that the presentation of 
the buzzer cue following extinction could re-trigger lever responses, demonstrating 
for the first time the role of cues in the reinstatement of drug self-administration 
and addiction. Grimm et al. (2000) demonstrated that presenting cues contingently 
during conditioning is essential for the development of drug reinforcement, and 
See et al. (1999) showed that the use of compound cues (tone + light) over using 
cues individually is even more effective. It has been shown that lever responses 
for cocaine or heroin in response to either a light and tone cue were similar in 
magnitude to each other (Panlilio et al., 1996, Panlilio et al., 2000). When the 
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compound tone and light cues were presented, there was a three-fold increase in 
responding for the lever compared to either cue alone under extinction conditions 
(saline infusions) and two-fold under maintenance conditions (heroin infusions) 
(Panlilio et al., 2000), demonstrating a strong effect of compound cues on drug 
seeking behaviour.  
Since then, a multitude of studies have shown the influence of cues in extinction 
and reinstatement in preclinical models of relapse with many drugs of abuse such 
as heroin, speedball (cocaine and heroin mix), alcohol and nicotine (reviewed by 
Perry et al. (2014)). These cues are putative correlates of the contextual cues 
formed when addicts repeatedly take drugs, which trigger cravings and prompt 
relapse. To a certain extent, these cues have good construct validity for 
cue-reactivity in humans, however cue-induced reinstatement is perhaps less 
representative of human behaviour. This is mainly due to the fact that animals 
undergo extinction training, which is not apparent in most humans, and no studies 
have investigated the possible consequences on the predictive validity of the 
behavioural model. There is still much to be discovered in the neuronal substrates 
involved in both animal reinstatement and human relapse, but what is currently 
known will be discussed below.  
See (2009) showed that antagonism of D1 dopamine receptors in the mPFC 
inhibited cue- and drug-primed reinstatement of heroin IVSA, demonstrating a role 
for dopaminergic signalling in in the PFC in cue-primed reinstatement. 
Interestingly, Shaham and Stewart (1996) found that dopamine receptor 
antagonists SCH23390 (D1 receptors), raclopride (D2) and haloperidol (D1 and 
D2) administered systemically blocked heroin-primed reinstatement of drug 
seeking in an intravenous self-administration paradigm, though this effect could be 
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due to an inhibition of the reinforcing effects of the heroin prime rather than an 
inhibition of the recall of the drug seeking behaviour. In the reinstatement of CPP, 
the role of dopamine becomes more controversial, since the reinstatement of CPP 
does not appear to be affected by DA receptor antagonists. Lesions of DA 
mesolimbic DA structures however block the reinstatement of CPP, adding 
confounding evidence to the role of dopamine. Ribeiro Do Couto et al. (2005) 
found that the dopamine receptor antagonists used in the study by Shaham and 
Stewart (1996) and the dopamine release inhibitor CGS10746B had no effect on 
the morphine-primed reinstatement of CPP in mice. The same study showed that 
the NMDA receptor antagonists memantine (20 and 40 mg/kg, i.p.) and MK-801 
(0.2 and 0.3mg/kg, i.p.) blocked morphine-primed reinstatement of CPP in mice, 
demonstrating an essential role of glutamatergic signalling in the reinstatement of 
CPP. The route of administration was however systemic and the brain region 
involved was not determined. Wang et al. (2002) performed electrolytic lesions of 
different brain regions in rats and found that lesions in the VTA and NAc shell (but 
not core) inhibited morphine-primed reinstatement, suggesting a possible role of 
dopaminergic signalling in drug-primed reinstatement of CPP. However, the brain 
regions were totally ablated in these lesion studies, therefore the damaged 
processes could be glutamatergic or GABAergic in nature (see Figure 1.3); and a 
more selective lesion of dopaminergic neurons is needed to study this matter 
further. Furthermore, electrolytic lesions can also damage nerve fibres surrounding 
the lesioned region, therefore the damage to off-target nerve fibres could be a 
contributing factor to the lack of reinstatement. 
Overall, there is a lack of definitive evidence implicating dopamine 
neurotransmission in the reinstatement of CPP with opiates. There are many more 
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studies which investigate and show a role of DA in cocaine reinstatement of CPP, 
therefore the lack of evidence with opiates could be explained by the 
generalisation of pathways involved in reinstatement for drugs of abuse. More 
recently, Assar et al. (2016) demonstrated that intracerebral infusions of 
SCH23390 (a D1 receptor antagonist) and sulpiride (a D2 receptor antagonist) into 
the CA1 of the dorsal hippocampus of male Wistar rats dose-dependently 
decreased the acquisition of morphine CPP. Infusions of SCH23390 before 
morphine-primed reinstatement of CPP dose-dependently attenuated the 
preference scores compared to saline-treated rats; however, these scores were 
still significantly different to the post-extinction test scores, suggesting the 
reinstatement of drug seeking behaviour was still occurring. With regards to the D2 
receptor, only the highest dose of sulpiride significantly inhibited morphine-primed 
reinstatement of CPP (Assar et al., 2016). Combined together, these data suggest 
that these D1/D2 receptors antagonists reducing the salient value of the morphine 
rather than affecting the motivation of the animal to seek the reward. 
Zhou et al. (2007) identified the role of cholinergic transmission in the NAc core by 
the administration of physostigmine (an acetylcholinesterase inhibitor), which 
inhibited cue-primed reinstatement of heroin IVSA. Context-induced reinstatement 
of heroin seeking was decreased by inhibiting glutamatergic transmission or 
dopamine receptors in the NAc shell but not core (Bossert et al., 2004, Bossert et 
al., 2007). 
Portugal et al. (2014) showed that morphine-primed reinstatement of CPP in mice 
was associated with a significant increase in long term potentiation in the dorsal 
hippocampus. Furthermore, the local inhibition of GluN2B subunit-containing 
NMDA receptors in the dorsal hippocampus blocked morphine-primed 
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reinstatement of CPP in mice (Portugal et al., 2014). Wright et al. (2018) showed 
by autoradiography that morphine-primed reinstatement of CPP in rats induced a 
significant increase in [3H]-AMPA binding in the ventral hippocampus (Figure 
1.12). These combined data indicate a strong link between glutamatergic synaptic 
plasticity in the hippocampus and morphine-primed reinstatement of CPP.  
Another study found using Western blots that morphine-primed reinstatement of 
morphine CPP in rats significantly increased GluN2B NMDA subunit expression in 
the NAc and hippocampus, but saw no change in the PFC or the amygdala (Ma et 
al., 2007). Stress-induced reinstatement on the other hand, increased GluN2B 
expression in the NAc and amygdala, suggesting a difference in the 
neurochemistry underlying the different stimuli for reinstatement. They found no 
change in GluN1 subunit expression in these regions. Systemic administration of 
the GluN2B subunit-selective NMDA receptor antagonist ifenprodil (1-10 mg/kg, 
i.p.) dose-dependently attenuated morphine-primed reinstatement, and at the 
highest dose, significantly decreased CPP scores compared to vehicle-primed rats 
(Ma et al., 2007). There was no effect of ifenprodil on forced-swim stress-induced 
reinstatement, again reinforcing the notion of differences in the neurotransmitter 
pathways involved in different types of reinstatement in the same paradigm. 
Further investigation of the brain regions involved showed that microinjections of 
ifenprodil into the NAc shell and CA1 region of the dorsal hippocampus; once per 
day for 3 days after extinction and prior to reinstatement significantly blocked 
morphine-primed reinstatement of CPP (Ma et al., 2007). These data suggest that 
an up-regulation of GluN2B-containing NMDA receptors in the NAc is a common 
phenomenon in stress and drug-primed reinstatement of CPP; however the 
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increase in expression in the hippocampus is specific to drug-primed 
reinstatement of CPP.  
The role of AMPA receptors in modulating motivational learning has been less 
extensively studied. Tzschentke and Schmidt (1997) found that the systemic 
administration of the non-selective AMPA receptor antagonist GYKI 52466 blocked 
the expression of morphine CPP in rats. Harris et al. (2004) showed that 
microinjections of the non-selective AMPA receptor antagonist CNQX into the VTA 
of rats inhibited the acquisition and expression of morphine CPP. At a molecular 
level, Billa et al. (2009) found that while the acquisition of morphine CPP in rats 
had no effect on AMPA receptor subunit expression in the hippocampus, saline 
extinction was associated with an increase in the phosphorylation of the GluA1 
subunit at serine 845 in postsynaptic fractions. They found no difference in the 
expression levels of GluA1 or GluA2 subunits during extinction. They also reported 
that repeated unpaired injections of morphine decreased the expression of GluA1 
and GluA2 subunits in postsynaptic fractions, suggesting an effect of morphine 
alone on AMPA receptor expression. In contrast, Moron et al. (2007) found that 
morphine administration increased GluA1 expression in the postsynaptic density in 
the mouse hippocampus (Moron et al., 2007). The above studies did not however 
observe the effect of inhibiting AMPA receptors or quantify AMPA receptor 
subunits after morphine-primed reinstatement of CPP. 
It is important to bear in mind that AMPA and NMDA receptor antagonists have 
been shown to impair memory in a variety of learning and memory tasks (for 
review, see Riedel et al. (2003)). The studies discussed above support the notion 
that neural pathways involved in the reinstatement of drug seeking are likely to be 
different (to a certain degree) to those mediating drug reinforcement and 
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extinction. There are two different processes occurring during saline extinction: the 
first is the original association is retrieved and the second is that a novel 
association is formed between the previously drug-associated environment and 
the new pairing with saline (Bouton, 2002). The new association interferes with the 
original one in the process of reconsolidation (Sara, 2000). It is probable that 
NMDA receptor antagonists disrupt the processing of conditioned responses 
brought into the reactivated state during extinction. The original preference could 
be reinstated by a morphine prime; however in AMPA or NMDA receptor 
antagonist-treated animals, the original association between the effects of 
morphine and the drug-paired chamber has been altered so as to block 
reinstatement (Cornish and Kalivas, 2000, Ribeiro Do Couto et al., 2005, Ma et al., 
2007, Engblom et al., 2008a). 
 
1.3.4.2. Drug-induced reinstatement of drug seeking 
Many studies have shown that drug priming injections act to renew the salience of 
the conditioned behaviour following abstinence (Stewart, 1983, de Wit and 
Stewart, 1983, Shaham and Stewart, 1996, Do Couto et al., 2003, Rogers et al., 
2008). Goddard and Leri (2006) passively administered cocaine intraperitoneally 
to rats and paired these infusions with a compound stimulus. They were then 
allowed to lever press for the conditioned stimulus under extinction conditions. 
After extinction, a single priming injection of cocaine reinstated lever pressing for 
the conditioned stimulus even though rats had not directly learned to lever press 
for cocaine (Goddard and Leri, 2006). This finding is in agreement with the current 
understanding that drug priming restores the incentive value of drug related cues 
and triggers the reinstatement of drug seeking.  
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As previously discussed, most (if not all) drugs of abuse activate the dopaminergic 
mesocorticolimbic pathways of the brain (Luscher and Malenka, 2011). There is 
some evidence of D1 receptor involvement in heroin-primed reinstatement. For 
example, the inhibition of D1 receptors in the mPFC inhibited the reinstatement of 
heroin self-administration (See, 2009). The selective D2 dopamine receptor 
agonist bromocriptine was found to reinstate heroin seeking (Wise et al., 1990), 
whereas D2-like antagonists (haloperidol and raclopride) block reinstatement 
(Ettenberg et al., 1996, Shaham and Stewart, 1996). Others found that heroin 
priming causes LTP-like changes in field excitatory postsynaptic potentials in NAc 
core neurons after mPFC stimulation, which was mediated by the inhibition of 
NMDA receptors in the NAc core (Shen et al., 2011). There is extensive literature 
on the potential use of dopamine receptor agonists and antagonists to treat 
addiction, however their success is limited by their poor efficacy and the significant 
adverse effects associated with dopaminergic medications. Dopamine receptor 
agonists can be used to alleviate the negative affective state associated with 
withdrawal, however these drugs may also exert reinforcing and psychotomimetic 
effects, limiting therapeutic use (Moreira and Dalley, 2015). Dopamine receptor 
antagonists are theorised to restore the abnormal dopaminergic signalling 
observed during addiction, however anhedonia, motor impairment and 
neuroendocrine balance render these compounds unattractive as addiction 
therapies (Moreira and Dalley, 2015). Investigation into additional pathways 
involved in reinstatement is therefore required to identify potential targets for the 
more effective treatment of addiction. 
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1.4. Cholinergic modulation of learning and memory 
processes 
1.4.1. Nicotinic receptors 
To date, 12 genes have been identified that code for subunits of mammalian 
neuronal nicotinic receptors, nine α (α2-10) and three β(β2-4) (Wonnacott et al., 
2005). These subunits combine in various permutations to form functional 
receptors, but the most widely expressed subtypes in the brain, and in the 
hippocampus in particular, are the homomeric α7 and heteromeric α4β2 nAChR 
(Albuquerque et al., 2009). These receptors have been implicated in a variety of 
diseases such as Alzheimer’s disease, schizophrenia, depression, nicotine and 






1.4.2. Cholinergic circuitry 
 
Figure 1.10: Overview of the main cholinergic pathways in the brain. Purple: cell 
bodies reside in the basal forebrain and project from the medial septum (ms), 
vertical limbs of the diagonal band of Broca (vdb), nucleus basalis of Meynert 
(bas) and substantia innominate (si) to the thalamus, hippocampus and throughout 
the cortex. The brainstem cholinergic system (green) is formed of cholinergic 
neurons in the laterodorsal tegmental (ldt) and pedunculopontine tegmental nuclei 
(ppt), which extend to the hindbrain, thalamus, lateral hypothalamus (LH) and 
forebrain. Cholinergic neurons in the striatum innervate local striatal neurons and 
the olfactory tubercle (not shown). Other abbreviations: BLA, basolateral 
amygdala; DR, dorsal raphe; EC, entorhinal cortex; hdb, horizontal limb of the 
diagonal band of Broca; lCj, islands of Calleja; IPN, interpeduncular nucleus; LC, 
locus coeruleus; SN, substantia nigra. (Woolf and Butcher, 2011).   
 
Acetylcholine (ACh) acts as a primary excitatory neurotransmitter in the 
neuromuscular junction and the parasympathetic nervous system (Wonnacott et 
al., 2005). In the central nervous system, nAChRs activated by acetylcholine can 
be excitatory like AMPA receptors, but are more often argued to play a 
neuromodulatory role, by modulating the excitation state of single or groups of 
neurons and their responses to further stimuli (Picciotto et al., 2012).  
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The development of the choline acetyltransferase (ChAT) antibody in the 1980s 
has allowed the identification of the major cholinergic cell bodies in the brain. 
Using immunohistochemistry in mammalian brain slices (rat, cat and monkey); 
Mammalian brains have been extensively immunolabelled to identify the main 
brain regions encompassing large numbers of cholinergic cells, and to determine 
their projections to other brain regions (Woolf, 1991, Woolf and Butcher, 2011). 
These projections are summarised in Figure 1.10. Although ChAT-positive 
neurons were found irregularly dispersed throughout some regions (such as the 
amygdala and globus pallidus), the cholinergic cell bodies could be summarised 
into three main areas of the brain.  
One main area is in the brainstem, more specifically the pedunculopontine 
tegmentum (PPT) and laterodorsal pontine tegmentum (LDT, green pathway, 
Figure 1.10), where cholinergic neurons innervate the thalamus and midbrain 
dopaminergic areas (Paul et al., 2015) and are involved in modulating REM sleep 
cycles, locomotor behaviour and in higher cognitive functions such as memory and 
gating sensory input (Garcia-Rill et al., 1987, Webster and Jones, 1988, Bosch 
and Schmid, 2008). Brainstem cholinergic neurons have also more recently been 
shown to provide direct innervation of the striatum and NAc using transgenic rats 
expressing fluorescent ChAT, and retrograde labelling (Dautan et al., 2014). The 
second major area of the brain is the basal forebrain (BF, purple pathway, Figure 
1.10), where cell bodies are concentrated into four regions: the medial septum 
(MS), vertical limbs of the diagonal band of Broca (vDB), nucleus basalis of 
Meynert (NBM) and the substantia innominate (SI), where cholinergic neurons 
project broadly and sparsely throughout the cortex, hippocampus, thalamus and 
olfactory bulb (Woolf, 1991, Paul et al., 2015). These cholinergic projections 
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appear to be involved in memory, arousal and other cognitive processes 
(Wonnacott et al., 2005). Finally, there is a collection of cholinergic interneurons in 
the striatum (Figure 1.10) which provide extensive innervation to local striatal 
neurons and to the olfactory tubercle; and these are involved in a variety of 
behaviours including locomotor behaviours (Vrijmoed-de Vries and Cools, 1986, 
Kelley et al., 1989, Albuquerque et al., 2009). 
Cholinergic neurons form loosely organised clusters of cells intertwined with 
monoaminergic neurons (Livingstone and Wonnacott, 2009). In particular, they 
co-exist with serotonergic neurons in the raphe nuclei, with noradrenergic neurons 
in the locus coeruleus (LC) and with dopaminergic neurons in the SN and VTA 
(Picciotto et al., 2012). Cholinergic neurons are few in numbers in the brain 
compared to other neuronal subtypes (glutamatergic and GABAergic, especially), 
but the number of cholinergic terminals in the brain is considerable as nearly all 
brain regions receive a cholinergic input (Woolf, 1991). Their influence on 
cognitive processes is therefore profound. This study will focus on the basal 
forebrain cholinergic projections, and more specifically, the septo-hippocampal 
pathway neurons projecting to the hippocampus (see Figure 1.10), due to their 
major roles in modulating learning and memory processes (Brayda-Bruno et al., 
2013).  
 
1.4.3. Acetylcholine receptors 
There are two classes of acetylcholine receptor, the fast-transmitting ionotropic 
nicotinic acetylcholine receptors (nAChRs), and the slower, modulatory G protein 
coupled receptor muscarinic acetylcholine receptors (mAChRs). There is evidence 
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of mAChR involvement in cocaine, opioid and ethanol addiction (Fink-Jensen et 
al., 2003, Dencker et al., 2011, Berizzi et al., 2018), particularly as they have been 
shown to modulate synaptic plasticity (Kauer and Malenka, 2007, Citri and 
Malenka, 2008) however this thesis will however focus on the role of nicotinic 
receptors.  
Nicotinic acetylcholine receptors are differentially localised within a neuron: on the 
soma, dendrites or synaptic terminals (Livingstone and Wonnacott, 2009). This 
diverse distribution of receptors can present a challenge to the functional 
interpretation of receptor activation; however it suggests a modulatory role of 
these receptors on the activity of a network rather than individual synaptic 
pathways. Presynaptic nAChRs induce the release of a variety of 
neurotransmitters when activated, such as GABA, glutamate, dopamine, 5-HT, 
norepinephrine and acetylcholine (Wonnacott et al., 2005, Albuquerque et al., 
2009). α7-nAChRs have been shown to modulate glutamate and GABA release on 
presynaptic terminals, whereas heteromers govern the release of other 
neurotransmitters as well (Albuquerque et al., 2009). Modulation of 
neurotransmitter release is potentially a method of nicotinic receptor-driven control 
of synaptic plasticity in specific brain regions. In rat hippocampal slices, the 
activation of α7nAChRs mediates a burst of glutamate release events, 
independent of incoming action potentials (Sharma and Vijayaraghavan, 2002). 
This burst of glutamatergic firing results in an increase in glutamate release and 
CAMKII-mediated release of neurotransmitters from presynaptic terminals. 
α7nAChRs are calcium-permeable receptors and activation of these receptors 
results in the slow, long-lasting influx of calcium, resulting in the release of calcium 
from intracellular stores (Sharma et al., 2008). Furthermore, the burst of 
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transmitter release is strong enough to induce depolarisation of the postsynaptic 
terminal in the absence of presynaptic action potential (Sharma et al., 2008), 
demonstrating how α7nAChRs have a robust control of neurotransmission in the 
CNS.  
Postsynaptic nAChRs depolarise neurons, can increase their firing rate and 
contribute to the expression of long-term potentiation (Albuquerque et al., 2009). A 
unique feature of α7nAChRs is that they are highly calcium-permeable, and as 
they are coupled to downstream calcium amplification mechanisms, they can 
trigger the release of intracellular calcium from the endoplasmic reticulum, 
resulting in a dramatic increase in free intracellular calcium concentrations (Dajas-
Bailador and Wonnacott, 2004, Sharma and Vijayaraghavan, 2008). This key 
feature of α7nAChRs makes them effective modulators of downstream calcium 
signalling cascades. 
α7nAChRs are widespread throughout the hippocampus, expressed on pyramidal 
neurons, granule cells and GABAergic interneurons (Figure 1.11). This review will 
focus on the direct α7nAChR-mediated effect on glutamatergic synapses, not the 
indirect effect of inhibitory interneurons activated by α7nAChRs. Acute nicotine 
application has been shown to increase the frequency of spontaneous miniature 
EPSCs in hippocampus neuronal cultures, suggesting these receptors are 




1.4.4. How does acetylcholine regulate learning and memory? 
 
Figure 1.11: Crossover of cholinergic (orange), glutamatergic (blue), dopaminergic 
(red) and GABAergic (green) pathways involved in learning and memory 
processes and nAChR subtypes present in each brain region. Taken from Holgate 
and Bartlett (2015). 
 
Basal forebrain cholinergic inputs have been demonstrated to play a major role in 
attention, learning, memory and consciousness. Neurotoxic lesions of the basal 
forebrain (BF) in rat brains by Bucci et al. (1998) induced a reduction in attention 
and the processing of a conditioned stimulus. Interestingly, the rats could still be 
conditioned to the cues when training procedures did not encourage attentional 
processing; which demonstrates that a level of memory processing is still intact. 
Other lesion studies of the BF have reported similar results in visuospatial 
attention (Chiba et al., 1999, Dalley et al., 2004) and spatial memory (Johnson et 
al., 2002, Chudasama et al., 2004).  
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Recently, Pitchers et al. (2017) demonstrated in a study that rats respond to 
motivationally salient information in different ways. They identified two types of 
responders: sign trackers (STs), which assert salient value to conditioned stimuli 
such as a lever, and have poor top-down executive control over behaviour, 
thought to be driven by dopamine, making them more impulsive; and goal trackers 
(GTs), which show more salience to the location of the reward delivery rather than 
the stimulus (e.g. a food cup) and display stronger top-down control over 
motivational behaviour, which is proposed to be controlled by cholinergic signalling 
(Flagel et al., 2011, Koshy Cherian et al., 2017). To test this distinction between 
ST and GT phenotypes, neurotoxic lesions of basal forebrain cholinergic neurons 
in rats were performed and their reinstatement responses to discrete cues in 
cocaine self-administration was measured (Pitchers et al., 2017). During 
reinstatement, GT animals showed significantly higher reinstatement responses to 
discrete cues than the ST animals. Furthermore, lesions of the basal cholinergic 
neurons led to the significant reduction of reinstatement in the GT group to the 
level seen in STs, suggesting the loss of cognitive control over motivational 
behaviour. The reinstatement response was the same in STs with lesioned BF 
cholinergic neurons and sham, suggesting no cholinergic modulation of behaviour 
in this group. This study shows strong evidence of basal forebrain cholinergic 
modulation of motivational behaviour; and in particular in the reinstatement of drug 
seeking behaviour; however the cholinergic receptor subtypes involved still need 
to be distinguished.  
Lesion studies of the septo-hippocampal pathway have shown it plays a major role 
in spatial memory (Johnson et al., 2002). Intra-hippocampal administration of 
nicotine enhances working memory, whereas the α4β2 and α7nAChR-selective 
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nicotinic antagonists DhβE and methyllycaconitine (MLA) have an inhibitory effect 
(Felix and Levin, 1997, Levin et al., 2002). A microdialysis study conducted by 
Fadda et al. (2000) showed that acetylcholine release in the hippocampus 
positively correlated to spatial learning and memory. The selective lesion of septal 
cholinergic neurons results in a loss of theta oscillations (4-10 Hz)  in the 
hippocampus (Apartis et al., 1998), which correlate with learning behaviours 
(Hernandez-Perez et al., 2016). Furthermore, the inhibition of choline uptake (to 
be re-synthesised into ACh) by hemicholinium-3 (HC-3) in the hippocampus of 
mice undergoing an inhibitory avoidance task led to long-lasting memory 
impairment despite choline uptake recovering 2 and 7 days post-injection (Boccia 
et al., 2004). This effect, and the fact that the HC-3 administration only had a 
deleterious effect on the behaviour immediately after memory reactivation, 
suggests that ACh synthesis plays a role in memory consolidation. Optogenetic 
activation of MS and vDB glutamatergic neurons resulted in the synchronisation of 
hippocampal theta oscillations in freely behaving mice, which is hypothesised to 
be via the modulation of local septal cholinergic pathways (Robinson et al., 2016).  
Moreover, in aged rats, there is significant cognitive impairment and decline which 
is positively correlated with a decrease in cholinergic markers in the 
septo-hippocampal region (Smith and Booze, 1995) and more recent lesion 
studies in rats show cognitive deficits, supporting these findings (Babalola et al., 
2012, Brayda-Bruno et al., 2013). 
These data provide evidence for a modulatory role of α7nAChRs in learning and 
memory processes. The next section will discuss the role of α7nAChRs in 




1.4.5. α7 receptors in reward 
There is extensive evidence of nicotinic receptors mediating the reinforcing effects 
of nicotine and being involved in nicotine dependence (Feduccia et al., 2012). The 
use of transgenic mice in nicotine addiction studies has revealed the differential 
effects of the different nicotinic receptor subtypes in regulating addictive 
behaviours. Mouse knockout studies of α4 or β2 subunits have revealed that while 
the  β2 subunit is important in the acquisition of nicotine self-administration and the 
initial stages of nicotine dependence (reviewed by Stoker and Markou (2013)), the 
α4 subunit is sufficient but not essential to these behaviours (Cahir et al., 2011, 
Madsen et al., 2015). Indeed, the majority of smoking cessation treatments such 
as varenicline, cysteine and sazetidine are targeted at α4β2 nAChRs (Rahman et 
al., 2015). 
α7 homomeric receptors appear to be involved in the later stages of nicotine 
addiction. α7 knockout mice are still able to acquire nicotine CPP (Walters et al., 
2006b) and nicotine self-administration (Pons et al., 2008), suggesting the 
acquisition of drug seeking behaviour is intact. Intra-VTA infusions of nicotine 
however, decreased nicotine self-administration in α7 knockout mice, suggesting 
these receptors might be important for modulating the reinforcing properties of 
nicotine (Besson et al., 2012). Furthermore, in these knockout mice, dopamine 
levels in the VTA were significantly higher in response to nicotine administration, 
suggesting a regulatory role of α7nAChRs on dopamine signalling in the VTA 
(Besson et al., 2012).  
Nicotinic receptors also modulate responses to other drugs of abuse (Rahman et 
al., 2015). For example, nicotinic receptors have been investigated as targets for 
treating alcohol addiction, as they have been shown to modulate the rewarding 
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effects of ethanol (Lě et al., 2006), and the non-selective nAChR antagonist 
mecamylamine has been shown to reduce ethanol self-administration and 
preference in rats (Ericson et al., 1998) and in humans (Young et al., 2006). In 
studies using cocaine, mecamylamine was shown to inhibit cocaine self-
administration (Levin et al., 2000) and decrease the acquisition of cocaine CPP 
(Zachariou et al., 2001), while DhβE reduced behavioural sensitisation to cocaine 
in rats (Champtiaux et al., 2006), involving nicotinic receptors in cocaine addiction 
and seeking behaviour. Chronic administration of low doses (0.03 and 0.1 mg/kg, 
p.o.) of varenicline (α7 agonist and α4β2*, α3β4 and α6β2partial agonist) had no 
effect on cocaine self-administration in primates, whereas higher doses (0.3 and 
0.56 mg/kg, p.o.) potentiated self-administration (Gould et al., 2011). 
Mecamylamine however had no effect on cocaine self-administration in monkeys 
(by either p.o., i.m. or i.v. administration), however the doses used were lower than 
the study performed in rats (Levin et al., 2000) and the administration of 
mecamylamine was chronic in the primate study rather than acute in the rodent 
study.  
 
1.4.6. α7nAChRs in reinstatement models 
Secci et al. (2017) used a kynurenine 3-monooxygenase (KMO) inhibitor, Ro 61-
8048 to elevate kynurenic acid levels in the brain, as kynurenic acid is 
hypothesised to act as a negative allosteric modulator of α7nAChRs. They used 
Ro 61-8048 to investigate its role in the reinforcement and reinstatement of 
nicotine and cocaine self-administration in rats and squirrel monkeys. They found 
that Ro 61-8048 dose-dependently inhibited nicotine self-administration in rats and 
monkeys (but not cocaine in monkeys), and the selective α7nAChR positive 
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allosteric modulator (PAM) PNU120596 restored this response in monkeys but not 
in rats, suggesting additional mechanisms to the downregulation of α7nAChRs 
may be exerting this effect on the acquisition of self-administration (Secci et al., 
2017). During reinstatement, Ro 61-8048 also significantly inhibited both drug and 
cue-primed reinstatement of nicotine IVSA (in rats and monkeys) and also cocaine 
self-administration (only in monkeys), and the α7nAChR PAM PNU120596 
rescued the effect of Ro 61-8048. This selective recovery of reinstatement by the 
α7nAChR PAM suggests more a selective modulation of reinstatement by 
α7nAChRs. A previous study also demonstrated a similar effect of kynurenic acid 
on cannabinoid self-administration and the reinstatement of cannabinoid seeking 
(Justinova et al., 2013). These findings potentially support a selective role of 
α7nAChRs in reinstatement, though there is limited research using kynurenic acid 
and as kynurenic acid also antagonises glutamate receptors in the brain 
(Albuquerque and Schwarcz, 2013), further work is needed to elucidate these 
findings further.  
Studies conducted by Liu et al showed that the nonselective nAChR antagonist 
mecamylamine and α4β2 nAChR antagonist DhβE significantly inhibited lever 
pressing during the acquisition of nicotine self-administration (Liu et al., 2007, Liu, 
2014). The α7nAChR-selective antagonist MLA, however, had no effect at this 
stage (Liu et al., 2007). Conversely, DhβE had no effect on the cue-primed 
reinstatement of nicotine IVSA, whereas MLA significantly and dose-dependently 
(2.5 and 10 mg/kg, i.p.) decreased the reinstatement of nicotine seeking (Liu, 
2014). These findings support differential roles for nAChR subtypes in nicotine 
reinforcement and cue-induced reinstatement of nicotine IVSA, and data from 
mouse knockout studies with respect to nicotine addiction (Stoker and Markou, 
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2013). This group has also identified an interaction of opioidergic and cholinergic 
pathways in the reinstatement of nicotine IVSA.  
These key findings have identified an intriguing role of α7nAChRs, which appear to 
selectively modulate the reinstatement of drug (nicotine and cocaine) seeking. 
This has yet to be shown in the reinstatement of seeking with opioid drugs and 
warrants further investigation. This study will focus on the role of α7nAChRs in the 
modulation of opioid seeking behaviour due to previous literature cited below.  
 
1.5. Work leading up to this thesis project 
1.5.1. MLA inhibits morphine-primed reinstatement of CPP 
We and others have shown that MLA, a potent and selective α7 nicotinic 
acetylcholine receptor antagonist, blocks morphine-primed reinstatement of CPP 
(as a correlate for relapse in response to contextual cues in humans) in mice and 
rats (Feng et al., 2011, Wright et al., 2018). Feng et al. (2011) found that MLA 
(4mg/kg, s.c.) pre-treatment 20 minutes prior to morphine-primed reinstatement 
significantly reduced the time spent in the drug-paired side in BALB/c mice. 
Interestingly, this inhibition of reinstatement lasted for three days after 
reinstatement, as subsequent morphine-primed reinstatement sessions were also 
inhibited in the absence of further MLA pre-treatment. Further work by Wright et al. 
(2018) extended the inhibition of morphine-primed reinstatement by MLA to 
C57BL/6J mice and Wistar rats. Furthermore, this study showed that  MLA had no 
effect on either the acquisition, expression, reconsolidation or extinction stages of 
CPP (Wright et al., 2018). These findings are compelling and suggest a possible 
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selective role of α7nAChRs in the reinstatement of CPP, which warrants further 
research.  
The overarching aim of this thesis is to gain a deeper understanding of the role of 
α7nAChRs in opioid dependence and relapse to inform potential therapeutic 
strategies. Morphine is a drug which is less commonly abused by addicts than 
other opioids, mostly due to its low potency and slow pharmacokinetics (Gottås et 
al., 2013). Heroin is more potent and reinforcing, with a rapid onset of action 
(Gottås et al., 2013) leading to it being widely abused, and is therefore a more 
relevant opioid in which to study the effects of MLA in behavioural paradigms of 
drug-seeking. The aim of this study is to extend findings on the role of α7nAChRs 
in the reinstatement of drug-seeking in behavioural paradigms used as human 
correlates of drug-seeking and relapse (Feng et al., 2011, Justinova et al., 2013, 
Liu, 2014, Secci et al., 2017, Wright et al., 2018). The CPP paradigm is a model of 
passive drug seeking triggered by contextual cues, whereas the IVSA paradigm is 
a more active model of drug seeking with volitional control of drug intake. Both of 
these paradigms may reveal intriguing aspects of the modulation of the 
reinstatement of drug seeking by α7nAChRs and should therefore both be studied.
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1.5.2. α7nAChRs modulate AMPA receptor expression in the ventral hippocampus during morphine-primed 
reinstatement of CPP 
 
 
Figure 1.12: A: Representative [3H]-AMPA binding density autoradiogram of binding following either MLA pre-treatment or 
morphine-primed reinstatement. Panels show coronal sections of the mPFC (top, bregma 1.94mm), striatum (second row, bregma 
1.42mm), dorsal hippocampus (third row, bregma -1.22mm) and ventral hippocampus (bottom, bregma -3.08mm). B: Quantitative 
AMPA receptor binding (fmol/mg tissue equivalent) shown for prelimbic cortex (PrL), infralimbic cortex (IL), ventral hippocampus 





Figure 1.13: Proposed model for the role of α7nAChR in modulating glutamatergic 
signalling in drug-primed reinstatement of CPP. During reinstatement, exposure to 
a priming dose of drug causes increased glutamatergic and dopaminergic 
signalling leading to restored LTP and the restoration of the drug-associated 
memory (following extinction), consequently triggering reinstatement. MLA blocks 
the action of ACh in the ventral hippocampus, which results in the inhibition of 
excitatory and inhibitory signalling required for LTP and the expression of the drug-
seeking behaviour (Wright, 2016). 
 
Recent data from our lab have shown a significant increase in [3H]-AMPA binding 
(Figure 1.12A) – but not [3H]NMDA binding – only in the ventral hippocampus after 
morphine-primed reinstatement of CPP, compared to the PFC (shown in Figure 
1.12B), other cortical regions, the dorsal hippocampus, CPu, NAc, amygdala and 
VTA (supplemental data shown in Wright (2016)); which is suggestive of an 
increase in AMPA expression. This increase in AMPA expression is postulated to 
be associated with the restoration of LTP and the drug-related memory triggered 
by the priming dose of morphine (see Figure 1.13). Interestingly, systemic 
treatment with MLA prior to morphine-induced reinstatement blocked this increase 
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in [3H]-AMPA binding (Figure 1.12A and B), suggesting α7nAChR modulation of 
the restoration of LTP in reinstatement, particularly in the ventral hippocampus. 
Autoradiography however does not distinguish cell surface from intracellular 
receptor expression, therefore it cannot be determined from these results than the 
increase in [3H]-AMPA binding correlates with an increase synaptic AMPA 
receptors, which underlies LTP. An additional aim of this thesis was therefore to 
address the limitations of autoradiography, which will be discussed further below. 
 
1.5.3. Aims of the Thesis 
There is a growing body of evidence that implicates α7nAChRs in modulating 
drug-associated behaviour (Rahman et al., 2015). The effects of 
methyllycaconitine (MLA) have been investigated in morphine CPP in mice and 
rats. The aim of this thesis is to extend this to a more relevant and reinforcing 
opioid, heroin.  
The aims of this thesis were to: 
1) Validate a heroin CPP model 
Heroin has rarely been used in conditioned place preference experiments. Of the 
few research papers studying heroin CPP (see Bardo et al. (1995) and Tzschentke 
(2007) for comprehensive reviews), only 2 to my knowledge studied heroin-primed 
reinstatement of heroin CPP (Leri and Rizos, 2005, van der Kam et al., 2009). This 
is partly due to the fact that in some countries, heroin is a restricted substance, 
whereas morphine is more widely available. In the first Results chapter (Chapter 2) 




2) Study the role of α7nAChRs in heroin-primed reinstatement of CPP 
The rat heroin CPP model was then utilised to investigate the role of α7nAChRs in 
heroin-primed reinstatement of CPP to extend results found by Feng et al. (2011) 
and Wright et al. (2018) in mouse morphine CPP. Results in Chapter 2 describe 
the effect of MLA on heroin-primed reinstatement of CPP. Based on previous 
literature and previous work in this lab, it was hypothesised that MLA would inhibit 
the heroin-primed reinstatement of CPP in rats. 
 
3) Optimise and validate methods of synaptic AMPA receptor quantification 
following reinstatement 
The location of α7nAChRs puts them in prime location to modulate synaptic 
plasticity implicated in motivational learning (Albuquerque et al., 2009), and 
previous findings by Wright et al. (2018) revealed a modulatory effect of 
α7nAChRs on total AMPA receptor expression in the ventral hippocampus in 
morphine-primed reinstatement of CPP. To investigate this role further, different 
methods of AMPA receptor isolation and quantification at the synapse were 
optimised and validated (Appendix A and B) to enable the quantification of AMPA 
receptors in the synapse following heroin-primed reinstatement of CPP in rats 
(Chapter 2). Based on previous findings in this lab (Wright et al., 2018), it was 
hypothesised that heroin-primed reinstatement would be correlated with an 






4) Study the role of α7nAChRs on heroin self-administration behaviours 
In Chapter 3, the effects of MLA were examined in this operant model of addiction, 
to complement the CPP study. The role of α7nAChRs on heroin IVSA was 
examined by studying the effect of MLA on the acquisition of lever pressing, the 
heroin- and cue-primed reinstatement of IVSA, the relative reinforcement of heroin 
(breakpoints of progressive ratio) and on the re-acquisition of heroin IVSA. It was 
hypothesised that as MLA inhibited the heroin-primed reinstatement of CPP but 
had no effect on the acquisition of heroin CPP (Chapter 2), it would inhibit the 
heroin- and cue-primed reinstatement of IVSA but have no effect on lever pressing 










2. CHAPTER 2 THE ROLE OF α7NACHRS DURING HEROIN-





2.1.1. Conditioned place preference 
A current major failure of addiction treatment is the lack of prevention of cravings 
which lead to relapse. Repeated drug consumption with the same contextual cues 
(locations, people, paraphernalia etc.) results in drug-paired associations which 
become cues for cravings (see Chapter 1, section 1.3.). In vivo behavioural 
paradigms are used to model various aspects of these drug-paired associations 
and how they can trigger relapse-like behaviour. This chapter describes the use of 
conditioned place preference (CPP) as a correlate of drug-associated memories 
and the role of α7nAChR in the reinstatement of this model.  
 
2.1.2. CPP as a correlate of drug-associated memory 
As described in Chapter 1 (Section 1.4.1) the CPP paradigm is a form of Pavlovian 
conditioning used to study motivational memory associated with a rewarding or 
aversive stimulus (for review, see Cunningham et al. (2006)). CPP has face 
validity for addiction processes in humans, as addicts report strong associations 
with environments in which they abuse drugs, which can trigger cravings (Bardo 
and Bevins, 2000). In fact, a human model of CPP has been explored (Childs and 
de Wit, 2009, 2013), where humans demonstrate a preference for a room in which 
they receive d-amphetamine compared to another room in which they receive 
placebo. The fact that CPP can be produced in humans reinforces the face validity 
of the rodent model, however it is important to remember that CPP is a correlate of 
a specific type of addiction-related behaviour which contributes to relapse, but it 
does not model addiction and relapse as a whole, especially as in CPP, the 
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behaviour is involuntary. However, there are many instances of drugs which have 
been shown to interfere with CPP in preclinical studies being FDA-approved 
addiction treatments, demonstrating the predictive validity of CPP (for review, see 
Tzschentke (2007)).  
CPP is limited by some factors. One concern is that some animals show an initial 
preference for one compartment during habituation (Napier et al., 2013); however 
using a balanced unbiased protocol can reduce the influence of pre-existing 
preference or aversion on the interpretation of results. The CPP procedure has 
also been argued to be relatively insensitive to drug dose, which potentially 
reduces its usefulness when measuring the value of a drug during conditioning 
(Napier et al., 2013). However the response magnitude is less important when 
measuring drugs that interfere with the expression of CPP once the behaviour has 
been acquired, and also when using priming stimuli to induce reinstatement after 
extinction. This distinction is clinically relevant as a drug that interferes with the 
conditioned behaviour in a drug-free state is more likely to reduce context-induced 
craving or relapse in an abstinent human. The focus of this thesis is to manipulate 
the drug-associated cues which trigger the reinstatement of drug-seeking 
behaviour therefore the magnitude of CPP is less important here. 
 
2.1.3. Nicotinic receptor role in opioid addiction 
There is evidence of interactions between opioids and nicotinic receptors. A study 
showed that methadone has non-competitive antagonist actions at α4β2 nAChRs 
and competitive antagonist actions at α7nAChRs in [3H]-epibatidine radioligand 
binding assays (Talka et al., 2015). Furthermore, methyllycaconitine (MLA), the 
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selective α7nAChR antagonist, blocked methadone-induced elevations of [Ca2+]i in 
calcium fluorescence assays. These results suggest a potential effect of 
methadone on nAChRs, however methadone has been shown to block various ion 
channels at medium and high concentrations (Matsui and Williams, 2010, Stoetzer 
et al., 2015), suggesting this effect may not be generalised to all opioids. 
In a model of withdrawal-induced conditioned place aversion (CPA), Ise et al. 
(2000) found that morphine pre-treatment could prevent 
mecamylamine-precipitated nicotine withdrawal CPA in rats chronically treated 
with nicotine. In addition, they showed that the non-selective opioid antagonist 
naloxone could also dose-dependently precipitate nicotine withdrawal CPA in 
these rats chronically treated with nicotine (Ise et al., 2000). Biala and Weglinska 
(2004) found that morphine, nicotine and MK-801 (an NMDA receptor antagonist), 
but not cocaine or amphetamine, enhanced locomotion in nicotine-experienced 
mice, which was blocked by L-type voltage-gated calcium channel blockers (Biala 
and Weglinska, 2004). Furthermore, Suh et al. (1996) found that nicotine 
enhanced the anti-nociceptive effects of morphine in tail-flick experiments in mice. 
In a passive avoidance task for the assessment of memory impairment, another 
study found that nicotine improved morphine-induced memory impairment 
(Ahmadi et al., 2007). These results suggest an interaction of the nicotinic and 
opioidergic systems in addiction.  
There is also extensive evidence of cross-reinstatement; the phenomenon of 
drugs other than those previously received which reinstate drug-seeking 
behaviour. Biala and Budzynska have repeatedly shown that morphine induced 
the reinstatement of nicotine CPP to the same extent as nicotine (Biala and 
Budzynska, 2006, Biala et al., 2009, Biala and Budzynska, 2010). They also 
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showed ethanol could reinstate nicotine CPP in mice (Biala and Budzynska, 
2010). To date, there is no evidence that nicotine priming reinstates morphine 
CPP (Feng et al., 2011), however Zarrindast et al. (2003) demonstrated that 
repeated doses of either morphine or nicotine to induce tolerance reduced the 
place conditioning effect of both morphine and nicotine in mice, suggesting some 
cross-tolerance between the effects of the two drugs and an interaction between 
opioid and nicotinic modulation of reward-seeking behaviour. This cross-tolerance 
was also observed by Vihavainen et al. (2008), who hypothesised this effect was 
not mediated by μ opioid receptors (MORs) due to no change in the number or 
affinity of  MORs following nicotine sensitisation by [3H]-DAMGO autoradiography 
in multiple brain regions. 
The mesocorticolimbic dopamine system is considered by some the major 
substrate of reward and reinforcement associated with drugs of abuse and natural 
rewards (Chapter 1, section 1.2.1, (Hyman et al., 2006, Stewart, 2008, Koob, 
2013)) and nicotinic receptors modulate dopaminergic signalling in these reward 
systems (Balfour, 2004, Hyman et al., 2006, Vihavainen et al., 2008). However 
other pathways (notably glutamatergic, see Section 1.2.3.) play increasingly 
important roles in the later stages of addiction, as there is little concrete evidence 
of dopaminergic signalling during the reinstatement of CPP (Section 1.4.4.). 
 
2.1.4. Evidence of glutamatergic signalling in the hippocampus in 
CPP 
As previously discussed in Chapter 1 (section 1.4.4.), there is extensive evidence 
of glutamatergic pathways modulating reward processes throughout the brain. 
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NMDA receptor involvement has been extensively studied in the modulation of 
morphine CPP. NMDA receptor antagonists have been shown to block the 
acquisition (Tzschentke and Schmidt, 1995, Zarrindast et al., 2007, Rezayof et al., 
2007, Kao et al., 2011), expression (Tzschentke and Schmidt, 1997, Rezayof et 
al., 2007, Portugal et al., 2014) and reinstatement (Ribeiro Do Couto et al., 2005, 
Popik et al., 2006, Ma et al., 2007, Portugal et al., 2014) of morphine CPP, 
involving brain regions such as the dorsal hippocampus (in acquisition, extinction 
and reinstatement), central amygdala (acquisition and expression), and NAc 
(acquisition and reinstatement). These data strongly indicate an important role of 
glutamatergic pathways in modulating opioid reward.  
Studies have shown that synaptic remodelling in the hippocampus is essential for 
the processing of cue-associated memories in the context of drug-related 
behaviours. Portugal et al. (2014) have shown that the acquisition of morphine 
CPP is associated with impaired LTP but increased basal synaptic transmission in 
field recordings in mouse hippocampus slices. Another study corroborating this 
finding reported a decrease in the number of dendritic spines in the CA1 region of 
the hippocampus following the acquisition of morphine CPP in mice (Fakira et al., 
2016); however, unpaired morphine administration also resulted in a reduction in 
dendritic spines, suggesting non-specific effects of morphine. The acquisition of 
morphine CPP was however shown to correlate with a significant increase in fos 
expression in the dentate gyrus of the septotemporal axis of the hippocampus 
(Rivera et al., 2015). Extinction is also associated with the disruption of LTP in the 
hippocampus, but morphine-primed reinstatement results in the robust 
enhancement of LTP in hippocampal slices, which is blocked by the local 
antagonism of GluN2B NMDA receptor subunits (Portugal et al., 2014), suggesting 
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this enhancement of LTP is NMDA receptor dependent. Furthermore, the inhibition 
of dorsal hippocampus activity by the administration of a GABAA agonist muscimol 
leads to the impairment of the acquisition, extinction and expression of cocaine 
CPP (Hitchcock and Lattal, 2018). These findings strongly support an important 
role of the hippocampus in all stages of CPP, though the majority of studies are 
conducted in the dorsal hippocampus.  
This thesis focuses on the role of synaptic plasticity in the ventral hippocampus in 
the reinstatement of CPP as previously in our lab, it was demonstrated that 
intracerebral infusions of the selective α7nAChR antagonist MLA into the ventral 
hippocampus only, resulted in the inhibition of morphine-primed CPP in rats 
(Wright et al., 2018). Furthermore, morphine-primed reinstatement of CPP was 
associated with a significant increase in [3H]-AMPA binding in the ventral 
hippocampus only, which was blocked by MLA (Wright et al., 2018).  
 
3.1.1. Evidence of α7nAChR in the reinstatement of CPP 
As discussed in Chapter 1 (sections 1.4.5 and 1.5), there are some reports 
suggesting a role of α7nAChR in CPP. A study found that the non-selective 
nAChR antagonist mecamylamine and the α4β2nAChR antagonist DhβE both 
inhibited the acquisition of nicotine CPP in mice, whereas the α7nAChR-selective 
MLA had no effect (Walters et al., 2006b). Furthermore, α7nAChR knockout mice 
were still able to acquire nicotine CPP, compared to β2 knockout mice, which were 
not (Walters et al., 2006b). Mice with α7nAChR knocked out from the NAc were 
unable to acquire nicotine CPP, but cocaine CPP was intact, suggesting a there 
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could be a role of α7nAChRs in the reinforcement of nicotine that is not 
widespread across all drugs of abuse (Harenza et al., 2014).  
Interestingly, recent studies have shown that MLA pre-treatment significantly 
attenuates morphine-primed reinstatement of CPP in mice and rats (Feng et al., 
2011, Wright et al., 2018). Wright et al. (2018) further demonstrated that MLA had 
no effect on the acquisition, expression, reconsolidation and extinction of 
morphine-primed reinstatement, which suggests an intriguing selective role of 
α7nAChRs in the reinstatement of CPP. In addition, morphine-primed 
reinstatement was associated with a significant increase in total [3H]-AMPA 
binding in the ventral hippocampus, which was blocked by MLA (Figure 1.12). 
These findings are compelling and form the basis of this thesis. 
 
2.2.  Aims of this chapter 
The main aim of this chapter was to investigate the role of α7nAChRs on the 
reinstatement of heroin-primed CPP in rats, extending previous findings with 
morphine (Feng et al., 2011, Wright et al., 2018). After establishing heroin CPP in 
rats, we hypothesised that: 
1) MLA would have no effect on the acquisition of heroin CPP 
This was investigated by MLA pre-treatment during conditioning of heroin CPP. 
2) MLA would inhibit heroin-primed reinstatement of CPP 
This was investigated by MLA pre-treatment 20 minutes prior to heroin-primed 
reinstatement of CPP.  
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The secondary aim of this chapter was to optimise and validate a method for 
quantifying synaptic AMPA receptors in brain slices from rats that underwent 
heroin-primed reinstatement; at a more sensitive subunit-specific level. We 
hypothesised that: 
1) Heroin-primed reinstatement would be associated with an increase in 
GluA1 and phosphorylated GluA1 (Ser845) at synaptic regions in the 
ventral hippocampus  
2) MLA pre-treatment would inhibit the reinstatement-induced increase in 
synaptic AMPA receptor expression 
This was investigated by the fixation of rat brains that underwent heroin-primed 
reinstatement of CPP, followed by immunolabelling of ventral hippocampus slices 
and visualisation by Li-Cor near-infrared scanning technology and confocal 
microscopy. 
 
2.3. Materials and Methods 
2.3.1. Statistical Analysis 
All CPP data are presented as mean ± standard error of the mean (SEM). Data 
were collected via a camera and analysed through a PC equipped with an auto-
monitoring system (Ethovision XT version 8.0). The conditioned place preference 
scores are presented as time spent in the drug-paired side-450 seconds (half of 
the post-test time) to give a preference score that represents an increase in time 
spent in the drug-paired side. Exclusions were made post-extinction if animals 
spent over 65% (10 minutes) of the total post-test test time (based on Cordery et 
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al. (2014)). Statistical outliers in each stage of conditioned place preference were 
determined using Grubbs’ test for outliers. During reinstatement, the last 
15 minutes of the reinstatement test was used for comparison with the post tests, 
as it has previously been shown by time course analysis of the reinstatement of 
morphine CPP that rats show more preference during the second half of the 30 
minute test (Mueller et al., 2002). All behavioural analysis was done in GraphPad 
Prism 5 by one- or two-way ANOVA with Bonferroni post-hoc analysis, where 
appropriate. 
Immunohistochemistry data were presented as means ± SEM. Two-way ANOVA 
analysis was used to determine an effect of treatment or differences between 
regions of the ventral hippocampus on the expression levels of total GluA1 and 
phosphorylated GluA1 at serine845.  
 
2.3.2. Drugs 
For CPP experiments, all drugs were dissolved in sterile sodium chloride solution 
(0.9% w/v, Hameln pharmaceuticals, Gloucester, UK) and filter sterilised using 
0.45 µm syringe filters (Millipore). Injections were administered subcutaneously 
(s.c.) and (heroin, MLA and saline) were given using a dose volume of 1mL/kg). 
The injection site (left or right side of the body) was alternated to allow the skin to 
recover before the next injection. Heroin hydrochloride (McFarlan Smith, UK) was 
stored in a locked cabinet while not in use. Heroin injections for conditioning and 
reinstatement (1mg/kg) were made up at 1 mg/mL and stored in 1 mL aliquots in 
sterile tubes at -20°C for up to one month. Methyll ycaconitine citrate (MLA, 
Abcam) was made up into 4mg/mL 1mL aliquots; which were then stored at -20°C 
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for a maximum of one month. Drugs were thawed at room temperature at least 30 
minutes before dosing. Aliquots were used once and were not returned to -20°C to 
prevent freeze-thawing of drugs. Heroin was used at a dose of 1mg/kg for both the 
conditioning and reinstatement phases as previous studies showed this dose was 
effective in producing CPP (Leri and Rizos, 2005, Tzschentke et al., 2006, Galaj et 
al., 2015, Galaj et al., 2016) and causing reinstatement (Leri and Rizos, 2005) 
 
2.3.3. Animals 
All experiments were performed in accordance with Home Office project licence 
held under ‘ASPA’ 1986 and approved by a local ethical review panel. Male Wistar 
rats (5-9 weeks) were bred from the University of Bath breeding colony. For CPP 
experiments, all animals were housed in fours in a behavioural holding room with 
controlled temperature (24±2°C), humidity (50-60%), and a 12:12h light-dark cycle 
(lights on 0700-1900). Food (standard rat chow) and water was available ad 
libitum. All animals were allowed to habituate to laboratory conditions for one week 
before experiments began during which they were handled daily in the 
experimental room. For the reinstatement of heroin CPP experiment, 48 rats were 
used before exclusions. For the effect of MLA on the acquisition of heroin CPP, 
24 rats were used (12 per treatment group). Animals were tested Monday-Friday 
and cages were cleaned weekly on Fridays after testing to allow a two day 




2.3.4. CPP apparatus 
The apparatus (MED Associates, UK) consisted of a two-compartment box 
(40x40 cm each), one with vertical and one with horizontal black and white stripes, 
separated by removable guillotine doors and a central neutral zone measuring 
(10x20 cm). The floors of each chamber were also different, one with 2 cm round 
holes or 1x1 cm square holes respectively (as shown in Figure 2.1). 
 
Figure 2.1: Rat CPP apparatus Left panel: rat CPP apparatus comprising of 
three compartments: one with circular holes in the floor and horizontal black 
and white stripes on the wall, one neutral middle compartment with a smooth, 
dark floor and one with square holes in the floor and vertical black and white 
stripes on the wall. Right panel: Layout of CPP boxes in the experimental 
room. CPP boxes are placed side by side, with alternate sides of the apparatus 
facing the wall in case of preference to one side of the room. Boxes were 
covered with Perspex lids to minimise noise and prevent rats from escaping. 
The boxes were places on rails with plastic sheets underneath to facilitate 
cleaning. Lights were dimmed by placing cardboard in front of the lamps, as 
seen in the right corner of the room. Cameras were mounted to the ceiling to 




2.3.5. CPP Procedures 
 
Figure 2.2: Diagram of the heroin CPP protocols for experiment 1 (top): the effect 
of MLA on the acquisition of heroin CPP, and experiment 2 (bottom): the effect of 
MLA on the heroin-primed reinstatement of CPP. Downward arrows ↓ represent 
saline or heroin injections during conditioning. Upward arrows ↑ represent MLA (or 
saline) injections 20 minutes prior to heroin.  
 
 
The CPP procedure consisted of six different trials: the Habituation trial 
(1x15 minute session/day for 2 days); Conditioning (1x40 minute trial/day for 
4 days), Post-conditioning test (1x15 minute trial), Extinction (1x30 minute trial/day 
for 4 days for mice and for 9 days for rats), Post-extinction test (1x15 minute trial) 
and Reinstatement (1x30 minute trial). The whole protocol and the steps used for 
each experiment are shown in Figure 2.2. Data was collected via a camera and 






On the first day of the study (Figure 2.2), each animal was placed in the CPP 
chamber and allowed to move freely between the two compartments for 
15 minutes, whilst the cameras tracked their movements. The software tracked the 
time spent in either compartment (in seconds), and the total distance moved (in 
centimetres), which determined any initial preference or aversion to one particular 
compartment. This test was then repeated the next day and the means of the data 
obtained on both days allowed the assignment of treatment groups in a 
pseudo-randomised trial for a counterbalanced design, where half the animals 
were conditioned to the horizontal-striped compartment, and half to the 
vertical-striped compartment; but also, where preference for a particular 
compartment was balanced by conditioning half the animals to their preferred side 




On day 5 (see Figure 2.2), rats received either saline (1mL/kg, s.c.) or heroin 
(1 mg/kg, s.c.) and were restricted to their corresponding compartment for 
40 minutes. On the following day, those that received heroin received saline and 
were restricted to the opposite side of the CPP apparatus. This was repeated over 
four days so rats all received two injections of heroin and two injections of saline 
during the conditioning sessions. After each session, the rats were returned to 




2.3.5.3. MLA pre-treatment 
The effects of MLA on the acquisition of heroin CPP in rats was tested in a 
separate cohort of 24 male Wistar rats (6-7 weeks old). After habituation, animals 
were pseudo-randomly allocated to one of two treatment groups. Group 1 received 
MLA (4 mg/kg, s.c.) 20 minutes prior to heroin conditioning (1 mg/kg, s.c.) and 
group 2 received saline (1 ml/kg, s.c.) 20 minutes prior to heroin conditioning 
(1 mg/kg, s.c.) and were then placed in the conditioned side for 40 minutes (as 
discussed in the previous section). Rats were also pre-treated before saline 
administration in the unpaired side. This was repeated over 4 days as shown in 
Figure 2.2. All pre-treatments and conditioning doses were administered daily in 
the experimental room and in between the pre-treatment and treatment injections 
animals were returned to their home cages. 
 
2.3.5.4. Post-conditioning test 
24 hours after the last conditioning day, the guillotine doors were removed and 
animals were allowed to roam freely in the CPP apparatus for 15 minutes. The 
time spent in each chamber and the total distance moved was recorded and 
analysed using the Ethovision software. A preliminary paired t test compared 
conditioning scores to habituation to determine the success of conditioning before 





Two days after the post conditioning test, rats received daily injections of saline 
(1mL/kg, s.c.) for 9 days (days 12-22, excluding the weekend, see Figure 2.2) and 
were restricted to either side of the CPP apparatus on alternating days. 
 
2.3.5.6. Post-extinction test 
24 hours after the last extinction session, the guillotine doors were removed and 
animals were allowed to roam freely in the CPP apparatus for 15 minutes and 
were tracked using the Ethovision software. Only animals meeting the criterion 
of <65% of the total post-test time (Cordery et al., 2014) were used in the 
reinstatement phase.  
 
2.3.5.7. Reinstatement 
On reinstatement day (day 26, see Figure 2.2), rats were randomly assigned to 
one of four treatment groups. Figure 2.3 shows the injection protocol for the 
treatment groups described below. Groups received either saline or MLA 
20 minutes prior to heroin or saline priming. Treatment groups were: the saline 
control group (S+S), which received saline (1 mL/kg, s.c.) followed by a priming 
dose of saline (1 ml/kg, s.c.); the heroin reinstatement group (S+H), which 
received saline (1 ml/kg, s.c.) before a priming dose of heroin (1mg/kg, s.c.); the 
MLA control group (MLA+S), which received MLA (4mg/kg, s.c.) followed by a 
saline priming dose (1 mL/kg, s.c.) and  the MLA reinstatement group (MLA+H), 
which received MLA (4mg/kg, s.c.) before a priming dose of heroin (1 mg/kg, s.c.). 
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Rats were placed free-roaming in the CPP apparatus immediately after their 
priming dose and were recorded for 30 minutes for a single reinstatement session. 
  
 
Figure 2.3: Injection protocol investigating the effect of MLA pre-treatment on the 
heroin-primed reinstatement of CPP. Treatment groups were: S+S: Saline control; 
S+H: heroin-primed reinstatement; MLA+S: MLA control; MLA+H: MLA 







2.3.6.1. Perfusion fixation 
Immediately following reinstatement, rats were perfused with paraformaldehyde 
(PFA) under terminal anaesthesia. Animals were anaesthetised by the inhalation 
anaesthetic isoflurane (Abbott, 2-3 cc/min, 1000cc/min O2) and depth of 
anaesthesia was established by checking blinking reflexes and tail and foot 
withdrawal reflexes in all animals. Once anaesthetised, the chest cavity was 
opened and the ribcage removed to expose the heart. The right atrium of the heart 
was pierced using scissors or a large gauge syringe needle until blood was 
observed. A 25 gauge syringe needle (Terumo 26 x 5/8”) connected to a 60 mL 
syringe filled with ice cold 0.1M PBS was placed into the left ventricle of the heart 
and the PBS was washed through at a rate of 2mL/minute. Systemic blood 
washout was considered successful when the liver lightened in colour, and death 
confirmed with the cessation of breathing and cardiac arrest and then the animal 
was perfused with 4% PFA (approx.. 60 mL) until the body was rigid. The brain 
was then removed and fixation was deemed successful if the brain was a pale 
white colour. Brains were then stored in 4% PFA at 4°C until further use. 
 
2.3.6.2. Sectioning 
One day prior to immunohistochemistry experiments, the brains were transferred 
to a 30% sucrose solution in 0.1 M TBS overnight. The following day, the brains 
were sectioned into 40 µm slices in cold 0.1M PBS using a Vibratome. Rat brain 
regions (prefrontal cortex: coronal sections, bregma +1.94 mm; ventral 
hippocampus, horizontal sections, bregma -3.08 mm) were determined using a rat 
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brain atlas. Slices were transferred to a 24 well plate containing 0.1M PBS with 1% 
sodium azide before immunolabelling. 
 
2.3.6.3. Immunolabelling for Li-Cor visualisation 
Slices were incubated for 1 hour at room temperature in blocking solution 
(0.1M TBS, 5% normal donkey serum (Sigma), 0.1% TX-100). Slices were then 
washed 3 times (0.1M TBS, 0.3% TX-100) and incubated on a shaker overnight at 
4°C with the primary antibodies: Rabbit anti-GluA1 (1:1000, Millipore) or rabbit anti 
GluA1 PhosphoSer845 (1:1000 Millipore) in 0.1M TBS with 2.5% normal donkey 
serum and 0.3% TX-100. The following day, the slices were washed 4 times every 
15 minutes with TBST (0.1M TBS and 0.05% Tween 20), then incubated at room 
temperature for 1-2 hours with the secondary antibodies raised against that of the 
primary antibodies: donkey anti-rabbit (1:1000, Li-Cor) in 0.1M TBS with 
2.5% normal donkey serum and 0.1% TX-100. Following four washes with TBST, 
slices were placed in 0.1M TBS before being mounted onto microscope slides, 
washed with distilled water and air dried. Slides were then sealed with mounting 
medium (Vectashield) and sealed for future analysis. According to the 
manufacturer, slices are viable for scanning for up to a year stored at 4°C, but 
slices were scanned usually 24 hours after being mounted. 
 
2.3.6.4. Immunoblotting for confocal visualisation 
Slices were incubated for 1 hour at room temperature in blocking solution 
(0.1M TBS, 5% normal goat serum (Sigma), 0.1% TX-100). Slices were then 
washed 3 times (0.1M TBS, 0.3% TX-100) and incubated on a shaker overnight at 
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4°C with the primary antibodies: Rabbit anti-GluA1 (1:500, Millipore), or rabbit 
anti-GluA1 PhosphoSer845 (1:500 Millipore) co-labelled with mouse anti-PSD-95 
(1:200, Abcam) in 0.1M TBS with 2.5% donkey serum and 0.3% TX-100. The 
following day, the slices were washed 4 times every 15 minutes with TBST (0.1M 
TBS and 0.05% Tween 20), then incubated at room temperature for 1-2 hours with 
the secondary antibodies raised against that of the primary antibodies: Alexa red 
568-tagged goat anti-rabbit (1:500, Life) and Alexa 488-tagged goat anti-mouse 
(1:500, Life). Following four washes with TBST, slices were rinsed in 0.1M TBS 
before being mounted onto microscope slides with mounting medium (Vectashield 
Hardmount), stored at 4°C and visualised 24-48 hour s after staining. 
 
2.3.6.5. Li-Cor visualisation 
Slides were scanned using a Li-Cor Odyssey Clx infrared scanner at 21 µm 
resolution at 700 nm wavelength. The detailed analysis of images is explained in 
Appendix B. An area outside of the brain slice was assigned as zero and regions 
of interest were highlighted for signal intensity measurements. These 
measurements were divided by the size of the highlighted area in pixels, giving a 
signal/pixel measurement. Background signal was subtracted Data were analysed 
by two-way ANOVA with Bonferroni post-hoc analysis compared to saline control.  
 
2.3.6.6. Confocal visualisation 
A confocal imaging system (Leica LSM880) with a x63 oil immersion lens was 
used for image acquisition. The detailed description of this method is in Appendix 
B. Each image was collected by averaging 5 scans at a resolution of 1024x1024 
78 
 
pixels. Regions of interest (dendritic layers of the CA1, CA3 and dentate gyrus) 
were scanned by lasers at 568 (GluA1 and GluA1 phosphoSer845, red), 488nm 
(PSD95, green) and 560nm (DAPI, blue). Slices were stained in duplicate and 
each slice was imaged in three different sites of each region of interest. To control 
for variability in brightness and contrast between images, all measurements were 
expressed in terms of ratios. All measurements were made using Fuji ImageJ and 
the colocalisation of the GluA1 signal with the PSD95 signal was used to 
normalise signals between slices. The Pearson’s R value using Costes regression 
analysis was used as a measure of protein colocalisation; where a value of -1 
indicated a total lack of protein colocalisation 1 a total protein colocalisation. 
Dendritic regions not containing cell bodies (identified by the absence of DAPI 
staining) were selected for quantification and the means of between 3-7 images 
was used. Data were analysed by two-way ANOVA with Bonferroni post-hoc 






2.4.1. Acquisition and extinction of heroin CPP 
 
Figure 2.4: Preference scores for the habituation (mean of days 1 and 2), post-
conditioning test (day 9) and post-extinction test (day 23). Data points are 
individual rat responses with mean±SEM overlaid. One-way ANOVA with 
Bonferroni post-hoc analysis vs habituation **p<0.01, n=38.  
 
The initial aim of this study was to validate heroin CPP in rats (Figure 2.4). During 
habituation, on average, the rats showed no preference for the drug-paired 
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chamber. Preference for the drug paired side appeared evenly distributed among 
rats, suggesting effective counterbalancing of the designated drug-paired 
chamber. In the post-conditioning test, rats spent on average 95 seconds longer in 
the drug-paired side compared to habituation; demonstrating a significant increase 
in preference for the drug-paired side. The spread of the post-conditioning 
preference scores showed that although this dose of heroin was effective in 
producing CPP, it was perhaps not optimal. This said, 63% of all rats showed a 
positive preference score, and 54% of these positively scoring rats showed robust 
preference (>100 seconds). There were still a proportion of rats (37% of total) that 
appeared to show aversion for the drug-paired side (negative preference values). 
Importantly however, these were the rats that showed a negative preference score 
during the post-conditioning test, but there was still an overall increase in 
preference relative to their habituation scores, therefore they were kept in the 
study. During the post-extinction test, the mean preference score was significantly 
reduced compared to habituation. There was no difference between mean post-
extinction and habituation preference scores. Again, the preferences were spread 
over a range of positive and negative scores, though the overall trend was a 
decrease in preference relative to the post-conditioning test, demonstrating a 
relative decrease in preference for the drug-paired side. The rats that showed the 
lowest negative scores were those that showed negative scores during 
habituation.  
Overall, these initial results showed that the conditioning dose of 1mg/kg heroin 
was effective in producing CPP in rats. Importantly, the CPP was not too robust, 
as the behaviour was extinguishable, an important factor for the study of 
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reinstatement. As the CPP was deemed successful, rats were progressed onto 
reinstatement, to study the effects of antagonising α7nAChRs on this behaviour. 
 
2.4.2. Pseudo-random assignment of treatment groups 
Following extinction, rats were pseudo-randomly assigned to one of four treatment 
groups: saline control (S+S), heroin reinstatement (S+H), MLA control (MLA+S) 
and MLA reinstatement (MLA+H), where they received either saline (S) or MLA 
20 minutes prior to a saline prime (S) or heroin prime (H) (see Figure 2.3 in 
methods section 2.3.5.7 for further detail). The study was pseudo-randomised by 
ensuring the preference scores observed during the habituation test, 
post-conditioning and post-extinction tests were all balanced, as demonstrated in 





Figure 2.5: Comparison of preference scores during habituation, post-conditioning 
and post-extinction tests for the pseudo-random assignment of treatment groups 
for reinstatement. Data points are individual rat responses with mean±SEM 
overlaid. Two-way ANOVA showed no difference between assigned groups. S+S: 
saline control group: n=10; heroin reinstatement group: S+H n=9; MLA control 
group: MLA+S n=9; MLA reinstatement group: MLA+H n=10.  
 
Figure 2.5 shows the habituation, post-extinction and post-conditioning preference 
scores for rats assigned to treatment groups. Two-way ANOVA analysis showed 
no difference in the preference scores between treatment groups, and the data 
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was evenly spread between treatment groups, suggesting the study was correctly 
balanced. 
To date, only 2 studies have investigated heroin-primed reinstatement of heroin 
CPP (to my knowledge) (Leri and Rizos, 2005, van der Kam et al., 2009). van der 
Kam et al. (2009) found that 0.25mg/kg heroin significantly reinstated heroin CPP 
in rats conditioned with 0.25mg/kg heroin. However, systematic review of this dose 
showed that it did not always produce CPP in rats (Bardo et al., 1995, Tzschentke, 
2007). Leri and Rizos (2005) tested 2 different priming doses of heroin (0.3 and 
1 mg/kg, s.c.) to reinstate CPP in rats conditioned with 1 mg/kg heroin. They found 
that only the dose of 1 mg/kg heroin produced significant reinstatement of CPP. 
Another study supporting this priming dose found that 1 mg/kg heroin caused the 
significant reinstatement of CPP in rats conditioned with morphine (Lu et al., 
2002). The heroin priming dose of 1 mg/kg was therefore chosen for this study and 




2.4.3. Effect of MLA on heroin-primed reinstatement of CPP 
 
Figure 2.6: Effect of MLA on heroin-primed reinstatement of CPP. Treatment 
groups were saline control (S+S, n=10), heroin reinstatement group (S+H, a 
Grubb’s outlier test showed one rat to be an outlier, therefore n=8 for 
reinstatement), MLA control group (MLA+S n=9) and MLA reinstatement (MLA+H 
n=10). Data points are individual rat responses with mean±SEM overlaid. Two-way 
ANOVA with Bonferroni post-hoc analysis vs post-extinction †††p<0.001; vs S+H. 
**p<0.005, ***p<0.001. 
 
The saline control group (S+S, Figure 2.6) showed no increase in preference for 
the drug-paired side compared to saline extinction, showing no effect of saline 
priming on reinstatement. In the heroin reinstatement group (S+H) there was a 
significant increase in the time spent in the drug-paired compartment compared to 
post-extinction, and compared to the saline control group. This demonstrated a 
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significant reinstatement of drug seeking behaviour in this treatment group. 
Interestingly, the reinstatement response was four times greater than the post-
conditioning preference scores, suggesting a robust recall of the drug-related 
behaviour. MLA pre-treatment had no effect on the reinstatement of CPP in saline-
primed animals, but significantly inhibited heroin-primed reinstatement of CPP 
(MLA+H).  
These results show that the selected priming dose of heroin (1 mg/kg, s.c.) was 
effective in reinstating CPP. They also demonstrate that MLA alone has no 
reinforcing or aversive properties as it failed to induce reinstatement. MLA 
pre-treatment was effective in significantly inhibiting reinstatement of 
heroin-primed CPP. This inhibition of reinstatement by MLA could be explained by 
MLA blocking the rewarding properties of heroin and therefore reducing the 
motivation to seek the heroin-paired chamber. To test this, the effect of MLA was 
investigated on the acquisition of CPP.  
 
2.4.4. Effect of MLA on the acquisition of heroin CPP.  
As the inhibition of heroin-primed reinstatement by MLA could be explained by the 
decrease in the rewarding effects of heroin, the effect of MLA on the acquisition of 
heroin CPP was tested. A new group of rats was used for this study (see methods 
section 2.3.5.3). Briefly, after habituation, rats (n=24) were pseudo-randomly 
allocated a treatment group, and received either saline (S+H, 1 mL/kg saline s.c.) 
or MLA (MLA+H, 4 mg/kg s.c.) 20 minutes prior to conditioning, where they 
received a heroin injection (1 mg/kg s.c.) and were confined to their assigned 
drug-paired side or a saline injection (1 mL/kg, s.c.) and were confined to the 
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unpaired side for four consecutive days. MLA was administered before both heroin 
and saline conditioning days. On the fifth day they were placed free-roaming in the 
chamber for 15 minutes in the post-conditioning test.  
 
 
Figure 2.7: Effect of MLA pre-treatment on the acquisition of heroin CPP. Rats 
underwent 2 habituation sessions (drug-free) and were then pseudo-randomly 
assigned a treatment group: Saline-pre-treatment (orange circles) or MLA (4 
mg/kg, s.c.) pre-treatment (blue squares) 20 minutes prior to all conditioning 
sessions. Data points are individual rat responses with mean±SEM overlaid. 
Paired t test habituation vs post-conditioning for each treatment group *p<0.05, 
S+H n=12, MLA+H n=12.  
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All rats underwent habituation and were then pseudo-randomly assigned a 
treatment group so there was no difference in habituation preference scores 
(Figure 2.7). In the post-conditioning test, both the saline and MLA pre-treatment 
groups showed a significant increase in preference for the drug-paired side 
compared to their respective habituation scores. Importantly, there was no 
difference in the post-conditioning preference scores between both treatment 
groups, demonstrating that MLA had no effect on the acquisition of heroin CPP. 
These results, combined with the previous section (2.4.3) demonstrated that MLA 
did not inhibit the heroin-primed reinstatement of CPP by reducing the rewarding 




2.4.5. Effect of MLA on locomotion during heroin CPP 
2.4.5.1. Habituation, extinction and acquisition 
 
Figure 2.8: Total distance moved (cm) during habituation, post-conditioning and 
post-extinction tests. Data points are individual rat responses with mean±SEM 




The habituation, post-conditioning and post-extinction tests were all carried out in 
a drug-free state. There was a slight decrease (by 10%) in the distance travelled in 
the post-conditioning test, compared to habituation (Figure 2.8). There was a 
significant 14% decrease in the distance moved during the post-extinction phase 




Figure 2.9: Effect of MLA pre-treatment on the distance moved during the 
acquisition (post-conditioning) of heroin CPP. Rats underwent 2 habituation 
sessions (drug-free) and were then pseudo-randomly assigned a treatment group: 
Saline-pre-treatment (orange circles) or MLA (4 mg/kg, s.c.) pre-treatment (blue 
squares) 20 minutes prior to all conditioning sessions. Data points are individual 
rat responses with mean±SEM overlaid. Paired t test, n=12 in each group.   
 
In rats that received either saline or MLA pre-treatment during the heroin 
conditioning phase (Figure 2.9), there was no difference in locomotion between 
both treatment groups during the post-conditioning test. Importantly, the post-test 
was administered in a drug-free state; therefore it cannot be determined whether 
MLA had any effect at this stage. It appears that there were no long-term effects of 





Figure 2.10: Total distance moved during heroin-primed reinstatement of CPP. 
Treatment groups are saline (S+S, n=10), heroin reinstatement group (S+H n=8), 
MLA control group (MLA+S n=9) and MLA pre-treatment on heroin reinstatement 
(MLA+H n=10). Data points are individual rat responses with mean±SEM overlaid. 
One-way ANOVA with Bonferroni post-hoc analysis vs S+S *p<0.05. 
 
During the reinstatement phase, the fact that some rats were in a drugged state 
(S+H and MLA+H) and others were undrugged (S+S and MLA+S) must be 
considered when comparing their distance travelled. There was no difference in 
the distance travelled between the saline control (S+S, Figure 2.10) and MLA 
control (MLA+S) groups, suggesting a lack of effect of MLA on this behaviour. 
There was however a significant decrease in locomotion in the heroin 
reinstatement group (S+H, Figure 2.10) compared to MLA reinstatement (MLA+H), 
suggesting a potential effect of heroin on the locomotion of the animals. The 
interesting effect was that the MLA reinstatement group (MLA+H) showed no 
difference in distance travelled compared to saline control and MLA control, 
suggesting a potential reversal of the effect of heroin on the distance moved 
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during reinstatement. The reduction in locomotion during heroin-primed 
reinstatement could potentially be explained by the drug conditioned memory 
being re-activated, leading animals to travel directly to the drug-paired side and 
remain in this compartment. MLA potentially blocks this re-activation of the drug-
associated memory; therefore animals spend more time exploring the apparatus. 
This was investigated by measuring the number of crossovers between CPP 
compartments.  
 
Figure 2.11: Number of zone transitions during reinstatement. Treatment groups 
are saline (S+S, n=10), heroin reinstatement group (S+H n=8), MLA control group 
(MLA+S n=9) and MLA pre-treatment on heroin reinstatement (MLA+H n=10). 
Data points are individual rat responses with mean±SEM overlaid. One-way 
ANOVA with Bonferroni post-hoc analysis comparing S+H vs MLA+H *p<0.05 
 
When analysing the number of transitions between CPP compartments, there was 
a significant decrease in transitions in the heroin reinstatement group (S+H, Figure 
2.11) compared to the saline control group (S+S). This suggests a reduction in the 
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exploration of the CPP apparatus. There was no effect of MLA alone on the 
number of transitions. In the MLA reinstatement group (MLA+H), there was no 
difference in the number of transitions compared to saline (S+S), suggesting a 
potential reversal of the effect seen in the S+H group; however there was also no 
significant difference compared to the heroin reinstatement group, mostly due to 
the increased variability observed in the MLA+H group.  
 
2.4.6. Quantification of AMPA receptors 
Following reinstatement, rats were immediately perfused with 
4% paraformaldehyde (PFA) under terminal anaesthesia (inhalable isoflurane, 2-3 
cc/min, 1000cc/min O2) to fix the brain tissue (see methods section 2.3.6.1). Brains 
were then sliced and immunolabelled for GluA1 AMPA receptor subunits, as these 
are shown to be increased at the synapse during LTP (Citri and Malenka, 2008, 
Henley and Wilkinson, 2013) and GluA1 AMPA receptor subunits phosphorylated 
at Ser845 as these are shown to be involved in the priming of AMPA receptors for 
LTP (increase channel open probability Roche et al. (1996)) and to be involved in 
the trafficking of AMPAR to the synapse (Roche et al., 1996, Oh et al., 2006, 
Derkach et al., 2007). Brains were then probed with the appropriate secondary 
antibodies for visualisation by either Li-Cor near-infrared scanning technology or 
confocal microscopy (details in methods section 2.3.6.3 and 2.3.6.4, respectively). 
The optimisation of both methods is described in Appendix B. Each brain slice was 
visualised by both methods to allow a comparison of the sensitivity of the 
visualisation method and to probe whether both methods would detect comparable 
changes in AMPA receptor expression. 
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2.4.6.1. Li-Cor quantification of AMPA receptor subunits 
 
Figure 2.12: Quantification of GluA1 and representative visualisation of GluA1 (A) and GluA1 phosphoSer845 (B) in the CA1, 
CA2/CA3 and dentate gyrus (DG). Images were scanned on a Li-Cor Odyssey Clx scanner at 700nm at 21μm resolution. Two-way 




Whole brain slice quantification of GluA1 subunits (Figure 2.12A) by Li-Cor 
near-infrared scanning technology in the ventral hippocampus showed the lowest 
levels of GluA1 expression were in the saline control group (S+S), through all 
3 regions of the ventral hippocampus. In the heroin reinstatement group (S+H) 
there was a 1.7-fold increase in GluA1 expression in the CA1, and a 1.6-fold 
increase in the CA2/CA3 and dentate gyrus, compared to saline control. There 
wasno significant change in GluA1 expression in the MLA control (MLA+S) and 
MLA reinstatement (MLA+H) groups compared to heroin reinstatement (S+H) due 
to large variability.  
GluA1 phosphoSer845 expression in the ventral hippocampus (Figure 2.12B) was 
also the lowest in the saline control group and remained consistent across all three 
regions of the ventral hippocampus. There were similar trends of expression were 
observed in all three regions between treatment groups. There was a slight 
increase in expression in the heroin reinstatement group (S+H) and the MLA 
reinstatement group (MLA+H), and a decrease in the MLA control group (MLA+S). 
Levels in the MLA reinstatement group (MLA+H) however were the highest, but 





Figure 2.13: Phosphorylated GluA1 signal normalised to GluA1. Two-way 
ANOVA, n=5 rats per treatment group. 
 
GluA1 PhosphoSer845 signals normalised to GluA1 (Figure 2.13) allowed the 
reduction of the variability in signal intensity between slices. In the CA1, in heroin-
primed animals, there was a ~30% decrease in phosphorylated GluA1 compared 
to saline control, though there was no significant difference. There was no change 
in phosphorylated GluA1 in the MLA control group or in the MLA reinstatement 
group. In the CA2/CA3 and dentate gyrus, there appeared to be a similar trend, 
but the MLA control group showed similar expression of phosphorylated GluA1 to 
the heroin reinstatement group. There appeared to be a trend of was a slight 
decrease in phosphorylated GluA1 in the heroin reinstatement group (S+H) in the 
CA1 by 30%, and in the CA2/CA3 and dentate gyrus, to a lesser extent (20%). 
Again, due to variability, these results were not significant.  
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There were consistent levels of GluA1 and GluA1 PhosphoSer845 across the 
regions of the ventral hippocampus in each treatment group, suggesting either a 
certain degree of consistency of the quantification method or a lack of sensitivity. 
Using the Li-Cor quantification method, there was no detectable effect of heroin-
priming or of MLA pre-treatment on GluA1 or GluA1 phophoSer845 expression in 
either the CA1, CA2/CA3 or dentate gyrus regions of the ventral hippocampus. To 
address the issue of a potential lack of sensitivity of this method, and to identify 
and quantify AMPA receptor subunits at the postsynaptic membrane, slices were 
also scanned using confocal microscopy. This would allow a direct comparison of 




2.4.6.2. Confocal quantification of AMPA receptor subunits 
 
Figure 2.14: Representative tile scan of the CA1 (left), CA3 (middle) and dentate gyrus (DG, right) regions of the ventral 
hippocampus probed for GluA1 AMPA receptor subunits (top) and GluA1 phosphoSer845 AMPA receptor subunits (bottom). 5x5 





Figure 2.15: Representative image of the highlighted dendritic layer of the CA1 
region of the ventral hippocampus, for GluA1 (red) and PSD95 (green) 





Figure 2.16: Quantification of GluA1 (A) and GluA1 phosphoSer845 (B)-containing AMPA receptors using confocal microscopy on 
rat brains from heroin-primed reinstatement of CPP experiments. Regions of interest were the CA1, CA2/CA3 and dentate gyrus 
(DG) regions of the ventral hippocampus. Two-way ANOVA, n=5 per group.
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Figures 2.14 and 2.15 show representative confocal images of regions of the 
hippocampus and dendritic layers visualised for quantification. Quantification of 
colocalisation ratios of GluA1 or GluA1 phosphoSer845 with PSD95 visualised by 
confocal microscopy (Figure 2.16) revealed a large amount of variability in the 
data. Analysis of GluA1 expression (Figure 2.16A) showed no change in 
expression in the CA1 region between treatment groups. In the CA2/CA3 and 
dentate gyrus, there was no difference in GluA1 expression in either the saline 
control (S+S) or MLA control (MLA+S) groups. There appeared to be a slight 
decrease In GluA1 expression in in the heroin and MLA reinstatement groups 
(S+H and MLA+H, Figure 2.16A), however due to variability there was no 
statistical difference between these groups.  
There was no difference in GluA1 phosphoSer845 expression between all ventral 
hippocampus regions and between all treatment groups, except for a small 
decrease in the CA1 in the saline reinstatement group (Figure 2.16B, not 
significant). Again, there was a wide variability in signals. 
Overall, with the confocal colocalisation quantification method, there appeared to 
be no effect of effect of heroin priming or of MLA pre-treatment on the expression 
of GluA1 or phosphorylated GluA1 subunits throughout the ventral hippocampus.  
 
2.4.6.3. Comparison of visualisation techniques 
There were no comparable trends in the expression of GluA1 or phosphorylated 
GluA1 between visualisation methods. In fact, in some instances, the opposite 
trend was observed. For example, Li-Cor visualisation showed a general increase 
in GluA1 expression in the heroin reinstatement group (S+H, Figure 2.12A), 
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whereas confocal visualisation showed a general decrease in expression of GluA1 
in this same treatment group (S+H, Figure 2.16A). Furthermore, Li-Cor detection 
showed general increases of GluA1 phosphoSer845 expression in the heroin 
reinstatement and MLA reinstatement groups (S+H and MLA+H Figure 2.12B) 
compared to saline control, whereas confocal detection showed relatively 
consistent levels of expression throughout the ventral hippocampus and a slight 
decrease in expression in the heroin reinstatement group in the CA1 (S+H, Figure 
2.16B). No significant difference in expression of GluA1 or phosphorylated GluA1 
subunits was detected in either visualisation method, and the methods did not 




2.5.1. Acquisition and extinction of heroin CPP 
Heroin (1 mg/kg) was effective in producing CPP, as rats showed a significant 
increase in preference for the drug-paired side compared to habituation. 
Acquisition of CPP with this dose of heroin is  comparable to findings by Leri and 
Rizos (2005), who used the same dose and the same route of administration (1 
mg/kg, s.c.) in Long-Evans rats. In their 20-minute post-conditioning test, they 
found on average that rats spent roughly 42% of the total test time in the heroin-
paired compartment, compared to 25% in the vehicle-paired side (there was a 
neutral compartment in this experiment as well). The habituation data was not 
shown in their publication. Other studies administered 1mg/kg heroin i.p. and 
found that rats spend approximately 50% (Tzschentke et al., 2006) and 60% 
(Galaj et al., 2015, Galaj et al., 2016) of total test time in the drug-paired side. In 
the present study, in the 15-minute post-conditioning test, rats spent 56% of total 
test time in the heroin-paired side, compared to 47% during habituation. These 
results show that the magnitude of CPP achieved in this study is also comparable 
with the findings of the studies mentioned above. Furthermore, these results are 
comparable with morphine CPP studies in rats and mice, which spent 
approximately 60% of the total test time in the drug-paired side in the post-
conditioning test (Feng et al., 2011, Wright et al., 2018), and a meta-analysis of 
opioid CPP showed that morphine and heroin CPP preference scores in rats were 
of the same magnitude (Bardo et al., 1995). 1mg/kg heroin was shown to have the 
most robust effect on CPP, though studies have rarely studied doses above 1 




During extinction, there was a significant reduction in preference for the drug-
paired side, compared to the post-conditioning test. There was no difference 
compared to habituation, suggesting successful extinction of the conditioned 
behaviour. Interestingly, the extinction of heroin CPP required double the number 
of extinction sessions than morphine CPP, suggesting a stronger association with 
the drug-paired compartment.  
Often, the priming dose used to trigger reinstatement is lower than the conditioning 
dose (Do Couto et al., 2003). In this instance, there was insufficient published 
evidence of lower doses of heroin reinstating CPP when, to my knowledge, only 3 
studies were found to induce heroin-primed reinstatement of heroin (Leri and 
Rizos, 2005, van der Kam et al., 2009) and morphine (Lu et al., 2002) CPP. The 
heroin priming dose used by Leri and Rizos (2005) (1mg/kg, s.c.) was therefore 
based on this publication. In our study, the priming dose of heroin induced a 
significant reinstatement of heroin CPP, and interestingly, this preference was 
larger than during the post-conditioning test. On average, rats spent 56% of total 
test time in the drug-paired side during the post-conditioning test, whereas during 
reinstatement, they spent 86% of total test time. This effect was also reported by 
Leri and Rizos (2005), who found that rats spent 84% of total test time in the drug-
paired side during reinstatement, compared to 42% during the post-conditioning 
test. The heroin-primed reinstatement of CPP in the present study are therefore in 
agreement with the findings by Leri and Rizos (2005). In morphine CPP studies, 
this effect of a larger reinstatement preference was also observed in mice and 
rats, but to a lesser extent than with heroin (Do Couto et al., 2003, Feng et al., 
2011, Portugal et al., 2014, Wright et al., 2018). The reinstating effects of heroin 
can be attributed to the rewarding properties of the drug, which produces an 
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incentive motivational state that reinstates the preference. During CPP, the 
previously neutral CPP chamber acquires a salient value through repeated 
exposure to the drug reward. The reinstatement of drug-seeking behaviour can be 
explained as the recall of this salient value by the heroin priming dose, which leads 
the animal to return to spending more time in the drug-paired chamber. This 
approach behaviour could reflect a reinstatement of craving which drives the 
animal to seek the environmental cues associated with the euphoric effects of the 
drug. As rats were tested in a drugged state during reinstatement, it is possible 
that the presence of the heroin prime provides a stronger activation of the drug-
associated memory (potentially by the recruitment of additional brain regions, see 
Chapter 1, section 1.3.4), which leads to the stronger preference response 
compared to the post-conditioning test.  
 
2.5.2. MLA inhibits heroin-primed reinstatement of CPP 
The key result from this study demonstrated that MLA blocked heroin-primed 
reinstatement of CPP. The data from this chapter extend the findings from our lab 
(Wright et al., 2018) and another study (Feng et al., 2011) showing that MLA is 
effective against reinstatement of morphine-induced CPP. Wright et al. (2018) 
however observed that systemic administration resulted in an attenuation of 
reinstatement of morphine CPP, whereas direct infusion into the ventral 
hippocampus resulted in the total inhibition of reinstatement. This is perhaps due 
to an increase in variability observed during reinstatement. In this thesis, the 
variability was greater in the MLA reinstatement group; however MLA treatment 
totally inhibited reinstatement (Figure 2.6). Here, we extend previous findings to 
show a similar effect against a more rewarding opioid, heroin. To our knowledge, 
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these are the only studies that have demonstrated the effects of MLA (or other α7 
nAChR antagonists) on reinstatement to CPP induced by drugs of abuse other 
than nicotine itself. 
Basal cholinergic activity appears crucial for cue-induced relapse as lesions of 
basal forebrain cholinergic neurons resulted in the significant reduction of discrete 
cue-induced reinstatement of cocaine seeking in rats (Section 1.4, Pitchers et al. 
(2017)), and α7nAChRs may mediate, at least in part, this cholinergic signalling.  
The dose of MLA (4 mg/kg) was based on previous literature evidence for its 
selectivity and efficacy in mice and rats (Feng et al., 2011, Wright et al., 2018). It 
binds to the α-bungarotoxin binding site on α7nAChRs (Ward et al., 1990), 
however it has also  been shown to bind to α3 and α6β2 subtypes at high 
concentrations (Mogg et al., 2002), though at the dose used in this study (4mg/kg), 
the brain plasma concentrations would be in the subnanomolar range (Nirogi et al., 
2012). Chilton et al. (2004) reported that lower doses of MLA (1 and 3.2, but not 
10 mg/kg) induced a reduction in locomotion in mice, though they were scored 
over a one hour period and the decrease in locomotion was reported as 
“sometimes present”. They did not however show the change in behaviour over 
time, which could have determined whether this decrease in locomotion was 
constant or transient during the testing period. There was no effect of MLA alone 
on the distance moved in the reinstatement session reported by Wright (2016) and 
in this thesis.  
The 20 minute pre-incubation time was to allow sufficient MLA to reach the brain 
before heroin-priming, where maximum brain plasma levels were reported at 
30 minutes after administration (Turek et al., 1995, Nirogi et al., 2011, Nirogi et al., 
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2012), though this was done with oral and intravenous routes of administration and 
there is currently no literature on the pharmacokinetics and bioavailability of MLA 
by the subcutaneous route of administration. This time frame also did not allow 
enough time to inhibit object recognition memory reported by Tinsley et al. (2011) 
which was observed 24 hours after MLA administration at a very low dose of MLA 
(87.5µg/kg, i.p.), but not 20 minutes post-injection. This effect was however 
attributed to the perirhinal cortex. Furthermore, MLA had no effect on the 
acquisition of heroin CPP as the post-conditioning test was performed 24 hours 
after the final conditioning session. In conclusion, the dose of MLA used in this 
study was justified based on previous publications.  
 
2.5.3. MLA has no effect on the reinforcing effects of heroin 
The specificity of MLA for blocking the reinstatement phase was confirmed by its 
lack of effect on the acquisition of heroin CPP, which was in accordance with 
previous research by this lab (Wright et al., 2018) demonstrating that MLA had no 
effect on the acquisition of morphine CPP. This suggests that MLA did not have an 
effect on the reinforcing properties of heroin, as the association of the context 
(drug-paired side) with the cue (heroin) was established despite MLA pre-
treatment. Furthermore, MLA was shown to have no effect on the expression, 
maintenance and reconsolidation of morphine CPP in mice (Wright et al., 2018). 
Together, these data suggest that α7nAChRs play a selective role in reinstatement 
of opioid CPP, but have no effect either on opioid reward, or on the ability of the 
animal to acquire opioid-induced CPP. Thus, these data support a selective role of 
α7nAChRs in modulating the reinstatement stage in the CPP model of opiate 
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relapse; which highlights α7nAChRs as potentially interesting targets in the study 
of relapsing behaviour.  
In studies examining acquisition of nicotine CPP, the data are somewhat 
equivocal. Walters et al. (2006a) showed that antagonism of α7nAChRs by MLA (5 
and 10mg/kg, s.c.) had no effect of the acquisition of nicotine CPP, with similar 
effects seen in self-administration paradigms using MLA (Grottick et al., 2000) or 
in α7nAChR knockout animals (Pons et al., 2008). In contrast, Harenza et al 
(2014) showed increased sensitivity for nicotine CPP acquisition in NAc α7nAChR 
knockout animals, indicative of enhanced nicotine-induced reward, whereas mice 
expressing a gain of function mutation of α7nAChR exhibited decreased sensitivity 
for nicotine CPP acquisition (Harenza et al., 2014). In the same study, however, 
MLA had no effect on acquisition of nicotine-induced CPP. Consistent with the 
idea that activation of α7nAChRs might decrease sensitivity to nicotine-induced 
reward is the study by Jackson et al (2017) who showed that pre-treatment of rats 
with the α7nAChR agonist, PNU282987, inhibited acquisition of nicotine-induced 
CPP. Opposite findings, however, were seen in the intravenous self-administration 
paradigm, where Markou and Paterson (2001) showed that MLA significantly 
reduced acquisition of intravenous nicotine self-administration. Overall, there is 
conflicting evidence as to whether α7nAChRs play a significant role in nicotine 
reward and associated learning paradigms, however it is possible that the effects 
of nicotine are blocked by either agonists or antagonists due to competitive nature 
(to a certain extent) for the same receptors or this effect is mediated by α7nAChR 
in other brain regions, such as the NAc (Harenza et al., 2014).  
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The evidence presented in this thesis for a selective MLA block of reinstatement 
but not acquisition is consistent with the literature on α7nAChRs in opioid-induced 
CPP. 
 
2.5.4. Effect of MLA on decreased locomotion 
Our lab previously observed an increase in locomotion in mice during the 
acquisition of morphine CPP and during morphine-primed reinstatement of CPP, 
which suggested a stimulant effect of morphine (Wright, 2016). This effect during 
reinstatement, but not acquisition was blocked by MLA pre-treatment. This 
stimulant effect of morphine and inhibition by MLA was also reported in 
reinstatement by Feng et al. (2011). Interestingly, during the present study, the 
opposite behaviour was noted. During acquisition, there was a slight (but not 
significant) decrease in locomotion (which MLA had no effect on, data not shown) 
and a significant decrease in locomotion during extinction, compared to 
habituation. Heroin priming significantly reduced locomotion during reinstatement 
and this effect was blocked by MLA. Heroin is a known drug of abuse with 
locomotor stimulant effects, like morphine (Andersen et al., 2009, Steidl et al., 
2017), though there is a difference between studying the acute effect of heroin in a 
study on locomotion; and the present study which measures locomotor activity in a 
specific behavioural task. Tzschentke et al. (2006) noted a biphasic effect of 
heroin in CPP, where lower doses of heroin (0.05-0.25 mg/kg) had a locomotor 
stimulant effect and higher doses (1 and 3.16 mg/kg) produced locomotor 
reduction in the drug-paired compartment; which agrees with our findings.  
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As the post-conditioning test was conducted in a drug-naïve state, it is difficult to 
compare locomotion during reinstatement to post-conditioning (locomotion was not 
recorded during conditioning sessions). As heroin priming is presumed to involve 
the reactivation of the reward-associated memory (Bossert et al., 2013), it is 
possible that recall is strong enough to drive the rats to move over to the drug-
paired side and remain there until the end of testing. The reversal of the decrease 
in locomotion by MLA could potentially be explained by the disruption of the re-
activated memory, therefore the rats spent more time moving between the CPP 
chambers again as the association was lost. This theory was tested by analysing 
the number of cross-overs between CPP compartments (Figure 2.11). The heroin 
reinstatement group showed a significant number of transitions between CPP 
compartments, suggesting a reduction in exploration of the apparatus. This could 
be interpreted as the recall of the drug-paired association of the compartment was 
robust; therefore animals sought the drug-paired chamber and remained there 
without further exploration. Interestingly, there was no significant difference in the 
number of transitions between compartments in the MLA group, suggesting MLA 
potentially disrupted this drug-associated memory and a return to exploratory 
behaviour. There was however also no difference in the number of transitions 
compared to the heroin reinstatement group; therefore it cannot be determined 
whether MLA blocked this reduction in zone transitions. Due to the wide variability, 




2.5.5. Methodological considerations 
2.5.5.1. Dose and route of heroin administration 
A meta-analysis of opioid drugs in CPP experiments from 1979-1992 assessed the 
importance of various methodological factors in establishing drug-induced CPP 
with opioid drugs (morphine and heroin) and psychostimulants (cocaine and 
amphetamine) in rats (Bardo et al., 1995). Following their criteria, this meta-
analysis found 208 groups of rats that had undergone CPP with the drugs 
mentioned above, and of these, only 39 were using heroin. For comparison, 76 
were using morphine, demonstrating the scarcity of heroin CPP data in the 
literature.  This comprehensive study showed there was a high correlation of 
heroin dose with the magnitude of CPP (Bardo et al., 1995). Doses of heroin ≥1 
mg/kg produced the strongest CPP, and of the 8 studies in this category, 5 used 
the dose of 1mg/kg (Bardo et al., 1995). More recently, other studies have also 
shown that 1mg/kg heroin produces CPP in rats (Leri and Rizos, 2005, 
Tzschentke et al., 2006, Galaj et al., 2015, Galaj et al., 2016). This was therefore 
the dose of heroin chosen to condition the rats in this study. This meta-analysis 
covered publications between 1976 and 1992, therefore a more recent search 
showed only a few more studies using heroin CPP, which agreed with the previous 
meta-analysis that the dose of 1mg/kg produced CPP in rats (for review, see 
Tzschentke (2007)).  
The same dose of heroin (1mg/kg) was also effective at producing reinstatement, 
in agreement with previous reports (Lu et al., 2002, Leri and Rizos, 2005). 
Although lower priming doses lower than the conditioning dose have been shown 
to be effective in reinstating CPP (to model an addict taking a small amount of 
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drug during abstinence, Do Couto et al. (2003)), there is no literature evidence for 
the effectiveness of a lower dose of heroin producing reinstatement of CPP.  
 
2.5.5.2. CPP parameters 
Other variables assessed by the meta-analysis were rat strain, sex, housing 
condition (grouped or individual housing), number of CPP compartments, route of 
administration of drugs, conditioning session number and duration and 
randomisation method (counterbalanced vs biased). They found that sex and rat 
strain had no effect on CPP. There was a strong effect of group housing and the 
presence of 3 CPP compartments (drug paired, unpaired and neutral). The 
majority of the studies analysed used the subcutaneous route of administration, 
however it was found that the intraperitoneal route may have a greater effect on 
(though only 6 cohorts used this route versus 33 subcutaneously). Due to the 
larger number of studies using subcutaneous administration, this was the route 
selected for the present study. Drug conditioning duration had a significant effect 
on CPP, whereas the number of conditioning sessions surprisingly had no effect. 
The CPP procedural parameters in this study were previously optimised by Wright 
et al. (2018), therefore these were not changed, but they were consistent with the 
strongest effects on heroin CPP shown by the meta-analysis (Bardo et al., 1995). 
The best CPP outcome for the randomisation method was the counterbalanced 




2.5.5.3. Clinical relevance of CPP 
It is important to emphasise that CPP is not directly a model of addiction as rats 
receive a total of 2 heroin injections during the conditioning phase in this study. 
This is not enough to get the animals addicted, but it is more a correlate of the 
drug-paired associations which are formed during drug taking. These associations 
then become cues for drug-taking and can trigger cravings and push recovering 
addicts to seek drugs (Wikler, 1973, O'Brien et al., 1992). CPP is a conditioned 
behaviour where a contextual stimulus is paired with a primary reinforcer and 
acquires secondary appetitive properties. The test for CPP in a drug-free state 
enables an investigation of the salience of the drug-associated context. There 
were also no noted physical signs of heroin withdrawal (based on observations 
during testing) such as wet dog shakes, increased bowel movements, jumping, 
increased body temperature etc. (Pinelli et al., 1997) observed during the saline 
extinction stage, reinforcing the notion that CPP is not a direct model of addiction, 
but a correlate of reward-based learning. 
CPP therefore provides a model for studying drug-seeking behaviour in response 
to a cue. A critique of this could be that the post-conditioning test is performed in a 
drug-naïve state therefore is not representative enough of human addiction, but 
this can be investigated further by using a model of drug-seeking where animals 
have volitional control of drug consumption, such as intravenous self-
administration (IVSA). In the IVSA model, animals are in direct control of drug 
intake by pressing the correct lever and many different aspects of the motivation to 




2.5.6. Role of AMPA receptors in heroin reward-based learning  
Previously, in our lab, autoradiographical quantification of total [3H]-AMPA binding 
showed a 17% increase in binding in the ventral hippocampus only after morphine-
primed reinstatement of CPP, and this was blocked by MLA (Wright et al., 2018). 
The aim of this study was to validate a method to quantify synaptic AMPA receptor 
expression at a subunit-specific level. Confocal and Li-Cor visualisation were 
completed side by side to investigate whether both of these methods would reveal 
similar patterns of expression.  
Li-Cor visualisation was investigated because an entire brain slice could be 
scanned and protein expression levels could be quantified by 
immunohistochemistry in an entire brain region. The methodology is still relatively 
novel and unused. The methodology was based on a study by Eaton et al. (2016) 
who argued that image capture and analysis yielded comparable quantification to  
Western blot and confocal microscopy (see Appendix B for more detail). The 
advantages of using infrared scanning technology are that it enables area-based 
measurements in whole brain slices. Moreover, the time-cost benefits of whole-
section image acquisition on an infrared system are considerable compared to 
confocal acquisition. A single brain slice could be scanned in approximately 5 
minutes, whereas confocal capture for one brain slice would take approximately 90 
minutes, incurring greater costs for booking the confocal microscope. Since the 
publication of the study (Eaton et al., 2016), only 2 other publications have cited 
using this methodology in brain slices,(Pellegrino et al., 2016, Chabrat et al., 2017) 
suggesting there could be limitations to this technique for protein quantification.  
Confocal visualisation was selected as an adjunct to Li-Cor quantification as it 
could produce high resolution images and quantify AMPA receptor subunits at the 
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synapse. It was hypothesised that this could be a more sensitive method to detect 
smaller changes in protein expression. The signal intensity of secondary 
antibodies depends on a variety of factors such as the thickness of the slice, the 
depth of focus, the laser power settings and the image capture settings (such as 
gain and offset, Dunn et al. (2011)). Where possible, laser power and image 
acquisition settings were kept the same between slices, but other factors such as 
the depth of focus could still interfere with the signal intensity. To circumvent this, 
the colocalisation ratio of the AMPA receptor subunit with a control protein, PSD95 
was used to normalise measurements between slices (see Appendix B for further 
detail). This was based on a publication by Zhang et al. (2014) who demonstrated 
a biphasic effect of glycine to induce long-term potentiation (LTP) or long-term 
depression (LTD) in rat hippocampal slices by the incubation in either a low 
(0.6mM) or high (1.5mM) concentration of glycine, respectively. They then used 
confocal microscopy to quantify the colocalisation of NMDA receptor subunits with 
PSD-95 in the dendritic region of the CA1. They found a significant 30% increase 
in GluN1 expression in this region following LTP induction by the low concentration 
of glycine, and a significant 40% decrease in GluN1 expression during LTD 
induction by the high concentration of glycine. They also found comparable 
changes in GluN1 expression by Western blot, demonstrating that the 
colocalisation of proteins could be used as a method of quantifying proteins 
consistently between brain slices. In this chapter, the measurement of 
colocalisation ratios failed to detect any effect of heroin priming or drug treatment 
on GluA1 or phosphorylated GluA1 expression, compared to saline control.  
The hippocampus is a major target of cholinergic projections from the basal 
forebrain. α7nAChRs are highly expressed in the hippocampus where they 
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modulate glutamate-mediated synaptic plasticity (Cheng and Yakel, 2015). 
Enhancement of synaptic transmission is correlated with an increase in the 
number of synaptic AMPA receptors (Kessels and Malinow, 2009). One of the 
ways this is manifested is by the phosphorylation of GluA1 subunits at serine 845, 
which correlates with the delivery AMPA receptors to extrasynaptic sites, which 
primes them for LTP (Soderling and Derkach, 2000, Oh et al., 2006). Due to the 
increase in total [3H]-AMPA binding observed previously in our lab (Wright et al., 
2018) in morphine-primed rat brains, we hypothesised that heroin-primed 
reinstatement would be associated with an increase in the phosphorylation of 
GluA1 subunits, and potentially an increase in GluA1-containing AMPA receptors 
in the synapse. As the findings from the present study are equivocal, they neither 
agree nor disagree with previous findings. There are methodological issues which 
need to be addressed. 
 
2.5.7. Methodological considerations 
One major reason for the lack of detection of AMPA subunit expression changes 
using either method is the wide variability in the results. It was noted that day-to-
day the measured signals varied greatly, suggesting a lack of consistency in the 
detection of signals. In the Li-Cor visualisation, brain slices from all treatment 
groups were scanned in parallel. With confocal visualisation, this was not possible, 
due to the time taken to acquire images; therefore this could contribute to the 
variability observed. As both methods of visualisation showed different trends in 
expression of these AMPA receptor subunits (as markers of LTP), it is difficult to 
determine for certain which method was more representative of the physiological 
changes in AMPA receptor expression occurring during reinstatement.  
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Billa et al. (2009) and Portugal et al. (2014) quantified synaptic AMPA or NMDA 
receptor expression (respectively) by isolating postsynaptic fractions using 
subcellular fractionation, and then quantified protein expression by Western blot. 
This group was able to quantify their receptors of interest at a subunit-specific 
level and reported changes in expression by an effect of drug treatment. I 
attempted to optimise this methodology for the purpose of this study, but was 
unable to replicate their findings (see Appendix A). Portugal et al. (2014) pooled 
mouse brain tissue to increase protein loading and detected changes in the pooled 
samples. For this study, I wanted to be able to detect changes at an individual 
level. Billa et al. (2009), however, were able to detect changes in AMPA subunit 
expression in individual rat brains, but due to time constraints and tissue 
limitations, I was unable to pursue subcellular fractionation further. 
Interestingly, Billa et al. (2009) found that the extinction of morphine CPP in mice 
is associated with an increase in phosphorylation of GluA1 at serine 845. It could 
be that the lack of change in phosphorylated GluA1 is explained by the 
phosphorylation of serine 845 being a key element of extinction rather than 
reinstatement. Extinction is however also a form of learning, as the association of 
the CPP compartment is re-written to no longer associate with the euphoric effect 
of the drug (Bouton, 2002); therefore it could be argued that the reinstatement of 
CPP could be triggering similar mechanisms of LTP as extinction. This hypothesis 
however conflicts with evidence from Portugal et al. (2014) who showed a 
disruption of LTP in the hippocampus during extinction of morphine CPP in mice, 
but a robust enhancement of LTP during reinstatement. Further work is needed to 
differentiate the molecular mechanisms underlying the motivational behaviour 




2.5.8. Contribution of other AMPAR subunits? 
There could also be changes in the expression of other AMPA receptor subunits, 
such as GluA2, which is also important in the modulation of synaptic plasticity 
(Isaac et al., 2007). This subunit is however more involved in long-term synaptic 
plasticity and the stabilisation of the synapse by the replacement of GluA1 
homomeric AMPA receptors with GluA2-containing AMPA receptors, which occurs 
over a period of hours (Isaac et al., 2007). We attempted to quantify these 
subunits as well, but due to technical issues with antibodies, there were insufficient 
data to be shown. It would be interesting in the future to quantify GluA2 subunits 
alongside GluA1, or to examine time-dependent changes in AMPA receptor 
expression by delaying the time of rat sacrifice after reinstatement  
 
2.5.9. Implication of the role of α7nAChR antagonism in opioid 
addiction 
Learning and memory are key elements of opioid addiction (Hyman et al., 2006, 
Isokawa, 2012) and in animal models, it has been shown that glutamatergic 
synaptic plasticity is a major substrate of the reward-associated learning paradigm 
that is CPP (Van den Oever et al., 2010, Portugal et al., 2014, van Huijstee and 
Mansvelder, 2014). There have been previous reports of nicotinic modulation of 
memory recall but these studies have been limited to stress- and emotion-related 
memory rather than to reward-based learning (for review, see Blake et al. (2014)). 
Bitner et al. (2007) showed that selective agonism of α7nAChRs increased 
cognitive performance in monkeys in a model of working memory, increased rat 
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social recognition as a model of short-term recognition memory and increased 
performance in a mouse model of long-term memory consolidation. Furthermore, 
the selective agonism of α7 nAChRs reversed sensory gating deficits induced by 
MLA in mice (Bitner et al., 2007). At a molecular level, α7 nAChR agonism 
increased the phosphorylation of downstream molecules (ERK1/2 and CREB) 
involved in memory consolidation processes involving calcium in the mouse 
hippocampus (dorsal or ventral was not specified, however images suggest 
dorsal). The α7nAChR subtype is therefore of particular interest as it is also 
calcium-permeable, suggesting a potential intervention in the phosphorylation of 
the downstream signalling molecules involved in memory processes (see Chapter 
1, section 1.4).  
Evidence from our laboratory has shown that MLA attenuates evoked LTP in the 
mPFC in mouse brain slices, suggesting a role of endogenous ACh in regulating 
glutamatergic signalling (Udakis et al., 2016), in concordance with others (Gu et 
al., 2012, Cheng and Yakel, 2015). Sabec et al. (2018) recently demonstrated that 
α7nAChRs expressed in the PFC are critical for the encoding of associative 
recognition memory in rats. Furthermore, they also found that α7nAChRs gate 
bi-directional plasticity at hippocampal-prefrontal synapses. These findings, 
demonstrate an essential role of α7nAChRs in regulating synaptic plasticity in 
learning and memory processes in the PFC and hippocampus. As synaptic 
plasticity underlies memory processes, it can be reasoned that antagonism of 
α7nAChRs will affect memory processes in these brain regions.  
In order to determine the precise brain region mediating the inhibitory effects of 
MLA, bilateral intracerebroventricular (i.c.v.) infusions into different rat brain 
regions (PFC, ventral HPC, dorsal HPC) were performed before morphine-primed 
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reinstatement (Wright et al., 2018). Only infusions of MLA into the ventral HPC 
significantly inhibited morphine-primed CPP. The vHPC is a brain region known to 
be the site of memory processing and the modulation of reward-related memories 
(Isokawa, 2012, Namba et al., 2018). These data fit in with the theory that the 
antagonism of α7nAChRs inhibits reward-related memory, and more specifically, 
the re-activation of those memories in reinstatement. 
 
2.6. Conclusions 
The behavioural data shown here demonstrate that: 
1) α7nAChRs do not mediate the primary reinforcing effects of heroin 
2) α7nAChRs play a selective role in the reinstatement phase of heroin CPP 
Although CPP is a robust method to study the drug-paired associations which act 
as triggers for relapse, this is a passive method of motivational memory. To 
explore further the role of alpha7 receptors in opiate reinstatement, MLA was 
tested in a more active model of volitional drug consumption: the reinstatement of 















3.1.1. Intravenous self-administration 
As discussed in the introduction (Chapter 1, section 1.3.2), intravenous self-
administration (IVSA) is an operant behavioural paradigm which is often used as a 
correlate of the complex aspects of motivational behaviour towards a drug reward 
in relapse in humans.  
In this study, animals were trained to self-administer heroin intravenously by 
pressing the active lever on an FR5 schedule of reinforcement. Subsequently, the 
behaviour was extinguished by the heroin reward being replaced with saline in the 
pump syringes. Three different aspects of motivation to seek the drug reward were 
investigated: the relative reinforcing effect of heroin, the re-acquisition of heroin 
IVSA, and the reinstatement of IVSA. The effect of antagonising α7nAChRs by 
MLA was investigated in each of these motivational states. Using a combination of 
tone and light cues with drug priming during reinstatement has been shown to 
have an additive effect on reinstatement compared to either priming method alone 
(Shelton and Beardsley, 2008, Fattore et al., 2010, Keogh et al., 2017), therefore 
for the purpose of this study, the combination of drug and cue-priming was used to 
induce the reinstatement of IVSA. 
The heroin IVSA was performed at RenaSci Ltd (Nottingham, UK). The self-
administration protocol was based on previous studies performed by RenaSci 
(Heal et al., 2013, Keogh et al., 2017), with doses of heroin widely reported to be 
effective in producing self-administration in rats (Stewart, 1983, Shalev et al., 
2002). Furthermore, the doses used in this study were based on dose-response 
studies at RenaSci (data not shown). As mentioned in the introduction (Sections 
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1.3.4.1 and 1.3.4.2), drug-primed and cue-primed reinstatement behaviours are 
governed by distinct, yet overlapping neurobiological substrates (Rogers et al., 
2008, Namba et al., 2018). In most studies, the two triggers of reinstatement are 
used separately in experiments. Studies have found that while cues or stress 
significantly prime the reinstatement of drug-seeking alone, the combination of 
both triggers has an additive effect on reinstatement of ethanol seeking (Liu and 
Weiss, 2002), cocaine seeking (Buffalari and See, 2009, Feltenstein et al., 2011) 
and heroin seeking (Banna et al., 2010). The combination of drug and cue-priming 
has however been rarely investigated. Shelton and Beardsley (2008) have found 
that the combination of cues and methamphetamine-priming has an additive effect 
on the reinstatement of drug seeking in rats. This effect has been further 
demonstrated with cannabinoids (Fattore et al., 2010) and more recently, cocaine 
(Keogh et al., 2017); though this has yet to be shown with heroin.  
The reinstatement of drug seeking can be triggered by non-contingent drug 
priming, the presentation of conditioned cues and stress in animals previously 
trained to self-administer drugs. Chapter 1 (Figure 1.9, section 1.3.4) 
demonstrated the distinct and overlapping pathways involved in drug- and 
cue-primed reinstatement of drug seeking, and this chapter focusses on the 
evidence of α7nAChR modulation of this drug-seeking behaviour.  
 
3.1.2. The role of α7nAChR in reinstatement of self-administration 
There are few reports of the role of α7nAChRs in the reinstatement of 
self-administration of drugs of abuse, and none currently that examine their role in 
heroin relapse.  
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As discussed in the introduction (section 1.4.5), there is a distinct differential role 
of nAChR subtypes in nicotine reinforcement and the cue-induced reinstatement of 
nicotine IVSA. Studies have demonstrated that while β2-containing nAChR were 
essential during the acquisition stage of nicotine self-administration, α7nAChRs 
were important in cue-primed reinstatement of nicotine seeking (Liu et al., 2007, 
Cahir et al., 2011, Liu, 2014). Furthermore, transgenic α7nAChR knockout mice 
were still capable of acquiring nicotine IVSA, whereas α4 and β2 subunit knockout 
mice were not (Pons et al., 2008). It was however shown in a contradicting study 
that there was no difference in nicotine self-administration or CPP compared to 
wild-type in α4 knockout mice (Cahir et al., 2011, Madsen et al., 2015). Nicotine 
self-administration was rescued in the α4 and β2 subunit knockout mice by their 
re-expression in the VTA, but not in the SN (Pons et al., 2008). In addition, MLA 
pre-treatment had no effect on the acquisition of nicotine CPP (Pons et al., 2008), 
and this was further demonstrated in α7nAChR knockout mice (Walters et al., 
2006b).  
This distinction of the specificity of α7nAChRs in self-administration behaviour was 
further demonstrated in squirrel monkeys (Secci et al., 2017). Secci et al. (2017) 
found that increasing levels of kynurenic acid, a proposed negative allosteric 
modulator of α7nAChRs, inhibited cue-primed reinstatement of nicotine IVSA in 
rats and inhibited cue-primed and drug-primed reinstatement of nicotine and 
cocaine IVSA in squirrel monkeys. They also demonstrated this effect on the 
drug-primed and cue-primed reinstatement of THC self-administration in monkeys 
in another study (Justinova et al., 2013). They demonstrated the inhibition of 
reinstatement was reversed by the α7nAChR PAMs PNU120596 (Secci et al., 
2017) and galantamine (Justinova et al., 2013). Increasing brain kynurenic acid 
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levels however also decreased the acquisition of nicotine self-administration in 
monkeys, which was inhibited by PNU120596, and this effect was not shown in 
rats (Secci et al., 2017), suggesting either that there are species differences 
involved, or that some of the effects of kynurenic acid were not mediated by 
α7nAChRs; but rather by competitive inhibition of the glycine co-agonist site of the 
NMDA receptor, or by antagonising AMPA or kainate receptors (which kynurenic 
acid binds to at higher concentrations, Bertolino et al. (1989), Prescott et al. 
(2006), Albuquerque and Schwarcz (2013)). Furthermore, kynurenic acid levels 
were found to be increased in the VTA and NAc shell in rats (Justinova et al., 
2013) and this reduced the ability of nicotine to stimulate dopamine release in the 
NAc shell. This effect was however not reversed by PNU120596, suggesting this 
inhibition of dopamine release could be via the antagonism of glutamate receptors 
rather than α7nAChRs. Additionally, kynurenic acid inhibited the acquisition of 
nicotine but not cocaine IVSA, and this effect was rescued by the α7nAChR PAM 
in monkeys. This conflicts with the previous findings by Liu (2014), who showed no 
effect of MLA on the acquisition of nicotine IVSA. These data are intriguing and 
could suggest a potential effect mediated by α7nAChRs in these addiction-related 
behaviours; however the non-selectivity of kynurenic acid for glutamate receptors, 
which mediate a variety of cognitive functions including reward-based learning, 
casts some doubt over the role of α7nAChRs in mediating these results. Further 
work with more selective compounds is needed to enhance these findings. 
The evidence discussed above and the findings in Chapter 2 have identified an 
intriguing role of α7nAChRs in selectively being involved in mediating relapse-like 
behaviour. This has yet to be shown in the reinstatement of self-administration 




3.2. Aims of this chapter 
The aims of this chapter were to determine the role of α7nAChRs in different 
motivational states in a rat model of heroin intravenous self-administration. Based 
on publications and the findings in Chapter 2, we hypothesised that: 
1) MLA would have no effect on the acquisition of lever pressing 
This was investigated by observing the effects of MLA pre-treatment on the lever 
pressing behaviour for a food reward.  
2) MLA would have no effect on the primary reinforcing effects of heroin 
This was investigated by observing the effects of MLA pre-treatment on the 
re-acquisition of heroin IVSA (heroin infusions) and on the relative reinforcement 
of heroin by analysing the breakpoints in a progressive ratio session.  
3) MLA would inhibit the reinstatement of drug seeking 
This was investigated by observing the effects of MLA pre-treatment on the 




3.3. Materials and Methods 
3.3.1. Drugs 
All drugs were made up in sterile sodium chloride solution (0.9% w/v, Baxter, UK) 
and filter sterilised using 0.2µm filters into sterile tubes or glass bottles. Heroin 
(MacFarlan Smith, UK) stock solutions (1 mg/mL) were prepared once weekly, the 
pH adjusted to pH 6.6-7.4, and stored at 4°C when n ot in use. Heroin dosing 
solutions (0.05 and 0.015 mg/kg/infusion) were prepared from stock when required 
and the pH adjusted to pH 6.6-7.4.  The training doses were selected due to 
previous studies showing they were effective in inducing heroin self-administration 
in rats (Shalev et al., 2002). Drug syringes were emptied at the end of each testing 
day and stored at 4°C overnight. Each day, they wer e re-filled with fresh heroin or 
saline solution each morning of testing.  
MLA (Abcam) dosing solutions (4mg/mL) were prepared in sterile saline, filter 
sterilised, aliquoted into 2 mL cryovials and stored at -20°C for up to one month, 
according to the manufacturer’s recommendations. The dosing volume for 
subcutaneous injection was 1mL/kg and MLA was dosed at 4mg/kg, s.c. 
20 minutes prior to each of the reinstatement sessions. The control group was 
dosed with 1mL/kg sterile saline prior to reinstatement.  
 
3.3.2. Animals 
All experiments were performed in accordance with Home Office project licence 
held under ‘ASPA’ 1986 and approved by a local ethical review panel. 26 male 
Sprague-Dawley rats (200-225g, Charles River) were housed in the same room as 
the testing boxes. On arrival, they were weighed on arrival and singly-housed in 
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large polypropylene cages containing rodent bedding and chew sticks. Cages 
were cleaned once a week and bottles twice a week to maintain hygiene. 
Experiments were carried out in the light phase (12-hour light/dark cycle, 
07:00 on/19:00 off) in a temperature-controlled (21°C ± 4°C) and humidity-
controlled room (55% ± 20%). 
 
3.3.3. Housing and diet 
Rats were given free access to food in food hoppers on arrival but were later 
mildly food restricted after acclimatisation. The day after their arrival, rats were 
weighed to monitor for overnight weight loss due to the stress of travelling and 
none was noted. They were handled and weighed each day for one week during 
the acclimatisation period (except on the weekend) to habituate them to the 
experimenters. Post-surgery, the cages were modified to prevent access to the 
underneath of the food hopper, to prevent causing damage to the in-dwelling 
catheter ports implanted in the back of the rats’ shoulders. 
Rats were fed a standard rodent diet of Teklad 2018 (Envigo, UK). Due to the 
modified cages, food was placed directly onto the cage floor, but water was 
accessed normally via water bottles. During the acclimatisation period, they were 
also fed approximately 3 food training pellets (45 mg dustless precision pellets; 
F0021-B, Bilaney Consultants Ltd.) with their Teklad 2018 diet each day, so that 
the rats recognised the pellets as food when they start lever-press training for food 
rewards. After the acclimatisation period, food was restricted to 10g/day over 
5 days. After this time, daily food intake was restricted to 90% of normal levels 
(normal levels were initially calculated as the mean daily food intake during the 
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acclimatisation period). Thereafter, body weights were monitored daily and the 
amount of food was adjusted to maintain age-appropriate growth. This regime was 
maintained throughout the remainder of the study, except for a 24 hour period 
pre-surgery and a 48 hour recovery period from surgery, during which time 
animals had free access to food. Approximately 48 hours post-surgery, daily food 
intake was again restricted to 90% of normal levels. 
 
3.3.4. Bodyweights 
Each rat was weighed daily from their date of arrival until the end of the 
experiment. The bodyweights were recorded and the food weight was adjusted 
according to bodyweight gain or loss (see below for further details). The figure 




Figure 3.1: Bodyweights of rats for the duration of the heroin intravenous 
self-administration experiment. Data points are mean bodyweights of the rats used 
in the analysis of this study, after experimental exclusions. Red arrows represent 
time points of food restriction (day 4), surgery (from day 16) and drug training 
(from day 23). Surgeries were staggered and performed during the week starting 




3.3.5. IVSA apparatus 
Eight operant chambers (MED Associates, Inc., St. Albans, Vermont, USA) 
located within sound-attenuating, ventilated cubicles (Model ENV-018MD; MED 
Associated, Inc.) were used for the duration of the experiment. The apparatus 
consisted of a chamber with Perspex walls and one stainless steel wall with two 
response levers, either side of a 5x5 cm opening located equidistant between the 
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levers available for food pellet delivery from a food hopper. The chamber was 
fitted with a house light, a 2.5 cm translucent stimulus light located above each 
lever and an audible tone generator. Data were collected and stored by a 
microprocessor and associated interface (MED Associates, Inc.).  
Each sound attenuating cubicle was equipped with an infra-red camera (Model 
170IR, RF concepts) from which images were relayed to a digital video recorder 
(Model RF2421, RF Concepts) and displayed on a computer monitor. The 
cameras allowed the operator to monitor animal activity inside the chambers, thus 
decreasing the time taken for acquisition of lever-pressing (by manually dispensing 
food pellets to aid learning) and preventing chewing of the access port tethers 
when connected.  
 
Figure 3.2: Images of operant boxes (A and B) which are housed in sound 
attenuating cubicles (C). Panel D shows a rat attached to port tethers for 





During the 6 days of acclimatisation, rats were handled and weighed daily and 
food intake was recorded. In addition to their food, rats were given 3 food training 




3.3.7. IVSA procedures 
 
 
Figure 3.3: Schematic of the experimental procedures for the duration of heroin intravenous self-administration. FR: fixed ratio of 
reinforcement, PR: progressive ratio. Upward blue arrows represent MLA (4 mg/kg, s.c.) or saline (1 mL/kg, s.c.) pre-treatment 
20 minutes prior to experiments. The downward black arrow represents rats undergoing surgery for intravenous catheterisation. 
Downward red arrows represent heroin priming (0.015mg, i.v.) immediately prior to being placed in operant boxes. During drug-and 
cue-primed reinstatement, rats were pre-treated with MLA (or saline, blue arrows) 20 minutes prior to heroin priming (red arrows) 




Table 3.1: Summary of testing conditions for each stage of the heroin IVSA study. 
The house light was illuminated in the boxes at all times. It did not go out during 
the 30 second time-out after each pump activation. 
 
3.3.7.1. Food training 
During food training, animals were food restricted to 10 g of standard rat chow per 
day to encourage rats to seek food rewards. Rats were weighed and placed in the 
apparatus to learn to press levers with a food reward. Light and sound cues were 
not presented at this time (see Figure 3.3 and Table 3.1 for details). Initially, rats 
were placed on a fixed ratio 1 (FR1) schedule, where 1 lever press dispensed one 
45 mg pellet of food and both levers were active. The maximum duration of the 
food training session was 1 hour with a cut-off of 50 food pellets if this was 
reached first. Once rats self-administered over 45 pellets on FR1, they were 
progressed either onto a final FR3 schedule of reinforcement where 3 lever 
presses were required to dispense 1 food pellet and only the designated active 
lever (left lever) would dispense a pellet. If the rats showed a preference for the 
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inactive lever, they were progressed onto the FR2 schedule and thenFR3 to aid 
learning. The number of food training sessions was kept to a minimum to establish 
a robust lever pressing response; responding was deemed stabilised on the FR3 
schedule for all rats when animals took over 45 pellets per session for 4 
consecutive days. 
At the end of each session, a maximum of 3 rats were placed in an enrichment 
area to socialise before being returned to their home cages. After all rats had 
completed the session, boxes were cleaned for the following day. All operant 
chambers were cleaned with 10% ethanol and the collection trays underneath the 
boxes were cleaned with Virkon at the end of the day. 
 
3.3.7.2. Effect of MLA on lever pressing 
When rats were considered trained for food lever-pressing (over 45 pellets per 
session for 4 consecutive days), 12 rats were randomly allocated to either saline 
or MLA pre-treatment group in a pilot study to assess the effect of MLA on lever 
pressing (for food reward, see Figure 3.3). 20 minutes prior to the lever pressing 
session, they received either saline (1mL/kg, s.c) or MLA (4 mg/kg, s.c.). They 
were then placed in the operant chambers to lever press for food pellets on an 
FR3 schedule for the maximum allotted time of 1 hour or until the maximum 50 
pellets were dispensed. Abnormal behaviours such as piloerection, head weaving 
and ataxia were monitored for regularly and recorded until 2.5 hours post-injection. 





All surgical procedures were performed by RenaSci staff, due to time constraints 
and the complexity of the procedure. Surgery was staggered, so that a maximum 
of 6 rats underwent surgery per day. 24 hours before surgery, rats were given free 
access to food. On surgery day, rats were weighed and administered with the 
antibiotic Baytril (5mg/kg, s.c.) and the anti-inflammatory carprofen (80mg/kg, s.c.), 
then anaesthesia was induced with inhalable isoflurane and the relevant areas 
were shaved. Practising aseptic technique, the catheter (silicone tubing, RenaSci 
Ltd) was implanted into the right jugular vein, secured to the vessel then tunnelled 
subcutaneously from the site of insertion to the mid-scapular region where the 
access port was to exit. The access port was implanted such that the direction of 
the cannula and catheter pointed rostrally, and then sutured into place to prevent 
the port from twisting. The wound was closed with sutures and dressed with 
antiseptic spray. Catheters were filled with sterile fluid (heparinised saline, 
30iU/mL) immediately post-surgery and after every experimental session to 
maintain catheter patency. Catheter patency was confirmed daily by drawing back 
and observing freely flowing blood in the catheter line. In 1 rat out of 26, blood was 
not drawn after surgery, so the rat was intravenously injected with a sedative 
(propofol, 1.625mg/kg, i.v.). As the rat failed to show immediate sedation upon 
injection of the propofol, the animal was terminated by a UK Home Office 
Schedule 1 procedure.   
Immediately following surgery, the rats were placed in cages with modified lids 
under an infrared lamp and with the cage on top of an electric blanket; with free 
access to food and wet mash on the cage floor. Their recovery from the 
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anaesthetic was closely monitored and they were routinely checked until 1 hour 
after consciousness was regained. 
Rats were allowed to recover from surgery for 48 hours during which time their 
catheters were not flushed. The sutures and general behaviour and aspect of the 
rats were checked. In the rare case of animals removing their sutures, the wounds 
were glued shut with tissue-appropriate superglue (GLUture, Abbott Laboratories). 
They were all administered Baytril (5mg/kg, s.c.) for 48 hours and weighed to note 
any post-surgery weight loss, and were given free access to food and water. Two 
rats were euthanised by Schedule 1 procedure to minimise suffering, due to them 
pulling out their sutures and opening their glued incisions multiple times.  
48 hours post-surgery, rats were weighed, sutures were examined and home-cage 
behaviour was recorded. The cannula port metal screw-on lid and plastic cap were 
removed and sterilised in 70% ethanol. The antibiotic timentin (ticarcillin 
clavulanate, 80 mg/kg, i.v.) was administered via the catheter, which was then 
flushed with heparinised saline (30 iU/mL) to prevent blockages. This was 
repeated daily until the end of the study. The plastic cap and metal screw-on lid 
were then coated with the antibacterial Posatex and tightly shut. The plastic caps 
and metal ports were cleaned as such daily. Rats were returned to the 90% food 
restriction they were on prior to surgery. 
 
3.3.7.4. Acquisition of heroin self-administration 
After recovery from surgery for 6-7 days, rats were trained to self-administer 
heroin in daily two-hour sessions (Figure 3.3). 
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Prior to drug training, the operant chamber food hoppers were emptied of any 
residual food training pellets and cleaned with 10% ethanol to remove any food 
smells, to ensure the rats do not continue to be motivated by food when lever 
pressing. The Skinner boxes were set up with infusion pumps with syringes and 
tubing running from the syringes was fed through metal tethers and flushed with 
the ethanol then air daily prior to filling with drug or saline. Sessions were started 
by a non-contingent infusion of heroin and simultaneous presentation of a stimulus 
cue light and a 2.9 kHz tone cue set at 65 dB (approximately 5 dB over the 
background noise in the boxes). These two cues were given for a 5 second period 
contingent with heroin drug infusions during the training period following the 
correct number of lever presses, corresponding with the approximate duration of 
drug infusion. The infusion volume was 0.4 ml / kg. 
Training was started on an FR3 schedule where heroin infusions were limited to a 
maximum of 20 per 2 hour test session. During sessions, the required number of 
presses on the active lever (the left lever) resulted in the delivery of a single i.v. 
heroin injection (0.05 mg/kg/injection heroin base) that was given as a 5 second 
infusion according to the bodyweight of the rat. Each infusion was accompanied 
by the presentation of the contingent light and tone cues. Each heroin infusion 
was followed by a 30 second time-out period during which time presses on the 
active lever would have no programmed consequences. The house light 
remained illuminated throughout the test sessions. 
 
At the end of each session, the catheters were flushed with 1mL/kg timentin 
(80mg/kg) and with 0.2mL heparinised saline (30iU/mL) and the plastic and metal 
caps were coated in the antibacterial Posatex and replaced. Up to 3 animals (no 
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more to prevent any damage to catheter ports) were placed together in a 
socialisation pen for up to 15 minutes at the end of their session to allow some 
socialisation time and reduce stress. At the end of the day, the operant chambers 
were cleaned with 10% ethanol and the collection trays cleaned with Virkon.  
Initially, rats were trained on 0.05 mg/kg heroin. When rats had learned lever 
pressing on FR3, the schedule was increased to an FR5 schedule. When lever 
pressing was stabilised, the heroin dose was reduced to 0.015 mg/kg on the FR5 
schedule, a dose also shown to produce self-administration in rats (Shalev et al., 
2002) with a maximum of 20 infusions per 2 hour session. 
 
The acceptance criterion for positive reinforcement for heroin acquisition was 
defined as three consecutive sessions where the mean number of infusions was 
12 or above. Once this criterion was met, animals were ready for saline extinction 
of responding. 8 rats of the remaining 23 did not reach the acceptance criteria for 




Rats that met the acquisition criterion above were transitioned into FR5 saline 
extinction in the absence of cues for 2 hour sessions with a maximum of 
25 infusions (see Figure 3.3 and Table 3.1). Syringe pumps were filled with saline 
and the session was started immediately in the absence of the cues or a non-
contingent infusion. On the FR5 schedule, rats received an infusion of saline with 
no cue presentation, with a 30 second time-out between infusions, for 2 hour 
sessions. The house light remained illuminated throughout the session. The room 
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was kept as quiet as possible as noise could interfere with extinction, and rats 
were kept in the operant chambers during the whole 2 hour period, regardless 
whether they reached the maximum number of infusions, to emphasise the lack 
of reward. At the end of the sessions, rats received 2-3 s.c injections of saline (1 
mL/kg) to acclimatise them to subcutaneous injections before reinstatement. 
Rats underwent a minimum of 5 sessions. The acceptance criterion for 
non-reinforcement with saline was defined as three consecutive sessions where 
the mean number of lever presses was ≤30% of the mean active lever presses 
during the last three heroin acquisition sessions. All of the remaining rats achieved 
the extinction criterion and proceeded onto reinstatement.  
 
3.3.7.6. Heroin- and cue-primed reinstatement of drug seeking 
Rats were subjected to heroin i.v. primed- and cue-induced reinstatement of 
responding on an FR5 schedule, for 4 consecutive days, with saline as contingent 
infusions (Figure 3.3). The 2 hour sessions were initiated by non-contingent 
presentation of the tone and light cues (Table 3.1). Animals were pseudo-
randomly assigned to one of two treatment groups:  
 
Group 1: Saline (1mL/kg, s.c.) + heroin i.v.-primed and cue-induced reinstatement  
Group 2: MLA (4mg/kg, s.c.) + heroin i.v.-primed and cue-induced reinstatement  
 
Saline or MLA was administered s.c. 20 minutes prior to the reinstatement 
sessions. The heroin priming dose (0.015 mg/kg) was administered by i.v. 
through the indwelling catheter immediately before the test session. During the 
reinstatement sessions, upon the correct number of lever presses (FR5), rats 
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received a saline infusion paired with the light and tone cues over 5 seconds. 
There was a 30 second time-out after each infusion, during which active lever 
presses had no programmed consequences. The house light remained 
illuminated for the duration of the session. The rats were given 4 reinstatement 
sessions over consecutive days. 
 
This reinstatement test aimed to observe the effect of MLA pre-treatment on drug 
seeking behaviour; therefore data were presented as the number of active lever 
presses during each session.  
 
3.3.7.7. Re-acquisition of heroin self-administration 
After the rats completed reinstatement of drug seeking, they were re-extinguished 
on saline as described in section 3.3.7.5 for 2-3 days until the animals achieved 
the criterion for extinction of lever pressing. They were then progressed onto the 
re-acquisition of heroin self-administration test, where heroin (0.015 mg/kg/inf) 
was available in the syringe pumps on the FR5 schedule of reinforcement (Figure 
3.3). The rats remained in their treatment groups and were pre-treated with either 
saline (1 mL/kg, s.c.) or MLA (4 mg/kg, s.c). 20 minutes prior to the reinstatement 
session. They were then placed in the Skinner boxes and the test session was 
initiated by a non-contingent infusion of heroin (0.015 mg/kg/inf), simultaneously 
presented with the tone and light cues for 5 seconds (Table 3.1). Each successful 
infusion was contingently presented with the tone and light cues, followed by a 
30 second time-out period where active lever presses resulted in no programmed 
consequences. Rats underwent a maximum of 6 re-acquisition sessions and 
received saline or MLA before each session, until responding was stabilised and 
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they reached the heroin acquisition criteria (≥12 infusions for 3 consecutive 
sessions). The last 3 sessions were taken for analysis. 
  
This test aimed to observe the effect of MLA pre-treatment on the re-acquisition 
of heroin IVSA; therefore data were presented as the number of infusions 
received during the session.  
 
3.3.7.8. Relative reinforcement of heroin 
Upon completion of the re-acquisition of heroin self-administration, rats were given 
a single progressive ratio (PR) session for heroin (0.015 mg/kg) in a four-hour 
session where the number of lever presses progressively increased for a single 
drug infusion (Figure 3.3). Table 3.2 shows the progressive ratio schedule and the 
escalating number of lever presses for a single heroin reward. Animals remained 
in their treatment groups and received saline (1 mL/kg, s.c.) or MLA (4 mg/kg, s.c.) 
20 minutes prior to the beginning of the session, which was then initiated by 
non-contingent presentation of the tone and light cues. PR results were presented 
as the mean break-points for each group.  
 
 
Table 3.2: Number of lever presses required for subsequent rewards on 




3.3.8. End of study 
At the end of the study, all rats were terminated using a UK Home Office Schedule 
1 method. The brains were not collected due to multiple experiments done on the 
same rats. 
 
3.3.9. Statistical Analysis 
All heroin intravenous self-administration data were presented as mean ± standard 
error of the mean (SEM). The total number of drug infusions, active and inactive 
lever presses per session in the drug training, extinction, reinstatement and 
relative reinforcement of heroin were recorded by Med Associates software.  
The total number of active lever presses in the drug- and cue-primed 
reinstatement of drug seeking sessions was recorded and compared statistically 
with those obtained for the mean of the last 3 extinction sessions.  
 
The total number of heroin infusions in the re-acquisition of heroin self-
administration was recorded and compared statistically to the mean number of 
infusions over the last 3 extinction sessions.  
 
All statistical analysis on the raw data was conducted in GraphPad Prism 
version 5. 
 
In some cases (5 minute time bins, time to first lever press, inter-injection interval 
and breakpoint), the statistical analysis was performed by RenaSci’s in-house 
statistician. The data was transformed by square root transformation, then back-
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transformed to normalize the data. Once the transformation was completed, the 
statistical methods could assume normal distribution with equal variance. The 
5 minute time bin data and time to first lever press were analysed by mixed linear 
model with treatment as a fixed factor and animal as a random factor. 
Comparisons within treatment groups and to saline extinction were by the multiple 




3.4.1. Effect of MLA on lever pressing 
To determine if MLA had any effect on lever pressing, a pilot study was conducted 
on a small cohort (n=6 for both groups) before drug training. Once animals had 
reached a stable number of food rewards, they received a subcutaneous (s.c.) 
injection of either saline (1 mL/kg) or MLA (4 mg/kg) – the same dose shown to 
inhibit morphine-primed reinstatement of CPP in previous studies (Feng et al., 
2011, Wright et al., 2018) and the heroin-primed reinstatement of CPP in 
Chapter 2 (Section 2.4.3.) – 20 minutes prior to the 2 hour food reward session on 
an FR5 schedule. The behaviour was noted and scored before, during (using 
cameras in the operant boxes) and after the food reward session at specific time-
points (see Table 3.3 and 4). This would determine any behavioural effects of MLA 













Vehicle: Saline 1.0 mL/kg s.c. 
Behaviour/physical signs Time Point (min) 
 
5 15 30 60 90 120 150 
Piloerection (mild) 
    
1/6 4/6 
 
No observed change 6/6 6/6 6/6 6/6 5/6 2/6 6/6 
Table 3.3: Observations of the effect of saline on rat normal behaviour. Scores are 




MLA 4 mg/kg s.c. 
Behaviour/physical signs Time Point (min) 
 
5 15 30 60 90 120 150 
Piloerection (mild) 
  
2/6 1/6 1/6 1/6 
 Head weaving (mild) 
 
1/6 1/6 1/6 1/6 
  Subdued (mild) 
 
1/6 
     
Body twitches (mild) 
     
1/6 
 
No observed change 6/6 4/6 4/6 4/6 4/6 4/6 6/6 
Table 3.4: Observations of the effect of MLA on rat normal behaviour at specific 
timepoints. Scores are represented as the number of rats displaying the behaviour 
over the total sample size. 
 
All of the behaviours noted post-MLA treatment were mild in nature. Some mild 
piloerection was noted during this test (Table 3.4), but as it was also noted in the 
saline control group (Table 3.3), this could be due to other factors such as the 
stress of receiving the injection, or it could also be due to stress from caging. It 
was noted that the nesting was sparse, which could have contributed to the 
piloerection. This was rectified and all nesting was increased in the cages until the 
end of the study. this appeared to reduce piloerection, as it was no longer noted 
later on in the study. The mild piloerection could also be due to the acidity of the 
MLA. On formulation, the MLA was pH tested and found to be around pH 3.1-3.6. 
The acidity of the drug could produce some irritation under the skin causing the 
piloerection. No other behavioural signs were noted in the saline control group, 
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which was expected. Some mild head-weaving was observed in some rats during 
the first 90 minutes of the test. One rat appeared slightly subdued in the first 
15 minutes of the test and one displayed mild body twitches at 120 minutes post-
injection, which disappeared quite rapidly. Overall, there were no major displays of 

















































Figure 3.4: A: Time to first lever press for food reward in rats treated with either 
saline (1mL/kg, s.c.) or MLA (4 mg/kg, s.c.) 20 minutes prior to the test session. 
Unpaired t test, p=0.956 B: Rate of lever pressing for food reward in rats treated 
with either saline (1mL/kg s.c.) or MLA (4 mg/kg s.c.) 20 minutes prior to testing. 
Unpaired t test, p=0.898. N=6 for both treatment groups. 
 
Lever pressing responses for food reward were recorded during this experiment. 
There was no difference in the time to first lever press between the MLA and 
saline-treated animals, showing no effect of MLA on either locomotion or the 
operant memory (Figure 3.4A). There was also no difference in the rate of lever 
pressing between treatment groups (Figure 3.4B), demonstrating no effect of MLA 
on lever pressing behaviour. This preliminary experiment showed there were no 
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major effects of MLA alone on the overall behaviour of the rats and MLA had no 
effect on the ability to acquire lever pressing for a food reward. 
 
3.4.2. Heroin self-administration and extinction 
Once rats had acquired lever pressing for heroin at a higher training dose 
(0.05 mg/kg/infusion, see methods section 3.3.7.4), they were trained on an FR5 
schedule of reinforcement with 0.015 mg/kg/infusion heroin with contingent tone 
and light cues. When responding had stabilised (mean of infusions of last 3 
sessions ≥12), the means of the last 3 training sessions were taken as measures 
of acquisition of heroin IVSA (Figure 3.5). They then underwent saline extinction 
in the absence of the tone and light cues until responding had reached the 
acceptance criterion (mean of active lever presses ≤ 30% of active heroin lever 
presses) and the means of the last 3 sessions were taken as a measure of 
extinction. Figure 3.5 below shows the acquisition of heroin self-administration 
and extinction of lever pressing in two cohorts of rats, group 1 and group 2. After 
extinction, each group was assigned a treatment group and received either MLA 






Figure 3.5: Number of active lever presses (A) and heroin (0.015mg/kg/infusion) 
infusions (B) during heroin self-administration (acquisition) and extinction in all 
rats. Rats were then pseudo-randomly assigned to a treatment group (group 1 and 
2) by counterbalancing their respective lever pressing and infusion responses (C 
and D) for subsequent reinstatement. All data points are the means of the last 3 
sessions for individual rats and the group mean±SEM bars overlaid. Kruskal-Wallis 
test with Dunn’s post-hoc analysis, vs acquisition **p<0.01, ***p<0.005. n=7 in both 
groups. Group 1 was assigned to the saline treatment group and group 2 to the 
MLA treatment group following extinction for subsequent reinstatement. 
 
After exclusions (see methods Section 3.3.7.4), all rats acquired stable lever 
pressing for heroin (172±16.8 presses, Figure 3.5A) and the mean number of 
infusions for all rats was 18±0.8 (Figure 3.5B), which was close to the maximum 
allowed in a session (20), showing robust acquisition of heroin self-administration. 
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Following saline extinction, there was a significant decrease in the number of 
active lever presses and the number of infusions (Figure 3.5A and B), 
demonstrating successful extinction of lever pressing behaviour. These results 
showed that rats had stably and robustly acquired heroin intravenous self-
administration, and this behaviour was successfully extinguished.  
Following extinction, the rats were pseudo-randomly assigned to one of two 
treatment groups prior to reinstatement, by counterbalancing the lever pressing 
behaviour and number of infusions. Figure 3.5 C shows there was no significant 
difference in the mean number of active lever presses between both groups of rats 
(group 1 mean=171±27 vs group 2 mean=172±22 lever presses). There was also 
no significant difference in the mean number of infusions between groups 
(17.6±1.2 vs 18.5±1.0, respectively, Figure 3.5D). During the extinction phase, 
there was no significant difference in the number of active lever presses or 
infusions between groups (Kruskal Wallis test group1 vs group 2; active lever 
presses acquisition: p=1, extinction p=0.28; infusions acquisition: p=0.66, 
extinction: p=0.33). Figure 3.5C and D showed that both groups were balanced in 
their responses during acquisition of heroin self-administration and during 













































Figure 3.6: Time for both randomly assigned groups to achieve acquisition criteria 
(A) and extinction criteria (B). Data are mean±SEM, n=7 per group. After 
extinction, group 1 was assigned to the saline control group and group 2 to the 
MLA treatment group.  
 
The majority of rats underwent heroin training for 16 sessions (2 rats required 
2-3 additional sessions, data not shown). When observing the ability of the rats to 
learn the heroin self-administration (i.e. to achieve the acceptance criteria for 
acquisition of IVSA), both groups had reached the acquisition criteria by 
session 11, and maintained a high level of responding until the final 16th session 
(Figure 3.6A). Extinction of lever responding was much quicker and within 
4 sessions, the majority of the rats had reached the acceptance criteria for 
extinction, in both groups (Figure 3.6B). This low response was stable during the 














7 320.7 56.6  <0.001*** 




7 1524.8 209.8   
Group 2 8 1210.3 260.1 0.291  
Table 3.5: Inter-injection interval during the acquisition of heroin self-
administration and saline extinction. Means were back-transformed from a square 
root transformation and SEMs were calculated from the residuals of the statistical 




When comparing the mean times between infusions (Table 3.5) during the 
acquisition and extinction of heroin IVSA between randomly assigned groups, 
there was no significant difference between groups. There was however a 
significant (~5-fold) increase in the inter-injection interval in both groups during 
extinction, demonstrating longer periods of time in between infusions, due to the 
lack of reward from saline.  
These data show that all rats acquired heroin self-administration, and this 
behaviour was extinguished. The pseudo-random assignment of treatment groups 
showed both groups behaved equally in both the learning of the lever pressing 
behaviour and in their responses once the behaviour was acquired. They were 





3.4.3. Effect of MLA on the heroin- and cue-primed reinstatement of 
heroin seeking 
Following extinction, group 1 from the pseudo-random division of the cohort was 
assigned to the saline treatment group and group 2 was assigned to the MLA 
treatment group. Rats received either saline (1 mL/kg, s.c.) or MLA (4 mg/kg, s.c.) 
and were placed in their home cages for 20 minutes. Immediately before the 
beginning of the reinstatement session, all rats received a heroin priming dose 
(0.015 mg/kg) intravenously. Rats were then immediately placed in the operant 
chamber and the session was initiated by a non-contingent display of the light and 
tone cues on an FR5 schedule of reinforcement with saline infusions delivered on 
the correct number of lever presses (see Table 3.1 for details). The reinstatement 
sessions were performed over four consecutive days, where the rats were treated 





Figure 3.7: Active lever presses of rats pre-treated with A: saline (1mL/kg s.c.) or B: MLA (4mg/kg, s.c.) 20 minutes prior to heroin 
and cue-primed reinstatement over 4 sessions (one per day). Data presented as individual rat responses with mean±SEM overlaid. 
One-way ANOVA with Dunnet’s multiple comparison post-hoc analysis vs extinction. *p<0.05, **p<0.005. n=7 for each group. 
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In the saline control group (Figure 3.7A), there was a significant ~3-fold increase in 
mean lever responses during the first reinstatement session compared to 
extinction, demonstrating a significant reinstatement of drug seeking behaviour. 
During session 2, lever pressing declined to approximately double extinction 
values and there was no significant difference. During the third reinstatement 
session, there was again a significant increase in lever responses (~3.5 times 
extinction presses). In the fourth session, active lever presses declined again to 
approximately double extinction values. 
In the MLA group (Figure 3.7B), during the three first reinstatement sessions, 
active lever responses doubled compared to extinction, but there was no 
significant difference. In session 4, there was a ~3-fold increase in lever 
responses, but due to the variability of the data, this was not significant (p=0.1). 
This suggested there could be a potential effect of MLA on the reinstatement of 
drug seeking. 
During reinstatement, in both treatment groups, it appeared that the variability in 
responses increased compared to extinction, as some rats showed high 
responses and others much lower responses in the same session. Interestingly, in 
the MLA group, there appeared to possibly be two subpopulations of responders: 
a group of 3 high responders, which showed a ≥3-fold increase in lever responses 
compared to extinction and a group of 4 low responders, which displayed lever 
≤double extinction responses. This could suggest a group of MLA-sensitive rats, 
which showed a lack of reinstatement, and a group of MLA-insensitive rats, which 
reinstated to drug seeking.  
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A direct comparison of individual rats’ responses during the acquisition of heroin 
self-administration and their reinstatement responses was made. Observing the 
data in this way would allow us to identify whether the highest responders during 
acquisition would be predictive of the highest responses during reinstatement; and 
to investigate the possibility of there being subpopulations of responders in 
reinstatement. Extinction values were omitted for improved clarity. 
 
Figure 3.8: Number of active lever presses of individual rats during heroin 
acquisition and the four drug- and cue-primed reinstatement sessions in the saline 
(A) and MLA treatment group (B). N=7 per group. 
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What was made apparent in Figure 3.8 was that during reinstatement, active lever 
responses were much lower than during acquisition, which was the opposite effect 
compared to heroin CPP (See Chapter 2, Figure 2.6), where rats spent more time 
in the drug-paired side during reinstatement than the post-conditioning test. In the 
saline group (Figure 3.8A), the reinstatement of active lever presses in session 1 
was relatively uniform, as shown by the general lack of crossover of the lines; in 
that the highest and lowest responding rats during acquisition remained the 
highest and lowest responders during reinstatement. This effect was generally 
constant during the subsequent reinstatement sessions, as the highest responders 
during session 1 remained the highest responders during sessions 2, 3 and 4. 
In the MLA group however (Figure 3.8B), there was more crossover seen from 
acquisition to the first reinstatement session, suggesting more variability in the 
responses. In fact, the two highest responding rats during acquisition in the MLA 
group showed the lowest lever responses in reinstatement. This increase in 
crossover from highest to lowest responder suggested that MLA could be having 
an effect on the reinstatement to lever responding, but that the effect is not 
consistent across all animals. This needs further investigation as the study is 
underpowered. Interestingly, in the subsequent reinstatement sessions, the 
hypothesised high responders (≥3x extinction responses) and low responders 
(≤2x extinction responses) remained generally constant from the first 
reinstatement session, with fewer crossovers than the initial session (except 
session 3). 
Due to the variability of the responding observed over the four reinstatement 
sessions in the saline control group, it was deemed appropriate to focus on the 
results obtained in the first session, as there was a significant reinstatement of 
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drug seeking behaviour in the saline group. As the rats received saline infusions 
during reinstatement, they also acted as extinction sessions, therefore affecting 
the subsequent reinstatement sessions. In order to determine if there was a 
relationship between reinstatement behaviour and initial acquisition of heroin 
IVSA, and to identify possibly subpopulations of responders in the MLA group 

























































































A. Saline B. MLA
 
Figure 3.9: Correlation and linear regression of active lever presses during acquisition and the first reinstatement session in the 




Correlation analysis of the lever pressing responses during the acquisition of 
heroin IVSA and the first reinstatement session (Figure 3.9) showed that in the 
saline control group there could possibly be a correlation between the number of 
active lever presses during acquisition and those during reinstatement, as the 
correlation was close to significance (p=0.07). It is therefore possible that the high 
responders during acquisition of heroin self-administration could be predictive of 
being high responders during reinstatement, however the study is underpowered 
and needs additional subjects to confirm this hypothesis. 
Although there were no statistically significant differences between the saline and 
MLA-treated cohorts, this analysis does suggest 2 interesting aspects. First, 
whereas there is clearly no correlation between number of responses during 
acquisition and reinstatement in the MLA group (r2 = 0.0084) there was a trend in 
the saline-treated group (r2=0.51). Further, in the MLA group, there appeared to be 
a group of 4 rats which showed low reinstatement responses, and 3 rats that 
showed higher reinstatement responses, supporting initial observations. 
Potentially, this could mean that there is a subpopulation of rats for which MLA 
had an effect, and another subpopulation where MLA had no effect. Further 
studies would be required to investigate this possible effect further, as this current 
study is underpowered. 
The responses during the first reinstatement session were compared between 




Figure 3.10: Active lever presses for saline reward in rats pre-treated with either 
saline (orange circles, 1mL/kg s.c.) or MLA (blue squares, 4 mg/kg s.c.) 
20 minutes prior to the first reinstatement session. Data points are individual rat 
responses with mean±SEM overlaid. Two-way ANOVA with Bonferroni post-hoc 
analysis. *p<0.05, n=7 per group. 
 
 
Figure 3.10 above shows the comparison of reinstatement responses in the 
control and MLA treatment groups in the first reinstatement session. Heroin and 
cue priming significantly increased active lever pressing in the saline control group 
compared to their saline extinction values, suggesting significant reinstatement of 
drug seeking. The MLA treatment group showed no significant difference in the 
number of active lever presses compared to extinction, suggesting a lack of 
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reinstatement of drug seeking behaviour. There was however no difference in 
lever pressing between treatment groups during reinstatement. We can therefore 
neither confirm nor reject the null hypothesis that there is no effect of MLA on 
reinstatement of drug seeking behaviour.  
The time-dependent effect of MLA on the drug- and cue-primed reinstatement of 
drug seeking was of interest; therefore the data was divided into 5 minute time 
bins. Keogh et al. (2017) analysed the cue and drug-primed reinstatement of 
cocaine IVSA in 5 minute time bins and found that there was a significant increase 
in lever presses within the first hour of the reinstatement session. The results from 
the present study were therefore divided into 5 minute time bins to observe the 
time-dependent changes in lever pressing behaviour in saline and MLA-treated 





Figure 3.11: Effect of MLA on active lever presses in 5 minute time bins during 
heroin- and cue-primed reinstatement of IVSA. Data were back-transformed from 
square root transformation and adjusted for differences between animals. SEMs 
were calculated from the residuals of the statistical model. Data are mean±SEM, 
saline: n=7; MLA: n=8. Multiple t test saline vs MLA, not significant. 
 
The analysis of the number of active lever presses in 5 minute increments (Figure 
3.11) revealed that only at 20 minutes was there a significant reinstatement of 
lever pressing compared to extinction in the control group. There was no 
significant reinstatement in the MLA group in any of the time bins. There was also 
no difference in lever pressing between treatment groups. This was mostly due to 
the large variability observed in both data sets. The time bin analysis did however 
reveal that the majority of the activity during the reinstatement session occurred 
during the first 30 minutes of the testing session, and that after the first hour of the 
reinstatement session, lever pressing was close to zero for the remainder of the 
session. This result was kept in mind for methodological consideration.  
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Overall, these combined results showed that heroin and cue priming significantly 
reinstated drug seeking behaviour in the control group, but there was no significant 
reinstatement in the MLA group. There was however also no difference in the 
active lever responses between treatment groups, so the null hypothesis that MLA 
had no effect on the reinstatement of drug seeking could not be rejected. Due to 
the large variability seen during reinstatement, the study was underpowered 
therefore additional subjects are needed to complete this study. 
Although there were no time-dependent effects of MLA on reinstatement, it was 
hypothesised that it could affect the initial motivation to seek the reward. The 
latency to first press was therefore compared during acquisition, extinction and 
reinstatement, and a potential effect of MLA on these behaviours was investigated. 
 
















































reinstatement MLA 8 57.2 18.9 0.567 0.805 0.713 
Table 3.6: Time to first lever press (s) during the acquisition, extinction and 
heroin- and cue-primed reinstatement of IVSA. Means were back-transformed 
from a square root transformation and SEMs were calculated from the residuals of 
the statistical model. Multiple t test comparing MLA vs saline in all sessions, 





The latency to first press was 107.7±37.5 seconds in the control group during 
acquisition (Table 3.6). There was no change in the latency to first press during 
extinction (106.3±28.5 seconds). The latency to first press during reinstatement 
was lower than during acquisition (33.7±21.4 seconds), though due to variability, 
this was not significant (p=0.151). In the MLA group, the latency to first press 
during acquisition was 74.9±17.7 seconds. The latency to first press remained 
constant throughout saline extinction and reinstatement (68.8±25.9 and 
57.2±18.9), showing no change in motivation to seek the lever. Despite a slight 
decrease in latency to first press in the saline group during reinstatement, there 
was no difference compared to the MLA group, suggesting MLA had no effect on 
the initial motivation to seek the lever.  
It was also hypothesised that MLA could affect lever pressing behaviour and the 
time to seek the next reward after infusions. The inter-injection interval was 
therefore recorded to probe for any potential changes in lever pressing behaviour.  






























   

















MLA 8 412.5 59.0 0.113 <0.001*** 0.268 
Table 3.7: Inter-injection interval during acquisition, extinction and heroin- and 
cue-primed reinstatement of IVSA. Means were back-transformed from a square 
root transformation and SEMs were calculated from the residuals of the statistical 
model. Multiple t test comparing MLA vs saline (not significant) and reinstatement 




During extinction, the inter-injection interval was far greater than during acquisition 
in both treatment groups, signifying a greater amount of time to seek the next 
infusions (Table 3.7). Heroin- and cue-primed reinstatement significantly 
decreased the inter-injection interval compared to extinction in both groups, 
demonstrating an increase in motivation to obtain the reward. Though there was a 
significant decrease in the inter-injection interval during reinstatement 
(714.4±219.8 s) in the saline control group compared to extinction (1524.8±209.8), 
this interval was still significantly higher than during acquisition (320.7±56.6 s). 
This potentially suggests although the motivation to seek the reward is increased 
compared to extinction, it is still lower than during acquisition; and as discussed 
above, the number of active lever presses during reinstatement was also lower 
than during acquisition (Figure 3.6). This could hint at a methodological flaw which 
will be discussed further in section 3.5. There was no significant difference in the 
inter-injection intervals during reinstatement between the saline group and the 
MLA group (though the time in the MLA group was lower, p=0.113) due to the 
variability in the control group. The lack of difference in the inter-injection intervals 
between treatment groups suggests that MLA had no effect on the motivation to 
obtain infusions during reinstatement.  
 
3.4.4. Effect of MLA on the re-acquisition of heroin self-administration 
The next experiment studied the effect of antagonising α7nAChRs on the 
re-acquisition of drug-seeking behaviour. Following the heroin- and cue-primed 
reinstatement for saline reward, rats underwent saline extinction sessions to 
reduce lever pressing responses to again meet the extinction acceptance criteria 
(section 3.3.7.5). They then remained in their treatment groups and received either 
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saline (1 mL/kg s.c.) or MLA (4 mg/kg s.c.) 20 minutes prior to being placed in the 
operant chamber. The 2 hour test session was initiated by a non-contingent 
infusion of heroin (0.015 mg/kg/infusion i.v.) and non-contingent presentation of 
the light and tone cues. Rats were on a FR5 schedule of reinforcement with heroin 
reward (0.015 mg/kg/inf).  
As this was an analysis of the re-acquisition of IVSA, the number of infusions was 
analysed rather than the number of active lever presses, as this signified the 
number of times the rat successfully pressed for a drug reward. Each rat 
underwent between 4 and 6 sessions, to stabilise responding and the last 




Figure 3.12: Number of heroin infusions in rats pre-treated with A: saline (1mL/kg s.c.) or B: MLA (4mg/kg, s.c.) 20 minutes prior to 
the re-acquisition of heroin self-administration over 3 sessions (one per day). Data points are individual rat responses with 




In the saline group (Figure 3.12A), there was a ~5-fold significant increase in the 
number of infusions taken during all three sessions, compared to extinction. 
Similarly, in the MLA group (Figure 3.12B), there was a significant, ~6-fold 
increase in heroin infusions, compared to extinction. This robust increase in heroin 
infusions suggested that both groups had significantly re-acquired heroin self-
administration. Responding was stable across all three sessions, as lower 
responders (2 in each treatment group) in session 1 remained the lowest 
responders in sessions 2 and 3. As the responding was stabilised during all three 
sessions, results from the first reinstatement session were used for comparisons 
between treatment groups. 
 
 
Figure 3.13: Effect of MLA on the first re-acquisition session. Data are individual 
rat responses with means±SEM overlaid. 2-way ANOVA with Bonferroni post-hoc 
analysis vs extinction: ***p<0.001, n=7 per group. 
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As mentioned before, both treatment groups showed a significant increase in the 
number of infusions taken compared to extinction. Further analysis (Figure 3.13) 
showed that there was no significant difference in the number of infusions received 
during re-acquisition between treatment groups, demonstrating that both groups 
has robustly re-acquired heroin self-administration, and that MLA treatment had no 
effect on the re-acquisition of this behaviour. 
 
Figure 3.14: Effect of MLA on the number of heroin infusions (0.05 mg/kg/infusion) 
in 5 minute time bins during the re-acquisition of heroin self-administration. Data 
were square root transformed and adjusted for differences between animals. Data 
were analysed by multiple t test, comparing saline vs MLA treatment (black 




The time-dependent effects of MLA during the re-acquisition of self-administration 
were also investigated (Figure 3.14). Analysis of the number of heroin infusions in 
5 minute time bins showed that the self-administration of heroin was sustained 
over the 2 hour period, compared to the reinstatement session, where the majority 
of activity was during the first 30 minutes of the session (Figure 3.11). The MLA 
group showed a significant increase in infusions at 10 minutes, compared to saline 
extinction and compared to saline control (10 minute time point, Figure 3.14). 
From 15 to 70 minutes, there was no difference in responses between the saline- 
and MLA-treated groups, however, the responses crossed over so that at 75 
minutes the responses in the saline-treated group were significantly higher than 
both the MLA-treated group and to extinction. Responses in the saline-treated 
group remained higher than those in the MLA-treated group until the end of the 2 
hour session. Over the 2 hour session there was a sustained significant increase 
in heroin responses during re-acquisition in both groups compared to extinction, 
showing that both groups had re-acquired self-administration behaviour. Overall, 
there was no significant difference in responding between treatment groups (apart 
from 3 individual cases at 10, 75 and 120 minutes); therefore it appeared that 




































   















MLA 8 58.7 13.6 0.004** 0.831 0.737 
Table 3.8: Effect of MLA on the time to first lever press during the re-acquisition of 
drug taking, vs heroin acquisition and vs saline extinction. Means were back-
transformed from square root transformation and SEMs were calculated from the 
residuals of the statistical model. Multiple t test re-acquisition vs acquisition (not 
significant), re-acquisition vs extinction (not significant), and saline vs 
MLA: **p<0.01. 
 
In the saline group, there was a large ~2.6-fold increase in the time to first lever 
press during re-acquisition compared to acquisition (p=0.053) and extinction 
(p=0.051), suggesting a decrease in the motivation to seek the lever initially (Table 
3.8). However, due to the large variability of the latency to first press in this group, 
this effect was not significant. In the MLA group, the time to first lever press was 
lower than in the saline group and more consistent across different stages of self-
administration (no significant change). During the re-acquisition of heroin IVSA, 
the time to first lever press in the MLA group  was significantly lower than in the 
saline group (p=0.004, Table 3.8), suggesting the MLA group were faster in 
retrieving the lever pressing behaviour during re-acquisition compared to the 
control group. The saline group took approximately 4 times longer than the MLA 
group to press the lever for the first time; however, the variability was very large in 
this group. This will be discussed in section 3.5.3. 
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To determine any further differences in lever pressing behaviour between 
treatment groups, the inter-injection interval was also studied.  
 






























   















MLA 8 283.3 68.6 0.287 <0.001*** 0.829 
Table 3.9: Inter-injection interval comparing re-acquisition of heroin IVSA to 
acquisition and saline extinction and between treatment groups. Means were 
back-transformed from a square root transformation and SEMs were calculated 
from the residuals of the statistical model. Multiple t test comparing reacquisition 
vs extinction: ***p<0.001, reacquisition vs acquisition (not significant) and saline vs 
MLA (not significant).  
 
The inter-injection interval recorded during the re-acquisition of heroin self-
administration showed that in both treatment groups, the times between infusions 
were similar to the times during the acquisition of heroin IVSA (Table 3.9). This 
result showed that in both groups, the lever pressing behaviour was restored and 
the motivation to obtain the heroin reward was the same as during the initial 
acquisition of the behaviour. There was also no difference during re-acquisition 
between treatment groups, supporting the finding that MLA had no effect on the 
re-acquisition of heroin intravenous self-administration (Figure 3.13). 
The combined results show that overall; MLA had no effect on the re-acquisition of 
heroin IVSA, as both saline and MLA-treated rats robustly re-acquired heroin 
173 
 
taking behaviour. In order to probe this finding further, the effect of MLA was 
tested on the relative reinforcement of heroin in a progressive ratio session.  
 




In order to observe the effects of MLA on individual rats’ motivation to receive a 
heroin infusion, they underwent a single progressive ratio session after the final 
re-acquisition session. Rats remained in their treatment groups and received either 
saline (1 mL/kg s.c.) or MLA (4 mg/kg s.c.) 20 minutes prior to being placed in the 
operant chamber. The testing session was initiated by a non-contingent infusion of 
heroin (0.015 mg/kg/infusion i.v.) with a simultaneous presentation of the tone and 
light cues. The test session was a minimum of 2 hours and the testing session was 
terminated either if rats had not pressed the active lever for 30 minutes, or if 4 
hours had elapsed. The schedule was progressively increased with each infusion 
(see section 3.3.7.8 for progressive ratio lever pressing schedule), so as to 
determine the motivation to receive a single infusion for each individual rat. This 




Treatment n Mean SEM p vs saline s.c. 
Saline s.c. 7 48.4 15.2  
MLA s.c. 8 94.7 32.4 0.201 
 
Table 3.10: Effect of MLA on lever pressing breakpoint. Means were back-
transformed from square root transformation and SEMs were calculated from the 
residuals of the statistical model, unpaired t test.  
 
The breakpoint responses for the MLA group were approximately double that of 
the control group, but with a higher SEM ( 
Table 3.10). For this reason, there was no difference in breakpoints between the 
treatment groups (p=0.201), suggesting MLA had no effect on the reinforcing 
properties of heroin. The latency to first lever press was then investigated to probe 
for any effects on the motivation to seek the reward. 
 















































MLA. 8 119.5 28.5 0.235 0.375 0.444 
Table 3.11: Effect of MLA on the time to first lever press during the relative 
reinforcement of heroin (progressive ratio, PR session), vs acquisition and 
vs extinction. Means were back-transformed from square root transformation and 
SEMs were calculated from the residuals of the statistical model. Multiple t test 




In the saline group, the time to first lever press doubled compared to acquisition 
and extinction; however, due to large variability in this group, this effect was not 
significant (p=0.235, Table 3.11). In the MLA group, the time to first lever press 
was slightly higher during the progressive ratio session compared to acquisition 
and extinction, though there was no significant difference (p=0.444 and 0.375, 
respectively). There was no effect of treatment on the time to first lever press 
during the progressive ratio session, therefore both treatment groups showed 
similar motivation to press the lever at the beginning of the session. These results 
suggest that MLA had no effect on the relative reinforcing effects of heroin, or on 




This chapter describes experiments designed to examine the effects of MLA on 
heroin intravenous self-administration (IVSA). MLA was initially tested on lever 
pressing for food reward and then tested on the heroin- and cue-primed 
reinstatement and the re-acquisition of heroin IVSA. MLA had no significant effect 
on any measures examined. The summary of results, methodology used, 
underlying mechanisms and implications for α7nAChRs will be discussed here.  
 
3.5.1. MLA had no effect on the rewarding effects of heroin 
 
There was no effect of MLA on lever pressing behaviour for a food reward (Figure 
3.4). Furthermore, MLA also had no effect on the relative reinforcing effects of 
heroin, shown by the lack of change in breakpoints (Table 3.10) and the time to 
first lever press (Table 3.11) during the progressive ratio session. These combined 
data strongly suggest that α7nAChRs do not play a role in modulating the 
Primary reinforcement of rewards: 
Behaviour studied 




Lever pressing for food reward No effect Figure 3.4 
Relative reinforcement of heroin (PR) No effect 
 
Table 3.10 
Time to first press (PR) No effect Table 3.11 
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rewarding effect of food or heroin. The results in the previous chapter of this thesis 
showed no effect of MLA on the acquisition of heroin CPP in rats, and this was 
supported by the study conducted by Wright et al. (2018), who showed no effect of 
MLA on the acquisition of morphine CPP in mice and rats. Together with the data 
shown in this chapter, this strongly suggests that MLA does not affect 
reinforcement produced by heroin, nor does it affect the animals’ abilities to 
acquire drug-seeking behaviour.  
These data are also in agreement with other studies. Liu (2014) showed 
α7nAChRs played no role in modulating the primary reinforcing effects of nicotine 
by a lack of effect of MLA on nicotine IVSA in rats. In addition, antagonising 
α4β2nAChRs blocked the acquisition but not the reinstatement of nicotine IVSA in 
rats (Liu et al., 2007, Liu, 2014), further demonstrating a selective role of nAChR 
subtypes in the different stages of addiction. Furthermore, mouse knockout studies 
have supported these findings that β2-containing nAChRs modulate the primary 
reinforcing effects of nicotine and α7nAChRs modulate the reinstatement of 
nicotine seeking (Walters et al., 2006b, Pons et al., 2008, Cahir et al., 2011, 
Madsen et al., 2015). Secci et al. (2017) demonstrated that kynurenic acid, acting 
as a negative allosteric modulator of α7nAChRs, inhibited both drug- and cue-
primed reinstatement of both nicotine and cocaine self-administration in squirrel 
monkeys. These data further demonstrate a differential and selective role of 
nicotinic receptor subtypes in drug reinforcement and support the findings in both 
this chapter and in Chapter 2.  
In contrast, other studies disagree with this and have shown that α7nAChRs are 
involved in modulating the rewarding effects of nicotine (Markou and Paterson, 
2001, Besson et al., 2012); however some of these effects could be due to 
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α7nAChRs in the VTA (Harenza et al., 2014), rather than the hippocampus, 
hypothesised in this thesis to mediate the effects of MLA on reinstatement. 
Knocking out α7nAChRs in the VTA in mice also reduced nicotine intra-VTA 
administration, suggesting α7nAChRs in the VTA may mediate nicotine reward 
(Besson et al., 2012). One study suggested that β2-containing nAChRs may 
regulate the initial nicotine consumption, but may regulate longer-term 
consumption of nicotine (Levin et al., 2009). The hypothesis of this thesis is that 
α7nAChRs in the ventral hippocampus modulate the reinstatement of opioid 




3.5.2. MLA had no effect on the heroin- and cue-primed reinstatement 
of drug seeking 
 
Heroin- and cue-priming significantly increased the number of active lever presses 
in the saline group, showing the reinstatement of drug seeking behaviour in this 
treatment group (Figure 3.10). Furthermore, the decrease in the inter-injection 
interval compared to during extinction phase suggests the re-activation of the rats’ 
motivation to seek the reward. In contrast, in animals pre-treated with MLA, heroin- 
and cue-induced reinstatement of IVSA was not significantly different to during the 
extinction phase. Potentially, this could suggest that antagonising α7nAChRs 
inhibited drug- and cue-induced reinstatement, however, as lever-pressing in the 






MLA group  
vs extinction 




Number of active lever 
presses 
Increase No change No effect Figure 3.10 




No correlation - Figure 3.9 
5 minute time bins No change No change No effect Figure 3.11 
Time to first lever press No change No change No effect Table 3.6 
Inter-injection interval Decrease Decrease No effect Table 3.7 
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group, we could neither accept nor reject the null hypothesis that MLA has no 
effect on the heroin- and cue-primed reinstatement of IVSA. The results are 
equivocal, and further work is needed to elucidate the effect of MLA on 
reinstatement, especially by increasing the number of rats due to large variability. 
The findings in this section do not corroborate the results of the study performed 
by (Liu, 2014), who showed that MLA inhibited the cue-primed reinstatement of 
nicotine IVSA.  
As previously discussed (Introduction, sections 1.3.4.1 and 1.3.4.2), studies into 
the pathways involved in the reinstatement of IVSA have shown the recruitment of 
different brain regions in response to either drug or cue-primed reinstatement 
(Bossert et al., 2004, Weiss, 2005, Rogers et al., 2008, Namba et al., 2018). There 
appears to be a distinct role of the hippocampus in cue-induced reinstatement, 
which has not been observed in drug-primed reinstatement (Rogers et al., 2008, 
Namba et al., 2018). Nirogi et al. (2012) showed by mass spectrometry that 
following i.v. administration of MLA in rats, the majority of MLA was detected in the 
hypothalamus (whole tissue dissected). The second highest concentrations of 
MLA were found in the hippocampus and striatum, regions of interest for the 
present study. Furthermore, Wright et al. (2018) showed that only intracerebral 
infusions into the ventral hippocampus (though only the PFC and hippocampus 
were examined) inhibited the reinstatement of morphine CPP in rats, suggesting 
the primary site of action of MLA in inhibiting the reinstatement of CPP is the 
ventral hippocampus (Wright, 2016, Wright et al., 2018).  Based on this evidence, 
it could be hypothesised that MLA treatment would have an effect on cue- but not 




Drug priming recruits neurons located in the VTA, NAc, mPFC, VP and PPT 
(Namba et al. (2018), section 1.3.4.2) whereas cue-priming recruits these regions 
as well as additional regions including the BLA and hippocampus (Rogers et al. 
(2008), section 1.3.4.1). The present study used a combination of drug and cue 
priming as this has been shown to have an additive effect on the reinstatement of 
lever responding with other drugs of abuse (Shelton and Beardsley, 2008, Fattore 
et al., 2010, Keogh et al., 2017). This increased reinstatement response could 
suggest the recruitment of additional circuits involved in mediating drug-primed 
reinstatement, which do not involve the hippocampus (Stewart, 2008, Namba et 
al., 2018). It is possible that the slight decrease in active lever presses caused by 
MLA in the reinstatement of drug seeking is due to the antagonism of α7nAChRs 
in the hippocampus in response to cue-primed reinstatement, but that the 
recruitment of further neurons in regions such as the mPFC, NAc, VTA, LDT and 
VP by drug priming had an overshadowing effect on the effect of MLA on lever 
responding. The only study observing the effect of MLA on the reinstatement of 
IVSA was performed by Liu (2014). They showed that MLA significantly inhibited 
cue-induced reinstatement of nicotine IVSA in rats in a dose-dependent manner 
(2.5 and 10 mg/kg, i.p.), however the higher dose was 2.5 times that used in this 
thesis. They did not study drug-primed reinstatement therefore further 
investigation into any differential effects of MLA on these different types of 
reinstatement is required.  
There are several potential explanations to the wide variability in the lever pressing 
behaviour in the MLA group during reinstatement. The first explanation could be 
that MLA has no effect on drug- and cue-primed reinstatement of IVSA and that its 
effect is specific to CPP. The differences in methodology will be discussed further 
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below. Another explanation is that there could be subgroups of rats that show 
either weak or strong reinstatement of drug-seeking behaviour regardless of 
acquisition behaviour. Brown et al. (2010) found that despite acquiring robust 
cocaine CPP, a subgroup of mice did not exhibit reinstatement in response to a 
cocaine prime. There were specific differences in brain region activation in these 
mice; implicating different patterns of brain activation could be indicators of 
reinstating and non-reinstating mice. This suggests that individual animals could 
exhibit different reinstatement propensities which could explain the variability in 
reinstatement responses; however this has yet to be demonstrated with heroin. 
The correlation analysis of lever responses during IVSA acquisition and 
reinstatement in the saline control group suggests that this explanation is however 
unlikely, as there did not appear to be distinct groups of responders in the saline 
group. In fact, it showed there could be a relationship between responses shown 
during acquisition and those during reinstatement and that strong responders 
during acquisition were predictive of being strong responders during 
reinstatement.   
Another explanation is potentially that there was a group of rats that were sensitive 
to MLA pre-treatment, which showed weak reinstatement and a group of rats that 
was insensitive to MLA, which showed stronger reinstatement of drug seeking. 
This is reinforced by the fact that the correlation analysis of responses during IVSA 
acquisition and reinstatement showed a complete lack of correlation in this 
treatment group, compared to a trend in the saline group. Furthermore, there 
appeared to be a group of high responders and a group of low responders in the 
MLA group regardless of responses during the acquisition of heroin IVSA; 
potentially suggesting MLA had an effect on one group and no effect on the other. 
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This could potentially reflect a difference in α7nAChR expression, receptor 
function or desensitisation between individual rats, which has not yet been 
investigated.  
 
3.5.3. MLA had no effect on the re-acquisition of heroin self-
administration 
 
Results from this study showed a robust re-acquisition of heroin self-administration 
in both treatment groups, shown by the significant increase in heroin infusions and 
the significant decrease in the inter-injection interval, compared to extinction. 
There was no effect of MLA pre-treatment on any of these behaviours. This 
suggests MLA pre-treatment had no effect on the re-acquisition of heroin IVSA. To 












Number of infusions Increase Increase No effect 
Figure 3.12 
5 minute time bins Some change Some change Some effect Figure 3.14 
Time to first lever 
press 
No change No change Decrease Table 3.8 
Inter-injection interval Decrease Decrease No effect Table 3.9 
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administration. In CPP, Wright et al. (2018) showed that MLA had no effect on the 
expression of morphine CPP in mice, where after the acquisition of morphine CPP, 
mice were treated with MLA 20 minutes prior to the post-conditioning test, for 
4 consecutive days following the post-test, and one week later. In all cases, mice 
spent significantly more time in the drug-paired compartment and there was no 
difference in preference between sessions (Wright et al., 2018).  This showed that 
MLA had no effect on the ability to re-express the previously acquired association. 
This experiment closely resembles the re-acquisition of heroin IVSA in this study; 
therefore the data in this chapter are in agreement with the morphine and heroin 
CPP acquisition data, where MLA was without effect. These results further support 
the notion that α7nAChRs do not modulate the primary reinforcing effects of heroin 
and there is a potential selective role of α7nAChRs in the reinstatement of drug 
seeking behaviour over the reinforcing properties of heroin. 
The time to first lever press was significantly lower in the MLA group compared to 
the saline-treated group during the re-acquisition of heroin IVSA. This could be 
interpreted as the MLA group showing a stronger motivation to seek the heroin at 
the start of the session than the saline-treated group. There was however no 
difference in the time to first lever press during acquisition, extinction or heroin- 
and cue-primed reinstatement in either treatment group, therefore it seems like 
this difference in the saline group is likely coincidental. Furthermore, both groups 
showed a decrease in inter-injection intervals during the re-acquisition, compared 
to extinction, and there was no difference in the intervals between treatment 
groups, suggesting that rats had similar motivations to obtain the rewards during 
the session. Overall, it seems like the aberrant responses in the saline group 
185 
 
account for the differences in the time to first lever press compared to the MLA 
group during the re-acquisition of heroin IVSA.   
 
3.5.4. Methodological Considerations 
3.5.4.1. The study was underpowered 
A major factor affecting the results in this chapter is that the study was 
underpowered. Initially, there were 26 rats in the study but a large number of rats 
were excluded from the study due to complications with catheters post-surgery 
and due to not meeting the acceptance criterion for the acquisition of heroin IVSA. 
A power analysis was performed prior to this study based on previous work at 
Renasci on the combination of drug- and cue priming on the reinstatement of 
cocaine seeking (Keogh et al., 2017). It was calculated that for 80% power to 
detect an effect of MLA, n=9 per treatment group was needed. Initially, the study 
began with 26 rats, or n=13 per group, which would theoretically have been 
sufficient. After exclusions, 14 rats remained, leaving just n=7 per treatment group. 
Due to the unexpected loss of ~40% of rats during acquisition and extinction, the 
study was underpowered.  
The drug- and cue-primed reinstatement of drug seeking is still of particular 
interest as, unlike during re-acquisition, the effect of MLA on reinstatement is still 
equivocal. In both treatment groups, the variance was greatly increased during 
reinstatement compared to acquisition and extinction  and has been previously 
reported in IVSA (Stewart, 1983, Shalev et al., 2002) and in CPP experiments (Do 
Couto et al., 2003, Tzschentke, 2007). 
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3.5.4.2. Food before training and other parameters 
In many self-administration studies, animals are often food trained prior to the 
transition onto drug training. It has been argued that the introduction of food in the 
training protocol can add confounds to reinstatement (Shalev et al., 2002). For 
instance, when drug training succeeds food training in the same experimental 
setup, it has been argued that the drug training comprises a component of 
extinction training for food; therefore reinstatement of lever pressing post-
extinction could be due to the reinstatement of food seeking rather than drug. This 
has rarely been controlled for, however a counterargument for this is that the food 
training was performed in the absence of the tone and light cues, and the drug 
training was performed in the presence of these cues. It could therefore be 
disputed that the presentation of the contingent cues with the drug marks this 
association specifically for the rewarding effects of the drug rather than the food. 
The presentation of the cues during reinstatement should therefore recall only the 
drug-associated lever pressing rather than lever pressing for food. In addition, in 
this study, rats were minimally trained with food to prevent strong associations of 
the lever with food which could confound the study. 
 
3.5.4.3. Drug withdrawal 
A methodological component which appears to have a major impact on 
reinstatement is the drug withdrawal period prior to reinstatement. Studies with 
cocaine have shown that cocaine- or cue-priming induced significant reinstatement 
of drug seeking behaviour, but this reinstatement response was greatly increased 
with increasing periods of withdrawal from cocaine compared to either one week 
or one day in rats (Tran-Nguyen et al., 1998, Grimm et al., 2001). A study by 
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Shalev et al. (2001) found that reinstatement of lever pressing behaviour by 
foot-shock followed an inverted U relationship with the period of heroin withdrawal 
in rats, with 6 and 12 days withdrawal showing maximal responding. Similar 
results were found  by Doherty and Frantz (2012), who found that rats showed 
greater cue-primed reinstatement of drug seeking following 12 days of heroin 
abstinence compared to one day of abstinence. Interestingly in this study, the 
reinstatement lever responses were much lower than during the acquisition of 
heroin IVSA; which is reflected in this thesis. Often, these studies found a lack of 
reinstatement on the first day of withdrawal. Furthermore, a study found that the 
type of extinction impacts heroin seeking (Venniro et al., 2017). The study found 
that only forced abstinence (removing subjects from drug self-administration 
environment) from heroin resulted in significant reinstatement after 21 days (but 
not one day) of abstinence in rats, compared to voluntary abstinence (discrete 
choice between drug or palatable food) (Venniro et al., 2017). These results must 
be taken with caution as analysis of their individual data revealed that only two of 
the rats showed high responses which drove the significant difference. In the 
present study, rats were extinguished for a minimum of 4 days before 
reinstatement, so perhaps increasing the time of withdrawal in this study could 
increase reinstatement responses.  
 
3.5.4.4. Combination of drug- and cue-priming 
A criticism of the methodology was that heroin- and cue-priming did not appear to 
produce as marked effects on reinstatement to lever pressing as previously 
reported with other drugs of abuse (Shelton and Beardsley, 2008, Fattore et al., 
2010, Keogh et al., 2017). One of the adjustments that was made during this study 
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was that the priming dose was lowered from 0.05 mg/kg i.v. to 0.015 mg/kg i.v. 
With the higher dose of heroin, the rats did not appear as active, were slightly too 
sedated and not motivated enough to press the lever and responding during 
reinstatement was low. It was inferred that this dose of heroin was too rewarding 
therefore the animals would require a longer interval before seeking a further 
infusion after being placed in the operant chamber. When the dose was lowered to 
0.015 mg/kg i.v., the animals were much more active in the chamber and the time 
to first lever press was reduced compared to that of the rats on the higher dose. 
Those rats that had received a higher heroin priming dose were then re-trained on 
the lower dose of heroin and re-extinguished to then receive the lower priming 
dose of heroin. 
 
3.5.4.5. Route and dose of heroin prime 
The route of administration of the heroin priming dose (0.015mg/kg, i.v.) could also 
be a reason for the lower reinstatement response than expected. The intravenous 
route is a way to produce an acute, short-lasting euphoric effect, which to a certain 
extent, triggered active lever pressing during the first 30 minutes of the 
reinstatement session. However, the reinstatement responses were still lower than 
during acquisition. Gottås et al. (2013) found that after i.v. infusion of 1.3 mg 
heroin, blood heroin levels peaked immediately, and were then cleared after 
approximately 10 minutes. They also measured brain extracellular fluid 
concentrations of heroin and found heroin brain plasma levels also peaked 
approximately 2 minutes after injection, then levels cleared after 5 minutes, 
demonstrating the rapid effects of heroin. Heroin’s metabolite, 6-
monoacetylmorphine (6-MAM), however is detectable in the brain ECF for up to 40 
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minutes, therefore intravenous administration could still be an acceptable route for 
heroin priming.  
In order to address the issue of the route of heroin administration, at the end of 
this IVSA study, a small pilot study was performed to test the lever pressing 
responses of the rats to a subcutaneous priming dose of heroin (Figure 3.15 
below). Animals were re-extinguished, then given a single heroin priming dose 
(0.25 mg/kg, s.c.) immediately before being placed in the operant chamber and the 
presentation of the tone and light cues. Lever pressing was on an FR5 schedule of 
reinforcement with saline infusions. During this testing period, the rats appeared 
motivated to press the lever and there was a significant increase in lever presses 
compared to extinction. The number of active lever presses in this preliminary 
experiment was much higher than during i.v. heroin- and cue-primed reinstatement 
of drug seeking (149.2±34.7 s.c. vs 53±27.1 i.v.); suggesting subcutaneous heroin 
priming could be an improvement to the experimental design. This could be due to 
the subcutaneous route producing a slower and/or more sustained level of heroin 




Figure 3.15: Preliminary experiment studying the effect of subcutaneous heroin- 
(0.25 mg/kg, s.c.) and cue-primed reinstatement of IVSA. Rats from both treatment 
groups (saline and MLA) were taken at the end of the study for this preliminary 
experiment. Data points are individual rat responses with mean±SEM overlaid. 
One-way ANOVA with Dunnet post-hoc analysis vs extinction: **p<0.01, n=6. 
 
3.5.4.6. Dose of MLA 
In the previous chapter of this thesis, there was a clear and total inhibition of 
heroin-primed reinstatement of CPP by MLA, similar to effects also shown by Feng 
et al. (2011) and Wright et al. (2018), who showed  a significant attenuation of 
morphine-primed reinstatement of CPP in mice and rats (respectively). 
Intracerebral delivery of MLA into the ventral hippocampus however resulted in a 
total abolition of the response (Wright et al., 2018), potentially reflecting a larger 
local dose that fully antagonises α7nAChRs in this region. The systemic dose of 
MLA could therefore be suboptimal for heroin IVSA, as Liu (2014) found a dose-
dependent effect of MLA (2.5 and 10 mg/kg, i.p.) on cue-induced reinstatement of 
nicotine IVSA. Increasing the dose of MLA does however pose certain risks, as 
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MLA displays non-specific effects at other nicotinic receptor subtypes (notably 
α6β2 nAChRs, Mogg et al. (2002)). There are however negligible levels of α6-
containing nAChRs in the hippocampus (see Figure 1.11, section 1.4.4 
Albuquerque et al. (2009)). 
The reinstatement sessions in this study were 2 hours long. MLA is detected in 
peak levels in the plasma after 30 minutes of oral and i.v. administration (Turek et 
al., 1995, Nirogi et al., 2012). Intraperitoneal administration of MLA resulted in 
increasing brain levels of MLA reaching a peak at 30 minutes post-injection and 
declining until approximately 90 minutes post-injection (Turek et al., 1995). The 
testing time is therefore sufficient for the potential detection of changes in 
behaviour induced by MLA, especially as reinstatement responses occurred in the 
first hour of testing. There are currently no time-dependent studies on brain levels 
of MLA following subcutaneous administration, therefore comparison to the results 
in this thesis is difficult, but the route and dose of MLA is worth considering for 
future studies.  
A behavioural side effect of using MLA appears to be novel object memory 
impairment, shown by the impairment of novel object memory recognition 24 hours 
after systemic administration of MLA (Tinsley et al., 2011). This study used 
surprisingly low concentrations of MLA (87.5µg/kg, i.p.) and found an impairment 
of novel object recognition 24 hours after systemic administration, but not 20 
minutes post-injection. Infusions of MLA into the mPFC resulted in the inhibition of 
the encoding, but not retrieval of associative recognition memory in rats, whereas 
infusion of DHβE resulted in the inhibition of retrieval but not encoding of these 
memories, demonstrating a subtype-specific differential role of nAChRs in 
associative recognition memory. Infusions of MLA into the PFC, however had no 
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effect on the morphine-primed reinstatement in rats (Wright et al., 2018), 
suggesting different networks involved in associative memory recognition and 
reinstatement of CPP.  
With additional time, the heroin self-administration protocol with the considerations 
discussed above could be improved to enhance lever responses. It would be 
interesting to investigate the effect of MLA on heroin-primed reinstatement and 
cue-primed reinstatement of drug seeking individually, and to study the effects of 
different doses of MLA. Wright et al. (2018) showed that i.c.v. infusions of MLA in 
the ventral hippocampus inhibited morphine-primed reinstatement of CPP in rats. 
It could be interesting to extend these findings in the heroin self-administration 
model, by administering MLA locally, rather than systemically prior to IVSA 
reinstatement.  
 
3.5.5. Differences between IVSA and CPP 
Learning and memory processes play a critical role in the development and 
maintenance of drug seeking behaviour. There are two types of addiction-related 
learning models: instrumental learning, where the animal learns there is an action-
outcome relationship between drug taking and the rewarding experience. The 
other is Pavlovian learning, where, with repeated drug experience, the animal 
associates the rewarding effects of the drug with a cue present at the time of drug 
taking (for review, see Perry et al. (2014)). CPP is a Pavlovian model of learning, 
which is more passive, where the occurrence of the reward does not depend on 
the action of the animal. IVSA is an instrumental model of learning and is a more 
active learning model, where the action of the animal dictates the reception of the 
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reward. Similar effects are mostly seen in the reinstatement of these two models 
(for review, see Aguilar et al. (2009)), suggesting the neurobiological basis of 
these two models of reinstatement generally overlap, however, the distinctions in 
the model could explain the disparities in the effects of MLA in the CPP and IVSA 
experiments in this study. 
A review by Aguilar et al. (2009) highlighted differences in effects of drug 
manipulations on either the reinstatement of CPP or self-administration with the 
same drug of abuse. This effect is especially noted in the case of cross-
reinstatement, where priming with other drugs of abuse can induce the 
reinstatement of CPP. Nicotine, ethanol and morphine all caused the 
reinstatement of cocaine CPP, whereas none induced the reinstatement of 
cocaine self-administration. Stressors such as food deprivation and spontaneous 
withdrawal had no effect on the reinstatement of morphine CPP, whereas they 
both reinstated heroin self-administration. Conversely, restraint stress induced the 
reinstatement of heroin self-administration, whereas it had no effect on the 
reinstatement of morphine CPP (Aguilar et al., 2009). Furthermore, dopamine 
receptor antagonists have been shown to inhibit the reinstatement of heroin self-
administration in rats (Ettenberg et al., 1996, Shaham and Stewart, 1996), 
whereas they seem to have no effect on morphine CPP in mice (Ribeiro Do Couto 
et al., 2005), suggesting neurobiological differences in CPP and IVSA. The data 
from this chapter, combined with other findings in previous literature could point to 
a distinct and specific role of α7nAChRs in modulating a specific drug-related 
behaviour which is modelled more closely by CPP. 
The methodological differences between CPP and IVSA could help to understand 
the differences in results observed in this thesis. Firstly, the acquisition of either 
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behaviour is very different. In CPP, rats received a total of two heroin injections 
during conditioning, whereas rats underwent 15-20 heroin IVSA sessions, with rats 
taking up to 20 infusions of heroin per session. Although the heroin administration 
is contingent with the presentation of cues in IVSA, the chronic administration of 
heroin may be reflected by differences in brain plasticity compared to CPP, which 
may reflect more acute changes on plasticity. Furthermore, CPP is a more passive 
model of drug-paired associations as there is no action required to display 
acquisition of the behaviour, except spending more time in the drug-paired 
compartment; whereas in IVSA rats have to actively press a lever on a tough 
reinforcement schedule (FR5) to obtain the reward. During extinction in IVSA, the 
rats still have to actively work for saline infusions until they give up, and there is no 
equivalent for this in CPP. The distinctions of a passive versus active model likely 
contribute to the differences in effects of MLA on either model obtained in 
Chapters 2 and 3.  
It is possible that CPP and IVSA are correlates for distinct addiction-related 
behaviours. CPP likely models drug-paired associations and drug preference (i.e. 
preference for a drug-paired compartment), which may not include psychological 
dependence on the drug (i.e. craving). Because of the greater exposure to the 
drug and the requirement of animals to work to obtain the drug, IVSA may model 
psychological dependence on the drug, and blocking their motivation to drug 






The results in this chapter showed that: 
1) MLA has no effect on the reinforcement of heroin self-administration 
2) MLA had no effect on the re-acquisition of heroin self-administration 
3) MLA had no significant effect on the heroin-and cue-primed reinstatement 
of drug seeking.  
These results suggest that α7nAChRs do not play a role in mediating the 
reinforcing effects of heroin, which extends previous findings (Liu, 2014, Wright et 
al., 2018). The role of α7nAChRs in the reinstatement of drug seeking in the IVSA 
model is not as clear as in the CPP model. Due to the wide variability in responses 
in this chapter, a larger study with a greater sample size is needed to elucidate 















The results described in this thesis have shown that the α7nAChR antagonist MLA 
has no effect on the acquisition of heroin CPP, or on either the re-acquisition or 
breakpoint of heroin intravenous self-administration; but did block the 
reinstatement of heroin CPP supporting a role for α7nAChRs in retrieval of drug-
associated memories. The effects of antagonising α7nAChRs on the heroin- and 
cue-primed reinstatement of IVSA are however still unclear, suggesting potential 
differences between CPP and IVSA as correlates of human relapse. Attempts 
were made to determine the neuronal mechanism by which MLA inhibits 
reinstatement of opioid CPP, focussing on AMPA receptor expression, but results 
were inconclusive. 
 
4.1. Putative model for the reinstatement of drug-seeking 
behaviour 
Figure 4.1 describes the putative model for synaptic plasticity mechanisms 
occurring during the stages of CPP. During the acquisition of heroin CPP, 
morphine, a metabolite of heroin acts at µ opioid receptors on GABAergic neurons 
in the VTA, inhibiting GABA release. This leads to the disinhibition of dopamine 
cells and results in an increase in dopamine release in the NAc, which mediates 
the rewarding effects of the drug (Hyman et al., 2006). Repeated administration of 
opioids leads to long-lasting changes within the reward circuitry, including 
excitatory neurotransmission (Luscher and Malenka, 2011). Glutamatergic, 
cholinergic and GABAergic pathways interconnect to modulate synaptic 
strengthening to induce long-term potentiation and increase AMPA receptor 
responsiveness to glutamate (Kauer and Malenka, 2007). During extinction 
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training, further changes occur, with the disruption of LTP (Portugal et al., 2014) 
and the formation of an alternate neutral memory. The drug-related memory is 
thus suppressed and the conditioned behaviour is extinguished (Bouton, 2002). 
During reinstatement, the exposure to a priming dose of heroin causes further 
glutamatergic and dopaminergic signalling, leading to plasticity changes that 
restore LTP (Moron et al., 2007, Portugal et al., 2014). The drug-associated 




Figure 4.1: Putative model for the acquisition, extinction and reinstatement of drug-seeking behaviour and the effect of MLA on 
reinstatement. At baseline, dopamine and acetylcholine neurons fire tonically, maintaining basal tone. Acute administration of heroin 
causes dopamine neurons to switch to burst firing leading to increased levels of dopamine in the NAc, which mediate the rewarding 
effects of the drug. During acquisition, repeated contextual administration of heroin results in plastic changes in the reward circuitry 
by the strengthening of glutamate signalling. During extinction, the context-associated memory is rewritten in the absence of the 
drug and leads to synaptic weakening, or the disruption of LTP. During reinstatement, exposure to a priming dose of heroin causes 
an increase in dopamine and glutamate firing leading to plasticity changes that restore LTP. The drug-associated memory is thus 
re-activated and this triggers reinstatement. MLA (red) is proposed to block α7nAChRs in the ventral hippocampus and VTA, which 
inhibits the excitatory and inhibitory signalling required for LTP, inhibiting the recall of the drug-associated memory, and thus 
preventing the expression of the conditioned behaviour. 
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The location of the hippocampus and its interconnectivity with the reward circuitry 
and cholinergic innervation places it in an ideal position to influence synaptic 
plasticity events occurring during the different stages of addictive behaviours 
(Woolf and Butcher, 2011, Kutlu and Gould, 2016). Importantly, it appears that 
hippocampal theta oscillations are considered particularly important in learning the 
significance of drug-associated stimuli, and α7nAChRs can alter these oscillations 
(Apartis et al., 1998, Cheng and Yakel, 2015, Hernandez-Perez et al., 2016, 
Robinson et al., 2016). Based on the results from Chapter 2 and the findings by 
Wright et al. (2018), it is proposed that opioid priming induces increases in diffuse 
acetylcholine in the hippocampus (and the VTA). This increase in ACh levels could 
activate α7nAChRs, which increases presynaptic intracellular calcium levels, 
leading to an increase in glutamate release from presynaptic terminals and the 
enhancement of postsynaptic excitability (Gray et al., 1996, Feduccia et al., 2012). 
This could favour the induction of alterations in synaptic plasticity, which is 
believed essential in the manifestation of reinstatement (Shen et al., 2011, 
Portugal et al., 2014) In-vivo measurements of field EPSPs after heroin-primed 
reinstatement of self-administration in rats have shown that heroin priming induces 
NMDA-dependent LTP in the NAc, concurrent with an increase in the diameter 
and density of medium spiny neuron spines. Furthermore, the inhibition of 
GluN2B-containing NMDA receptors by the direct administration of either an 
antagonist or siRNA into the NAc inhibited heroin-primed reinstatement (Shen et 
al., 2011).Furthermore, CPP studies have shown that, while the acquisition of 
morphine CPP is associated with enhanced basal synaptic transmission but 
impaired LTP in the mouse hippocampus, morphine-primed reinstatement of CPP 
results in a robust enhancement of LTP, which is blocked by an GluN2B-selective 
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antagonist administered directly in the hippocampus (Portugal et al., 2014). This 
evidence is compelling as both studies show a strong involvement of NMDA-
dependent LTP in the reinstatement of opioid seeking in brain regions known to be 
involved in modulating drug-seeking behaviours. 
In Chapter 3, there was no significant effect of MLA on the cue- and drug-primed 
reinstatement of IVSA, which conflicted with the CPP results of Chapter 2. This 
prompts reflection on the behavioural and neurochemical differences that govern 
reward-related learning paradigms. As mentioned previously, numerous brain 
regions contribute to the development and expression of addiction-related 
behaviours. It is possible that IVSA involves other brain regions such as BNST, 
ventral pallidum and lateral habenula, to a greater extent than CPP (Brown et al., 
2010). These brain regions have yet to be shown to be modulated by 
α7nAChRs.and as such; antagonism of α7nAChrs in the ventral hippocampus 
would be insufficient to block IVSA. 
The major difference between CPP and intravenous self-administration is that the 
former is a classical Pavlovian model of drug-related learning, whereas the latter is 
an operant model. Both of these paradigms are used to study addiction-related 
behaviours, and the reinstatement stage of these paradigms appears to have a 
certain predictive validity as conditions that trigger craving and relapse (drug re-
exposure, contextual cues and stress) in humans also reinstate drug seeking in 
animals.  
Treatments for addiction to drugs of abuse have come from preclinical studies and 
either reduce withdrawal symptoms, substitute for or block the reinforcing effects 
of the drug of abuse (Bart, 2012). Reviews of these treatments however show that 
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in the long term, they may not prevent relapse (Dong et al., 2017), which sheds 
light on another limitation of current behavioural paradigms, which have short time 
frames. Studies have shown that to a certain extent, there are distinct and 
additional brain regions that mediate cue- and drug-induced reinstatement 
compared to drug reinforcement and abstinence (Stewart, 2008, Rogers et al., 
2008, Namba et al., 2018). In reinstatement studies, the majority of compounds 
that have an effect on cue-induced reinstatement of self-administration have the 
same effect in drug-primed reinstatement (Perry et al., 2014). There are however 
exceptions which highlight potential differences in the brain regions involved in the 
reinstatement in response to either stimulus, especially in studies with opioids. For 
example, D1 and D2 receptor antagonists appear to have no effect on stress-
primed reinstatement of heroin seeking, whereas they inhibit drug-primed 
reinstatement (Shaham and Stewart, 1996). Additionally, an OX1 orexin receptor 
antagonist decreased the cue-primed reinstatement of heroin seeking but had no 
effect on drug-primed reinstatement (Smith and Aston-Jones, 2012). A limitation of 
studies of potential treatments on the reinstatement of opioid self-administration 
however is that the effects of the drug are rarely studied on the reinstatement in 
response to both stimuli in the same study. Further research into the potential 
differences in contributions of brain regions is therefore needed.  
There are also instances of pharmacological manipulation of the reinstatement of 
CPP and IVSA studies which contradict each other, bringing into question whether 
CPP and IVSA are isomorphic paradigms. The main argument of this is the 
contradictory evidence of dopaminergic transmission in the reinstatement of CPP 
or IVSA. As previously discussed in Chapter 1 (Section 1.4.4.1.), many studies 
have shown that antagonising  dopamine receptors (D1 and D2) inhibited the 
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drug-primed reinstatement of heroin IVSA (Shaham and Stewart, 1996, See, 
2009); whereas they appear to have no effect on morphine-primed reinstatement 
of CPP (Ribeiro Do Couto et al., 2005), and lesion studies in CPP suggest a 
potential role of dopaminergic transmission, however methodological 
considerations limit these findings (Wang et al., 2002). Aguilar et al. (2009) have 
summarised many other differences in findings in the reinstatement of either CPP 
or IVSA with opioids and cocaine and have shown that stressors (such as restraint 
stress or food deprivation) which induce the reinstatement of morphine or cocaine 
CPP do not all reinstate heroin or cocaine IVSA, cross-reinstatement of opioid 
CPP and IVSA with other drugs of abuse produce different responses, and 
manipulations of the corticotrophin system (for opioid drugs) and glutamatergic 
transmission (for cocaine) also have opposing effects in both behavioural 
paradigms. 
The advantage of CPP is that it is a relatively inexpensive and simple model for 
measuring reward-based learning. On the basis of detecting drug reinforcement, 
both CPP and IVSA can be argued to be overlapping techniques, as drugs such 
as cocaine, heroin and methamphetamine that produce CPP produce self-
administration. Conversely, drugs that have been shown not to produce CPP 
(such as dopamine, opioid and acetylcholine receptor antagonists or 
antidepressants) also do not produce self-administration (Bardo and Bevins, 
2000). There are however some instances of drugs that produce either CPP or 
self-administration and do not produce a response in the other method (LSD, 
buspirone, PCP, pentobarbital Bardo and Bevins (2000)). 
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4.2. How do CPP and IVSA relate to human relapse? 
Although both CPP and IVSA are well established methods with a certain 
predictive validity for reward-related behaviours, they are more likely correlates of 
a specific type of behaviour which is observed in addicts and not of addiction as a 
whole. Addiction is defined as a chronically relapsing disorder consisting of 
compulsive drug seeking and taking despite negative consequences. In CPP, the 
drug-paired association is made with very few drug administrations, so this occurs 
in the absence of a compulsive drug-seeking state. In IVSA, animals voluntarily 
self-administer drugs, but there is no negative consequence to taking the drug. 
Would these behaviours be different in the presence of a negative consequence? 
This could be investigated by introducing a mild punishment element to the 
paradigm, where animals would receive a mild punishment paired with each 
infusion (in the case of IVSA) or in paired with each entry to the drug-paired side 
(in the case of CPP), and the animal would have a choice to seek the reward 
despite the punishment (Vanderschuren and Everitt, 2004, Pelloux et al., 2007). 
Theoretically this could model the compulsive need to take drugs despite negative 
consequences seen in humans. An alternative method could also be by devaluing 
the reinforcer by pairing it with an aversive drug. Concurrent injections of lithium 
with food has been shown to decrease responding for food, but not when it is 
paired with cocaine or ethanol, indicating habitual use over the drug’s incentive 
value (Panlilio and Goldberg, 2007). The escalation of use is another aspect of 
addiction for some drugs that is not seen in a fixed ratio paradigm of IVSA or CPP. 
In the case of CPP, this is difficult to model. In IVSA studies, animals given 
extended access to drugs have been shown to increase their rates of drug intake 
over time, related to a loss of control over intake (Bozarth and Wise, 1985). 
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Furthermore, it has repeatedly been shown that reinstatement is more likely in rats 
that have been given extended access to drugs. There are ethical limitations to 
this method as rats and primates will neglect grooming, feeding or will overdose 
(Bozarth and Wise, 1985).  
 
4.3. α7nAChRs as a clinical therapeutic target 
This work and previous studies (Feng et al., 2011, Liu, 2014, Wright et al., 2018) 
have begun to reveal the α7nAChR as an interesting target for the treatment of 
addiction to substances of abuse (nicotine and opioids so far). What makes it a 
particularly interesting target is that is seems to specifically modulate relapsing 
behaviour, which is a major failure of current treatments. The CPP results suggest 
that MLA inhibits either the drug or cue-primed association of the drug and the 
context, which is a well reported trigger for cravings. The IVSA results from this 
thesis suggest that antagonising α7nAChRs may be effective in blocking the 
triggering of cravings by passive cues, but perhaps it is not effective in blocking 
the more active aspect of taking drugs and relapsing. It is unlikely that 
antagonising α7nAChRs is sufficient to treat addiction when given alone, but 
potentially as an adjunct to current therapies which prevent the negative affective 
states of withdrawal and block the reinforcing effects of the drug of abuse. The 
premise of treatment would be that it should be taken prior to being exposed to a 
drug-associated stimulus; therefore the timing of treatment is also crucial. We 
have not yet shown whether blocking α7nAChRs following the exposure to a cue 
would still prevent reinstatement, which would correlate for an addict being 
exposed to a drug-paired stimulus and taking treatment at that time. If a compound 
had rapid absorption rates, then this could be taken as a preventative method for 
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when a patient is about to enter a high-risk situation (e.g. An environment 
associated with prior drug use) or taken ‘on demand’ when a patient’s craving level 
increases. This as-needed approach to treating addiction has been used for 
treating alcohol addiction with the opioid receptor antagonist nalmefene, which has 
been shown to significantly reduce drinking (Francois et al., 2015), however the 
methodology of clinical studies has brought the significance of their results into 
question (Fitzgerald et al., 2016).  
Although α7nAChR antagonists might work as on-demand therapies, it is unlikely 
that they would be clinically relevant as chronic treatments, as α7nAChRs are 
present in many brain regions and involved in a variety of cognitive behaviours, 
and putative treatments targeting α7nAChRs for cognitive disorders such as 
schizophrenia and Alzheimer’s disease, are agonists (Albuquerque et al., 2009). 
Antagonising α7nAChRs may therefore produce negative cognitive and emotional 
states in patients that would result in the discontinuation of treatment. A better 
route of therapeutic investigation might be to explore negative allosteric 
modulators (NAMs). This approach would allow the down-regulation of α7nAChR 
activity, whilst still allowing basal endogenous function thereby reducing aversive 
side effects. An interesting endogenous NAM is kynurenic acid, which has been 
proposed to be a NAM of α7nAChRs (Albuquerque and Schwarcz, 2013), and has 
been reported to inhibit the reinstatement of nicotine, cocaine and cannabinoid  
IVSA in squirrel monkeys (Justinova et al., 2013, Secci et al., 2017). Kynurenic 
acid is also an antagonist of the three classes of ionotropic glutamate receptor, 
AMPA, NMDA and kainate, with a similar affinity for NMDA receptors as 
α7nAChRs. To a certain extent, kynurenic acid has benefits as a glutamate 
receptor antagonist due to its neuroprotective and anticonvulsant effects; however 
207 
 
the non-selective inhibition of excitatory currents in the brain is bound to have a 
multitude of undesirable effects. Furthermore, the affinity of kynurenic acid for the 
α7nAChR is still unclear, ranging from 10 to 100µM (Albuquerque and Schwarcz, 
2013), depending on the methodology used (cell cultures or brain slices, method 
of drug application, age of animal, native or heterologous receptor expression 
etc.), therefore further work is needed to characterise kynurenic acid as an 
α7nAChR NAM. Nonetheless, future compounds could be developed based on the 
structure of kynurenic acid but with improved affinity for α7nAChR over glutamate 
receptors. Multiple α7nAChR positive allosteric modulators (PAMs) are currently 
being investigated as potential treatments for cognitive diseases (Yang et al., 
2017), and the structure-activity relationship can be studied to identify residues 
that govern positive and negative modulation. Recently, Gill-Thind et al. (2015) 
have developed α7nAChR ligands differing only in methyl substitutions on a single 
aromatic ring, which greatly alters their pharmacology and identified 5 different 
subclasses of α7nAChR ligand, including PAMs and NAMs. In addition, the recent 
improvement of the acetylcholine binding protein model by introducing further 
humanising mutations will allow accurate studies of the crystal structure of 
α7nAChR allosteric binding sites for rational drug design (Delbart et al., 2018). 
These are promising avenues for drug discovery and potential therapeutics. 
This rate of absorption into the brain would be a factor of the dose, the route of 
administration and the pharmacokinetics of the compound, all of which need to be 
considered to produce an effective anti-relapse therapy. MLA has been shown to 
have a short elimination half-life following i.v. administration (approx. 1.3 hours) 
and a low bioavailability following oral administration (approx. 17%) (Turek et al., 
1995, Nirogi et al., 2012). Peak plasma levels of MLA were reached at 30 minutes 
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following both i.v. and oral administration (Nirogi et al., 2012). In addition regional 
brain distribution in rodent brains showed that MLA was rapidly taken up into the 
brain (approx. 10 mins after i.v. administration). For the facilitation of daily 
treatment, the bioavailability of an α7nAChR ligand would need to be improved. 
However, as MLA enters the bloodstream easily, There appears to currently be no 
literature on the pharmacokinetics of MLA in humans.  
The route of administration would depend on the compound, but a rapid delivery to 
the brain would be needed to abolish arising cravings. The route of administration 
of a potential therapy would depend on whether it would be used chronically or on 
demand. For example, varenicline is used chronically; therefore it needs to reach a 
steady state but does not need a fast onset of action. Dermal patches and oral 
administration are slow routes of administration which achieve a steady state in 
the patient and do not need a fast onset of action; therefore they would be better 
for chronic use. For an ‘on-demand’ treatment, faster routes of administration are 
required to rapidly prevent craving symptoms. Inhalers, nasal sprays and buccal 
delivery (under the tongue) are rapid methods of drug delivery for high risk 
situations. This would depend on the properties of the ligand, but this type of route 
of administration would potentially produce more rapid delivery than oral 
consumption. The advantage of an α7nAChR NAM is that it is likely to have little 
abuse liability: nicotine is an agonist, and primarily targets heteromeric nAChRs to 

















The aim of this thesis was to examine the role of α7nAChRs in motivational 
memory in the context of drug reward using conditioned place preference and 
intravenous self-administration (IVSA). The major findings and conclusions are 
below: 
• Systemic pre-treatment with the selective α7nAChR antagonist 
methyllycaconitine (MLA) results in the selective inhibition of the 
reinstatement of heroin CPP in rats. 
• The effect of MLA on the drug- and cue-primed reinstatement of heroin 
IVSA is still undetermined. 
• MLA has no effect on the motivational value of heroin, demonstrated in both 
CPP and IVSA paradigms. 
• The synaptic plasticity events occurring during reinstatement and the effect 
of MLA on plasticity are still undetermined.  
The results from this thesis corroborate the previous evidence of a role of 
α7nAChRs in modulating the reinstatement of CPP selectively, and extend their 
findings with a more rewarding and clinically-relevant opioid, heroin. The aim was 
also to extend these findings in the IVSA model, but due to the study being 
underpowered, further work is needed to elucidate the role of α7nAChRs in the 
reinstatement of this behavioural paradigm. Further work is also needed to 
determine the synaptic plasticity events which occur at the different stages of CPP 
and IVSA, and to elucidate the role of endogenous acetylcholine in modulating 
relapse-like behaviour in these paradigms. Understanding the associative 
memories that are formed between drugs of abuse and contextual stimuli has 
crucial implications for treatment, as one of the major failures of current therapies 
is the lack of prevention of relapse.  
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5.2.  Future Work 
5.2.1. Improving the behavioural paradigms 
As previously discussed, while both the CPP and IVSA paradigms are well-
established correlates for specific types of addiction-related behaviour, they are 
not complete models of addiction. To improve these models, the protocol could 
include traits more relevant to humans, such as an element of seeking reward 
despite negative consequences (foot-shock punishment), extended access to 
drugs, voluntary abstinence during extinction and potentially an element of choice 
during reinstatement.  
The main issue with the results in Chapter 3 (IVSA) was that the study was 
underpowered. The study would need to be repeated with additional subjects in 
each treatment group. Furthermore, as previously mentioned, although there are 
overlapping brain regions involved in drug- and cue-primed reinstatement, there 
are also distinct regions which are activated in response to either stimulus. In this 
study, reinstatement was achieved by exposure of drug AND cue. The next aim 
would be to repeat this study but expose the animals to drug OR cue to observe 
any potential effect of MLA on either cue- or drug-primed reinstatement of self-
administration. Additionally, MLA could be delivered intracranially, as this was 
shown to have a more pronounced effect on reinstatement of morphine CPP when 
administered directly into the ventral hippocampus than systemically (Wright et al., 
2018). It is also possible that the dose of MLA needs to be increased for IVSA 
experiments, as Liu (2014) found a more marked effect on the reinstatement of 




5.2.2. Investigating the role of cholinergic pathways in reinstatement 
To determine a temporal role of cholinergic signalling, levels of diffuse 
acetylcholine could be measured in regions of interest during reinstatement. 
Regular microdialysis experiments would not allow real-time measurements of 
endogenous acetylcholine levels in brain regions, however, there is a technique for 
in-vivo measurements of ACh with a sub-second resolution (Sarter and Kim, 
2015). This method would allow the time-dependent changes in cholinergic 
transmission during the different stages of motivational memory paradigms. This 
could then be correlated with the in-vivo behaviour to further our understanding of 
cholinergic transmission in drug seeking behaviour. 
The invention of optogenetics and its broad applications has greatly advanced our 
understanding of neuronal networks underlying behaviour. This method allows the 
temporal control of genetically defined neurons in live animals by light (Deisseroth 
et al., 2006). Witten et al. (2010) have shown that the optogenetic activation of 
cholinergic interneurons in the NAc increases the frequency of inhibitory currents 
and suppresses medium spiny neuron spiking, and vice versa. This study also 
showed a role of cholinergic interneurons in the acquisition of cocaine CPP in 
mice, as the silencing of these interneurons resulted in a decrease in preference 
for the drug-paired chamber (Witten et al., 2010). These experiments demonstrate 
that there is potential to use optogenetic manipulation of cholinergic inputs to brain 
regions to determine their role in addiction-related behaviours, which could also be 
applied to the IVSA paradigm.  
Microdialysis and optogenetics could allow the measurement and manipulation of 
cholinergic pathways but do not enable the investigation of the role of these 
pathways in drug-seeking behaviour at a receptor-specific level. The use of other 
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models and methods could enhance our knowledge of the selective role of 
α7nAChRs in reinstatement. 
 
5.2.3. Investigating the selective role of α7nAChRs in reinstatement 
The use of transgenic animals can be useful to study the selective role of 
α7nAChRs in reinstatement. It has previously been shown that mice lacking the 
α7nAChR subunit are still able to acquire nicotine CPP (Walters et al., 2006b) and 
IVSA (Pons et al., 2008), however it is possible that compensatory mechanisms 
account for the lack of α7nAChRs. It could be more relevant to use conditional 
knockouts (Hernandez et al., 2014) to induce deletions specifically in a tissue 
neuron type. This could allow a targeted and selective investigation into the role of 
α7nAChRs on dopaminergic glutamatergic or GABAergic signalling in a specific 
brain region, such as the ventral hippocampus in behavioural paradigms. 
Temporal control of α7 gene expression by inducing knockouts during later stages 
of development of the animal could also allow a study of the role of these 
receptors without confounding results from compensatory mechanisms, though 
currently, there are no such transgenic animals in existence to our knowledge.  
Immunohistochemical quantification of fos expression (acting as a marker of 
neuronal activation) in neurons could also reveal different brain regions activated 
during the reinstatement of IVSA and CPP. The effect of MLA on the activation of 
these brain regions or the investigation of the α7 knockout mice could shed some 
light on the role of α7nAChRs in regulating the activation of these brain regions. 
There are also c-fos-GFP transgenic mice and more recently, rats, which have 
GFP tags transcribed onto fos to identify recently synthesised fos (Barth et al., 
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2004, Katoh et al., 2014). These transgenic animals could be used to identify 
specific brain regions recently activated in response to different stimuli, and to 
investigate the role of α7nAChRs in regulating the activation of these regions.  
 
5.2.4. Investigating synaptic plasticity events during reinstatement 
There are also differences in brain regions involved in the reinstatement of CPP 
and IVSA. Due to these differences, it could be beneficial to identify the synaptic 
plasticity events or activation of brain regions during reinstatement, in both 
behavioural models, and the effect of MLA on these events. This could be done by 
improving the techniques used in the current study for synaptic AMPA receptor 
quantification. The current study investigated synaptic plasticity changes occurring 
immediately after memory recall and focussed on the phosphorylation of GluA1-
containing AMPA receptors, however other changes also occur at later stages of 
LTP to stabilise the synapse. For example, the GluA2 AMPAR subunit also plays a 
significant role in the regulation of synaptic transmission by regulating receptor 
kinetics, single channel conductance and calcium permeability (Oh and Derkach, 
2005). It is one of the most tightly regulated subunits in terms of gene expression, 
RNA editing, receptor assembly and trafficking, suggesting it plays a major role in 
AMPAR structure, function and synaptic transmission. During LTP, calcium-
permeable GluA1 homomers are exchanged for Ca2+-impermeable 
GluA2-containing AMPAR to stabilise the synapse (Isaac et al., 2007). It is 
therefore important to measure the synaptic expression of this subunit as well as 
GluA1 in future studies.  
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Another method of measuring synaptic strength is electrophysiology. The role of 
α7nAChRs in the modulation of synaptic plasticity is well documented and 
previous work in this lab has shown that MLA inhibits LTP in the mPFC (Udakis et 
al., 2016); and this has also been reported in the hippocampus (Cheng and Yakel, 
2015). Further electrophysiological experiments could be used to elucidate 
changes in LTP in the ventral hippocampus after the reinstatement of either CPP 
or IVSA, and the effects of MLA on LTP. In addition, improvements in in-vivo 
electrophysiological methods could allow real-time recordings of synaptic 
transmission occurring during the behavioural paradigm. Transgenic α7 knockout 
mice (mentioned below) could also be used in these experiments to determine 
their effect on signalling in these behavioural paradigms.  
 
5.2.5. Clinical relevance 
As previously discussed (Chapter 4, section 4.3), the use of an antagonist is not 
clinically relevant due to undesirable generalised effects. A more relevant ligand 
for α7nAChRs would be a negative allosteric modulator. To progress the findings 
in this thesis further, it would be interesting to investigate the effects of an 
α7nAChR NAM on the reinstatement of heroin CPP. As there are few effective 
α7nAChR NAMs currently in existence, much work is initially needed in the 
development of such a compound. As previously discussed, some novel α7nAChR 
NAMs have been developed with structural homology to a previously discovered 
allosteric agonist (Gill-Thind et al., 2015). Perhaps one of these compounds could 
be an interesting ligand for preclinical studies, however it still remains to be 
determined if the allosteric site is the same as that characterised by Neill Millar. A 
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concern of using a NAM however is that its effect on reinstatement will be more 
dilute and potentially non-existent, as receptors will retain basal levels of function. 
The present study has confirmed that MLA selectively inhibits the reinstatement of 
heroin CPP, which corroborates previous findings with morphine (Feng et al., 
2011, Wright et al., 2018). It seems this effect is therefore generalised to opioids, 
and drugs of abuse share common neurobiological mechanisms to a certain 
extent, therefore we could hypothesise that MLA may inhibit the reinstatement of 
other classes of drugs of abuse. There is already some evidence of nicotinic 
receptor (and even α7) involvement in addiction processes for other drugs of 
abuse, such as alcohol, cocaine, cannabinoids, ethanol (Rahman et al., 2015) and 
methamphetamine (conflicting evidence (Verrico et al., 2014, Pittenger et al., 
2017)), though there is still much to be investigated. 
These future experiments would extend the findings from the current study in 
terms of the role of α7nAChRs in the reinstatement of drug seeking in behavioural 
paradigms. Additionally, these experiments could allow us to develop and improve 




AN INTRODUCTION TO THE APPENDICES 
 
Appendix A will show the optimisation of subcellular fractionation and Western blot 
experiments to quantify AMPA receptor changes in the postsynaptic membranes 
in the hippocampi of mice that underwent morphine-primed CPP. Appendix B will 
expand on the novel use of near-infrared scanning technology for 
immunohistochemistry, alongside confocal microscopy as a novel method of 
synaptic protein quantification. These different methods aim to extend 
autoradiography data found in our lab further to identify subunit-specific changes 

















As previously discussed, Wright et al. (2018) found a significant increase in [3H]-
AMPA binding in the ventral hippocampus of mice that underwent morphine-
primed reinstatement of CPP. This increase in [3H]-AMPA binding was blocked by 
MLA administration prior to morphine-primed reinstatement, suggesting a 
modulatory role of α7nAChRs on glutamatergic signalling in the ventral 
hippocampus during reinstatement. Autoradiography however only measures the 
total number of receptors bound, regardless of subcellular location or the subunit 
composition of these receptors. To elucidate changes occurring at a synaptic level, 
subcellular fractionation accompanied by Western blot quantification was selected 
to isolate postsynaptic membranes.  
Subcellular fractionation is a method of separating organelles, such as nuclei, 
mitochondria, plasma membranes and ribosomes, based on their density. It is 
ideal for the enrichment and isolation of low abundance proteins in specific cellular 
compartments. The fractionation process involves the disruption of the cellular 
organisation and the fractionation of cellular compartments using differential 
centrifugation (Lassek et al., 2015). The methodology used in this study was 
based on methods used by Billa et al. (2009) and Portugal et al. (2014), who 
isolated postsynaptic membrane fractions using density gradient centrifugation to 
show changes in synaptic plasticity during different stages of morphine CPP (in 
mice and rats). This technique would allow the isolation of postsynaptic 
membranes from whole brain region homogenates for the quantification of proteins 
inserted in the postsynaptic membrane. NMDA-dependent LTP is characterised by 
the insertion of AMPA receptors in the postsynaptic membrane (Luscher and 
Malenka, 2012), and studies have demonstrated synaptic plasticity alterations in 
220 
 
CPP (Ma et al., 2007, Billa et al., 2009, Portugal et al., 2014). Subcellular 
fractionation would therefore allow the quantification of AMPA receptors only at 
postsynaptic membranes, excluding extrasynaptic and intracellular receptors 
stores, to characterise changes in synaptic plasticity in morphine CPP. The aim of 
this study would then be to apply this technique to investigate the role of 
α7nAChRs in modulating these changes in synaptic plasticity.   
 
A.2. Materials and methodology 
Animals 
Initial optimisation of the subcellular fractionation and Western blot experiments 
was performed using tissue taken from naïve male C57/BL6 mouse brains (6-9 
weeks). Thereafter, hippocampi were dissected from animals (C57/BL6 mice (8-10 




Subcellular fractionation methods were based on previous publications by Billa et 
al. (2009) and Portugal et al. (2014). The steps of the protocol are shown in Figure 
A.1. 
Mouse hippocampi (whole hippocampi, right and left side pooled) were processed 
following the methodology by Portugal et al. (2014). Hippocampi were 
homogenised on ice using a glass homogeniser in 1.5 mL homogenisation buffer 
containing 0.32 M sucrose (to maintain osmotic pressure), 0.1 mM CaCl2, 1 mM 
221 
 
MgCl2 and 1 mM phenylmethylsulfonyl fluoride (PMSF, protease inhibitor). 
Approximately 200 µL of hippocampus homogenate were reserved for 
immunoblotting prior to centrifugation. The remaining homogenate was transferred 
to 10 mL polycarbonate tubes (Beckman Coulter) and the sucrose concentration 
was then increased to 1.25 M by adding 1.86 mL 2 M sucrose (with 0.1 mM 
CaCl2). The homogenate was then overlaid with 1 M sucrose. The less dense 1 M 
sucrose remains in suspension above the denser 1.25 M sucrose-containing 
homogenate. Tubes were centrifuged at 100 000 x g for 3 hours at 4°C (Beckman 
Coulter Ultima ultracentrifuge). The synaptosome fraction at the 1.25/1 M sucrose 
concentration interface was collected using a syringe. To isolate synaptic 
junctions, the synaptosomes were diluted 1:10 in 20 mM Tris-Cl, pH 6 containing 
1% TX-100 and mixed at 4°C for 20 minutes prior to centrifugation at 40 000 x g 
for 20 minutes. To separate the presynaptic membranes from the postsynaptic 
membranes, the pelleted synaptic junctions were collected and resuspended in 
Tris-Cl, pH 8 containing 1% TX-100, mixed for 20 minutes at 4°C then centrifuged 
at 40 000 x g for 20 minutes. The postsynaptic membrane fractions (postsynaptic 
densities, PSD) are insoluble at pH 8, whereas the presynaptic membrane 
fractions (PAZ) remain soluble. Samples were kept on ice for the duration of 
experiments or stored at -80°C until further use.  
 
Protein Concentration Determination 
The method used for measurement of protein concentrations was the Bio-Rad DC 
protein assay, similar to the Lowry assay but improving on the stability of the 
reagents in the presence of protein and the rapidity of the colour change (Noble 
and Bailey, 2009). This assay measures proteins in detergent, where other 
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methods of protein measurements would be inappropriate due to interference with 
dyes (e.g. Bradford protein assay).  
Standard protein concentrations were made up with serial concentrations of BSA 
(0.025-2 mg/mL) in the same buffer as the samples to measure. A blank sample 
contained the buffer alone. Reagent A* was made up with 20 µL of reagent S per 
1 mL of reagent A. 5 µL of the standards and samples were added to a clear, 
96-well plate (Corning), then 25 µL of reagent A* and 200 µL of reagent B and 
mixed. The samples were incubated for a minimum of 15 minutes before 
measuring the absorbance in a microplate spectrophotometer at 750 nm. Each 
standard and sample was measured in duplicate for increased accuracy. The BSA 
standard curve was used to measure sample protein concentration.  
 
Immunoblotting 
Protein samples obtained from subcellular fractionation were boiled at 70°C for 10 
minutes in Laemlli buffer to denature proteins and remove quaternary structures to 
allow efficient running. Equal amounts of protein (5, 10 or 20 µg) were run along a 
protein ladder (NEB Colorplus P7709s) at 120 V for 1 hour and 20 minutes in a 
7.5% acrylamide gel and electrotransferred onto PVDF membranes at 0.45A for 
45 minutes. Some PVDF membranes were cut horizontally between the 80 kD and 
58 kD markers to allow blotting for different proteins on the same membrane. 
Membranes were then blocked with 5% (w/v) BSA in TBST (20 mM Tris, pH7.4, 
0.1% Tween 20 (w/v), and 150 mM NaCl) for 1 h at room temperature. Proteins 
were probed with primary antibodies: rabbit anti-PSD-95 (1:1000, Abcam), chicken 
anti-syntaxin-1 (1:2000, Sigma) rabbit anti-GluA1 (1:1000, Millipore), rabbit 
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anti-GluA1 (phosphoSer845, 1:1000, Millipore), chicken anti-βIII tubulin (1:500, 
Abcam) and incubated overnight at 4°C. Tagged secon dary antibodies used were: 
donkey anti-rabbit (1:10000, Li-Cor) and donkey anti-chicken (1:10000, Li-Cor). 






Figure A.1: Mouse morphine CPP injection protocol. Downward arrows ↓ represent 
saline (10 mL/kg) or morphine (10 mg/kg) injections. The morphine priming dose 
was 5 mg/kg, i.p. No testing was done on weekends (days 10-11 and 17-18). 
 
Morphine CPP procedures were conducted in the same way as in Chapter 3. The 
experimental protocol is represented in Figure A.2. The mouse CPP apparatus is 
shown in Figure A.2. Briefly, all mice were handled one week prior to 
experimentation. Mice underwent two habituation sessions to establish baseline 
preference and the means of the sessions were taken as their baseline 
preference. They were pseudo-randomly assigned a compartment (vertical stripes 
or black, slightly different apparatus due to the lack of a neutral zone, see Figure 
A.2.1) paired with morphine (10 mg/kg, i.p.) and an unconditioned compartment 
with saline (10mL/kg, i.p.) on alternate days, over 4 days. On day 9, mice were 
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recorded free-roaming for 15 minutes in the post-conditioning test. Extinction 
consisted of 4 days of saline injections in the drug-paired and unpaired 
compartments on alternate days. The post-extinction test was conducted in a 15 
minute session on day 16. On day 19, the mice were either given a saline prime 
(10 mL/kg, i.p.) or a morphine prime (5 mg/kg, i.p.) and recorded for 30 minutes in 
the reinstatement test. The first 15 minutes of reinstatement was used for analysis. 
Results were analysed by one-way ANOVA and Newman-Keuls post-test in 
GraphPad Prism (version 5).  
Mice were then immediately sacrificed by Schedule 1 dislocation of the neck and 
the dissected hippocampi were snap frozen in ice cold isopentane before being 





Figure A.2: Top: mouse CPP apparatus. The left compartment comprises of black 
walls with a round-holed floor, whereas the right compartment has vertical stripes 
and a square-holed floor. Both compartments are separated by a guillotine door, 
seen open here. Bottom: the CPP apparatus placed inside the sound attenuation 
chamber. Cameras are mounted to the ceiling to record mice inside the boxes. 
 
A.3. Aims 
The aim of this study was to identify and optimise an appropriate experiment to 
detect and quantify changes in postsynaptic AMPA receptor expression or 
phosphorylation following reinstatement of morphine CPP. Based on previous 
findings, (Wright et al., 2018), these experiments focussed on the whole 
hippocampus (due to tissue constraints). Successful experimental optimisation 
would then allow more detailed examinations into AMPA receptor 
expression/phosphorylation at different stages of behavioural studies and to 




Western blot validation in naïve mice 
Syntaxin-1 and PSD-95 were used as selective markers for the presynaptic and 
postsynaptic membranes (Billa et al., 2009). Syntaxin-1 is a protein present in 4 
isoforms of approximately 35 kD, part of the SNARE complex involved in docking 
and fusing vesicles to the plasma membrane for the release of neurotransmitters 
(Shin, 2011). The antibody selected was selective to membrane-bound syntaxin-1, 
thus increasing chances of its detection in the presynaptic membrane. PSD-95 is a 
95 kD protein belonging to the membrane-associated guanylate kinase (MAGUK) 
family which acts as a postsynaptic docking protein for larger signalling molecules 
(de Bartolomeis and Tomasetti, 2012). These two membrane-bound synaptic 
proteins were selected as positive controls for successful isolation of the pre- 
(syntaxin-1) and postsynaptic (PSD-95) membranes by subcellular fractionation.  
 
Figure A.3: Western Blot detecting PSD-95 (red) and syntaxin-1 (green) protein 
bands in rat hippocampus. 20 µg of samples were loaded in each well. HPC: 
whole hippocampus homogenate, PAZ: presynaptic fraction, PSD: postsynaptic 
density fraction. 
 
In the unprocessed whole hippocampus homogenate Error! Reference source 
not found.(HPC, Figure A.3), both syntaxin-1 and PSD-95 were detected. In the 
presynaptic fraction (PAZ) only syntaxin-1 was detected, indicating the presence 
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of the presynaptic marker in this fraction. PSD-95 was present in the postsynaptic 
fraction (PSD), indicating the presence of the postsynaptic marker in the correct 
fraction. Syntaxin-1 was however also detected in the PSD fraction, though levels 
were much lower than in the hippocampus homogenate.  
To try and remove presynaptic contamination in the PSD fraction, the PSD sample 
was resuspended in tris pH 8 and the final centrifugation step of subcellular 
fractionation was repeated (see methods section). This did not succeed in 
removing the presynaptic terminals, and Western blot showed the PSD fraction no 
longer expressed PSD-95 (data not shown). 
Overall, these results showed the isolation of postsynaptic membranes (PSD) from 
a whole hippocampus homogenate, though with some presynaptic membrane 
contamination. Due to the lack of presynaptic AMPA expression (Billa et al., 2009), 
it was not deemed necessary to further process the postsynaptic fractions without 





Figure A.4: Relative quantification of βIII-tubulin signals in 10, 20 and 30 µg of 
whole hippocampal homogenates (HPC) and postsynaptic density (PSD) samples 
loaded.  
 
βIII-tubulin was selected as the loading control as actin was not detectable in the 
postsynaptic fractions. βIII-tubulin is a neuronal-specific form of β-tubulin which is 
anchored to the membrane and therefore should not be washed away during 
subcellular fractionation. Figure A.4 above shows that βIII-tubulin detection was 
relatively proportional to the amount of protein sample loaded in both the whole 
hippocampus homogenate (HPC) and in the PSD fractions (PSD). As the 
relationship was more linear in the 20µg sample, it was opted to load 20µg of 
samples for Western blot quantification. Once antibodies against GluA1 and 
phosphorylated GluA1 (Ser845) were titrated on naïve mouse brain samples, 
these proteins were probed for in mouse brains that underwent morphine-primed 




Morphine-primed reinstatement of CPP 
 
Figure A.5: Morphine-primed reinstatement of CPP. All mice underwent 
habituation, extinction and morphine conditioning. They were then divided into 
morphine- (n=14) or saline-primed (n=12) reinstatement groups. One-way ANOVA 
with Bonferroni post-hoc analysis. Post-conditioning vs Habituation ¤¤p<0.01, 
morphine-primed reinstatement vs post-extinction ***p<0.001. Data are 
mean ±SEM. 
 
During habituation, mice showed no preference for the drug-paired side (Figure 
A.5). In the post-conditioning test, mice showed significant preference for the drug-
paired side. This behaviour was then significantly reversed post-extinction. There 
was no effect of saline priming on preference; however morphine priming 
significantly increased animals’ preference for the drug-paired side, demonstrating 
the reinstatement of the drug-seeking behaviour. Immediately following 
reinstatement, mice were sacrificed and their hippocampi were dissected and 
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processed as described in the methods section above. AMPA receptor subunits 
GluA1 and phosphorylated GluA1 were probed in postsynaptic membranes to 



















AMPA receptor quantification following reinstatement 
 
 
Figure A.6: Effect of morphine or saline-primed reinstatement on GluA1 (A) and 
GluA1 phosphoSer845 (PGluA1, B). Signals were normalised to βIII-tubulin in 
mouse hippocampal homogenates (HPC) and postsynaptic fractions (PSD). 
Representative blots show GluA1 and phosphor GluA1 in red and βIII tubulin in 
green. Data are means±SEM. Unpaired t test, not significant, saline: n=5, 




Western blot quantification (Figure A.6A) showed that there was no difference in 
the expression of GluA1 subunits between saline and morphine-primed animals in 
either the whole hippocampus homogenate (HPC) or the postsynaptic membranes 
(PSD). There seemed to be a slight increase in the expression of GluA1 subunits 
phosphorylated at serine 845 (Figure A.6B) in the PSD in the morphine-primed 
animals, though this effect was not significant. Data showing GluA2/3 expression 
was inconclusive due to the loss of signal in multiple blots resulting in an 
incomplete data set (only n=2). 
These data show that there was no consistent, significant effect of morphine-
primed reinstatement on the expression of GluA1 or phosphorylated GluA1 




The mouse morphine CPP data agree with the findings by our and others’ many 
previous studies that these doses of morphine produce significant preference post-
conditioning, and induce a significant reinstatement of drug-seeking behaviour 
((Do Couto et al., 2003, Feng et al., 2011, Wright et al., 2018); for review, see 
Bardo et al. (1995)). The aim of this study was to successfully reinstate mice in 
morphine CPP and to collect the brains for biochemical analysis of postsynaptic 




Validation of subcellular fractionation and Western blot methodology 
This study aimed to optimise and validate the subcellular fractionation 
methodology used by Billa et al. (2009) and Portugal et al. (2014) to expand on the 
increases in AMPA receptor binding in the ventral hippocampus triggered by 
morphine-primed reinstatement of CPP, described by Wright et al. (2018). This 
method would then be used to quantify postsynaptic AMPA receptor expression at 
a subunit-specific level.  
Quantification of GluA1 and phosphorylated GluA1 at serine 845 at postsynaptic 
membranes showed no effect of morphine priming compared to saline control. 
These data do not complement the findings by Wright et al. (2018), nor do they 
directly contradict them. It is possible that attempting to determine changes at a 
subunit specific level dilutes any changes in expression seen by total [3H]-AMPA 
binding by autoradiography. Billa et al. (2009) however found that there was an 
increase in the phosphorylation of GluA1 subunits at Ser845 during the extinction 
phase of morphine CPP in rats, therefore demonstrating that this methodology can 
still be sensitive enough to detect subunit-specific changes in AMPA receptor 
expression at the postsynaptic membrane. Furthermore, Portugal et al. (2014) 
found that LTP was enhanced during morphine-primed reinstatement of CPP in 
mice, which was inhibited by an NMDA receptor antagonist injected directly into 
the dorsal hippocampus. In this thesis, mouse hippocampi were used, and 
proteins in individual samples were measured, whereas mouse brain sampled 
were pooled in the study by (Portugal et al., 2014), which could account for the 
differences in detection. Overall, the data found in this thesis do not support these 
previous findings.  
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Initial validation experiments showed that subcellular fractionation was successful, 
due to the lack of PSD-95 (the postsynaptic marker protein) in the presynaptic 
fraction (PAZ). The postsynaptic density (PSD) contained PSD-95 and syntaxin-1, 
suggesting incomplete separation of pre- and postsynaptic membranes during 
solubilisation, but as AMPA receptors are not expressed presynaptically (Billa et 
al., 2009), this was considered negligible. There is evidence showing syntaxin-3 is 
involved in trafficking AMPA receptors to the postsynaptic terminal by exocytosis 
from vesicles during LTP (Jurado et al., 2013), so it is possible the anti-syntaxin 
antibody is non-specifically binding to syntaxin-3 present in the postsynaptic 
membrane. (Billa et al., 2009) showed no syntaxin-1 in their PSD fractions, though 
a faint band is visible and these studies used enhanced chemiluminescence (ECL) 
as their detection method, which is less sensitive to small amounts of protein, 
especially when detecting larger amounts of protein on the same blot. The near-
infrared scanning technology used in this study is more sensitive to small amounts 
of protein; therefore it is possible there are traces of syntaxin-1 in their PSD 
fraction which are not detectable by ECL.  
The use of βIII-tubulin was deemed acceptable as a loading control due to the 
proportional increase in detection with the amount of protein loaded and due to it 
being membrane-bound, there was less risk of protein loss during subcellular 
fractionation.  
Western blot is a well-established technique that has been used to detect the 
expression of protein in a semi-quantitative manner, by allowing the measurement 
of protein expression relative to others, but it does not determine the absolute 
quantity of protein. Using tagged secondary antibodies to detect protein bands has 
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allowed the better detection of more than one protein on the same blot and 
improved detection of both faint and strong protein bands.  
Overall, it appears that no changes in GluA1 and phosphorylated GluA1 AMPA 
receptor subunits were detected by subcellular fractionation and Western Blot.  
 
A.6. Conclusions 
This study could not replicate the methods used by Billa et al. (2009) and Portugal 
et al. (2014). The results from this study were inconclusive in quantifying AMPA 
receptor subunit expression changes in mouse hippocampi which had undergone 
morphine-primed reinstatement of CPP. Other methods were therefore explored to 
further investigate the synaptic changes in AMPA receptor expression at a subunit 
level in the ventral hippocampus. Immunohistochemistry was selected as the 
method of immunolabelling, as it would more closely resemble autoradiography 
visualisation in that it would allow region-specific quantification of protein signals in 
the ventral hippocampus. Two novel methods of quantification were explored and 
developed: near-infrared whole-slice imaging by Li-Cor scanning technology, and 


















This appendix complements the data in Chapter 2 and discusses the optimisation 
of two different methods of AMPA receptor visualisation and quantification using 
immunohistochemistry: whole-slice visualisation by near-infrared Li-Cor scanning 
technology and protein colocalisation measurement by confocal microscopy. 
 
Li-Cor immunohistochemistry 
Li-Cor near-infrared scanners are marketed for improved Western blot detection 
and analysis. They remove the need of additional steps after secondary antibody 
application by the use of near-infrared tagged secondary antibodies, significantly 
reducing experimental time. Furthermore, the signal wavelength is considered 
more stable than an enhanced chemiluminescent (ECL) enzymatic detection, 
which has a variable signal over time. Another convenient trait of this detection 
method is the ability to label multiple targets on the same blot (or slice), reducing 
the need to strip or cut membranes. The detection method also allows the 
detection of faint and strong bands, reducing the risk of saturation. Interestingly, 
the Li-Cor near-infrared scanner is also marketed for immunohistochemistry use, 
however, few publications have explored this use as of yet.  
The methodology for Li-Cor whole brain slice scanning was based on a recent 
publication by Eaton et al. (2016), who validated the use of this technique for the 
quantification of D2 dopamine receptors in the mouse hippocampus, cortex and 
striatum. They showed that scanning of whole mouse brain slices yielded images 
of suitable quality for accurate morphometric measurements, which were 
comparable to measurements taken on a light microscope, showing the images 
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are of sufficient resolution to recognise the major brain structures. They compared 
D2 receptor distribution in the cortex, hippocampus and striatum and found that 
the distribution was comparable to images obtained by confocal microscopy. 
Furthermore, quantification of the signals in these brain regions was comparable 
to quantification by Western blot. This study validated the use of near-infrared 
scanning technology for the quantification of protein signals in whole brain slices. 
The advantage of using this technology is that it allows the quantification of protein 
signals in a whole brain region of interest. However, similarly to autoradiography, 
the signal detected represents the total protein expression, regardless of 
subcellular location. In order to complement this method, confocal microscopic 
quantification of protein colocalisation in the dendritic regions of the hippocampus 
was explored as an adjunct to Li-Cor immunohistochemistry.  
 
Confocal microscopy immunohistochemistry 
The method of protein colocalisation using confocal microscopy 
immunohistochemistry was based on a publication by Zhang et al. (2014), who 
investigated the bidirectional effects of glycine on NMDA-mediated synaptic 
plasticity in the CA1 region of the hippocampus in rats. They found that incubation 
of rat hippocampal slices in low concentrations of glycine (0.6mM) resulted in long 
term potentiation, as seen as an increase in excitatory postsynaptic currents in the 
CA1. Using immunohistochemistry and the measurement of NMDA receptor 
subunit expression, they found that 0.6mM glycine induced an increase in GluN1 
NMDA receptor subunits. Conversely, they found that high concentrations of 
glycine (1.5 mM) resulted in long term depression in the rat hippocampal slices. 
This also coincided with a decrease in GluN1 and GluN2A expression in the CA1.  
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This publication measured NMDA receptor subunit expression in the dendritic 
region of the CA1 by confocal microscopy. They co-stained their slices with 
antibodies for GluN1 NMDA subunits and PSD95 as their postsynaptic marker, 
then measured the colocalisation ratios of both proteins, to account for variability 
in brightness and contrast. This would allow the normalisation and comparison of 
signals between slices. They also quantified the NMDA receptors by subcellular 
fractionation and Western blot, and found the confocal colocalisation correlated 
with the Western blot quantification.  
 
Figure B.1: Left: Immunohistochemical labelling of GluN1 (green) and PSD95 
(red) and visualisation by confocal microscopy with highlighted dendritic branch 
(white box). Bar: 20µm. Higher magnification of dendritic branches are shown in 
the lower panel (bar: 2µm). Right: Colocalisation ratio of GluN1 with PSD95 as a 
normalised measurement of GluN1 expression in dendritic regions. Taken from 





Naïve male Wistar rats (approx. 6-8 weeks old) were intracardially perfused as 
described in the methodology section of Chapter 2. 24 hours prior to slicing, brains 
were placed in a 30% sucrose PBS solution. Brains were sliced 40µm thin and 
placed into 24-well plates for immunolabelling (See Chapter 2, section 2.3.6 for 
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details). Slices were incubated overnight at 4°C wi th primary antibodies: GluA1 
(1:1000, rabbit, Millipore), GluA1 phosphoSer845 (1:1000, rabbit, Millipore) and for 
confocal microscopy, co-labelled with anti-PSD95 (mouse, 1:300, Abcam). Slices 
were then incubated for 1 hour at room temperature with, for Li-Cor 
immunohistochemistry: donkey anti-rabbit (1:500, Li-Cor) or goat anti-rabbit (Alexa 
Fluor568, Invitrogen) and goat anti-mouse (Alexa Fluor 488, Invitrogen). Slices 
were then mounted on slides with DAPI counterstain. 
For Li-Cor immunohistochemistry, slices were scanned using a Li-Cor Odyssey 
Clx infrared scanner at 21µm resolution. Images were acquired and analysed 
using Li-Cor ImageStudio version 4.0.  
For confocal microscopy, images were acquired with Zeiss Zen Black, then 






Quantifying antibody signals 
 
Figure B.2: Representative method of quantification of GluA1 signal intensity in 
the dorsal hippocampus. The top yellow box shows the background set to zero. 
The CA1/CA2 (171000), CA3 (70800) and dentate gyrus (67700) regions of the 
hippocampus are highlighted with their signal intensities (arbitrary units). An area 
of the cortex is also highlighted with its signal intensity (15800).  
 
Different methods of quantification were trialled, but the optimal settings described 
below were determined. Figure B.2 above shows a representative image of the 
quantification method used. An area outside of the brain slice was set as the 
background, where the signal would be 0. All other signal intensities measured 
were relative to this background. The brain region of interest was highlighted by 
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using the freehand analysis tool. This would allow the selection of the entire 
regions of the hippocampus for signal measurement. The signal measured in a 
particular area was divided by the size of the shape drawn (in pixels) around the 
area. This allowed the normalisation of signals between brain slices, where the 
region of interest could vary in size. All signals were therefore given as 
signal/area. The antibodies were then titrated to determine the correct 















Figure B.3: Top: Quantification of GluA1 (left) and GluA1 phosphoSer845 (right) 
antibody titration signals. Data points are means±SEM, n=4 per titration. Bottom: 
Representative scans of brain slices for the corresponding antibody titration.  
 
Titration of the antibodies showed a near linear relationship between the antibody 
concentration and the signal intensity (Figure B.3). As previously mentioned, the 
signals detected during scanning are absolute values; therefore they could not be 
altered by adjusting the brightness and contrast settings. All slices were scanned 
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using the same parameters; therefore they were deemed to be comparable. The 
linear relationship of antibody dilution to signal intensity allowed the selection of 
any dilution so 1:1000 dilution was selected for future experimentation as the 
signal intensity was detectable but low enough to potentially detect changes in 
AMPA receptor expression without saturating the scanner. This also made 
experiments more economical as less antibody was required. 
 
Slice orientation   
When slicing coronal sections of the brain, there was some variability in the level 
of the hippocampus due to not slicing at an exactly straight angle, and often, slices 
were obtained with one half of the brain showing the dorsal hippocampus, and the 
other with the ventral hippocampus (as shown in Figure B.4). As the ventral 
hippocampus was the region of interest in this study, it was important to 
differentiate between the dorsal and ventral hippocampus clearly. In order to 
achieve this, horizontal sections of the brain were performed, as in this orientation; 





Figure B.4: Brain slice sectioning orientation to obtain the ventral hippocampus. 
Left: coronal sectioning of the hippocampus often resulted in both dorsal and 
ventral hippocampus sections due to crooked slicing. Right: Horizontal sections 




In order to remove any non-specific background signals from the secondary 
antibody, a control slice was run alongside stained slices where they were 
incubated in the absence of the primary antibody and then probed with the 
secondary antibody. The corresponding regions of interest (ROI) were highlighted, 
and then the signal was divided by the area of the drawn region. This value was 
then subtracted from the signals previously measured.  















Subcellular localisation of phosphorylated GluA1 
An interesting finding while optimising Li-Cor immunohistochemistry experiments 
was the difference in distribution of the phosphorylated and total GluA1 subunits in 
the hippocampus. This was clearly visible in brain slices scanned on the Li-Cor 
scanner, as shown in Figure B.6A. In all slices, it appeared that GluA1 staining 
was concentrated in the dendritic regions of the hippocampus (Figure B.5A), 
whereas phosphorylated GluA1 appeared concentrated in the somatic region 
(Figure B.6A). This difference in distribution was further investigated using 
confocal fluorescence microscopy, where slices were stained for GluA1 or the 
phosphorylated GluA1 (Ser845), with βIII tubulin to act as an intracellular marker. 
Results also showed a clear difference in distribution.  
 
Figure B.5: Distribution of GluA1 AMPA receptor subunits visualised by Li-Cor 
near-infrared scanning technology (A) and confocal fluorescence microscopy (B-





Figure B.6: Distribution of GluA1 phosphoSer845 AMPA receptor subunits 
visualised by Li-Cor near-infrared scanning technology (A) and confocal 
fluorescence microscopy (B-E). B: GluA1 phosphoSer845, C: βIII tubulin, D: 
merged with DAPI, E: brightfield view.  
  
 
Analysis of GluA1 staining by confocal fluorescence microscopy showed that 
GluA1 was present in the cell bodies and dendrites, (Figure B.5B-D). Analysis of 
the phosphorylated GluA1 subunits showed a distinct grouping in the somatic 
region of the hippocampus (Figure B.6A). Higher resolution imaging of the CA1 
showed that they were located on the soma, and this distribution was again 
different to the total GluA1 seen in Figure B.5B. It was not possible to determine 
whether phosphorylated GluA1 was present intracellularly or at the cell surface, 
therefore a Z stack was performed using confocal microscopy to address this 
question. The Z stack produced a 3-dimensional image by scanning multiple 
layers of the somatic region. Interestingly the Z stack revealed that the 
phosphorylated GluA1 subunits appeared to be expressed both intracellularly and 




One of the limitations of using autoradiography was that it only showed the total 
amount of AMPA present in a brain slice, without accounting for intracellular 
stores. Visualisation by the Li-Cor near-infrared scanner did not address this issue, 
as the whole brain slice was scanned and the resolution was not high enough 
ensure the capture of dendritic regions alone. The method of measuring 
colocalisation ratios in dendritic branches would therefore allow the quantification 
of synaptic proteins in the absence of intracellular stores (Zhang et al., 2014), 





Figure B.7: Antibody titration for confocal microscopy. Data are means±SEM. n=3 




The antibody titration, unlike the Li-Cor near-infrared antibodies, showed a non-
linear relationship of the antibody dilution with the signal intensity. A 1 in 1000 
titration was also attempted but the signal was not detectable on the confocal 
microscope (data not shown). For the purpose of this study and to conserve 
antibody stocks, the titration of 1:500 was selected so the signal was detectable, 
but low enough to detect any potential changes in AMPA receptor expression. 
 
 
Figure B.8: Left: Representative confocal tile scan of the CA1 region of the 
ventral hippocampus image with a representative region of interest highlighted 
(yellow box) for quantification in the dendritic layer. Right: Region of interest 63x 
magnified for quantification of protein colocalisation. Green (top left): PSD95, red 
(bottom left): GluA1 PhosphoSer845, blue (top right): DAPI, bottom right images 
are merged channels 
 
Figure B.8 shows representative confocal images in the CA1 region of the 
hippocampus. The cell body region was visible, and importantly, the dendritic layer 
was clearly distinguishable. This would allow the selection of dendritic regions for 





The Pearson’s correlation coefficient (PCC) was used as a measure of 
colocalisation as this metric includes normalisation. This would allow for the 
variation in intensity coming from the difference in acquisition settings such as the 
depth focus, brightness, contrast, gain offset and background. The normalised 
values of colocalisation therefore ranged from 1, signifying complete correlation; to 
-1, demonstrating complete anti-correlation (Dunn et al., 2011).  
The dendritic layers of the hippocampus were clearly visible in brain slices (Figure 
B.8), and DAPI staining was used in order to select a region lacking cell bodies. 
The region to analyse was highlighted and analysed for colocalisation using the 
coloc2 plugin in ImageJ. An example of the analysis is shown in Figure B.9 below.  
 
 
Figure B.9: Representative image demonstrating the colocalisation analysis on 
the dendritic branches of the hippocampus. One dendritic branch is highlighted in 
yellow. Red: GluA1 phosphoSer845, green: PSD95. Right: analysis output from 
ImageJ showing the Pearson’s correlation coefficient (R value) 
 
As the baseline correlation of GluA1 or GluA1 phosphoSer845 with PSD95 in 
control rats was neither 1 nor -1 (see Chapter 2, section 2.4.6), this method would 
be able to detect any changes in the colocalisation of AMPA receptor subunits with 
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PSD95, translated as the changes in insertion or removal of AMPA receptors in 
the postsynaptic membranes. 
 
B.3. Conclusions 
Whole brain slice immunohistochemistry and visualisation by the Li-Cor 
near-infrared scanner is an interesting method of protein detection and 
quantification at a whole tissue level. The hypothesis was that the results from this 
method would mirror those obtained by Wright et al. (2018), but at a subunit-
specific level. The drawback of this method however, similarly to autoradiography, 
is that it does not differentiate between somatic and synaptic proteins. This is the 
reason the visualisation by confocal microscopy was introduced, as the 
colocalisation of AMPA receptors with the postsynaptic marker PSD95 would allow 
the measurement of synaptic proteins in the dendritic layers of the hippocampus. 
The hypothesis was that using the higher resolution confocal microscopy would 
complement and add further information to the data obtained by whole brain slice 
immunohistochemistry.  
These methods were both applied on the rat brains from the four reinstatement 
groups of the heroin CPP described in Chapter 2, to explore the effects of MLA on 
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